SQLite format 3\00\00\00@  \00\00\00[\00\00\00h\00\00\00\00\00\00\00\00\00	\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00[\00.Xl\00g\00gg\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\81=;;\82tablesqlitestudio_temp_tablesqlitestudio_temp_tableCREATE TABLE sqlitestudio_temp_table(  id INT,  Medicine TEXT,  Generic TEXT,  Uses TEXT,  Side_effects TEXT,  Dosage TEXT)l\00\9F\82tabletblWordtblWordCREATE TABLE tblWord (id INTEGER PRIMARY KEY AUTOINCREMENT, Medicine TEXT, Generic TEXT, Uses TEXT, Side_effects TEXT, Dosage TEX\810\827tabletblWordtblWordCREATE TABLE tblWord (id INTEGER PRIMARY KEY AUTOINCREMENT, Medicine TEXT, Generic TEXT, Uses TEXT, Side_effects TEXT, Dosage TEXT, Brand_Names TEXT)P++Ytablesqlite_sequencesqlite_sequenceCREATE TABLE sqlite_sequence(name,seq)\00\00\00\94\81ytabletblWordtblWordCREATE TABLE tblWord (id INTEGER PRIMARY KEY AUTOINCREMENT, Medicine TEXT, Generic TEXT, Uses TEXT, Side_effec\00\00\00\00\00\00\00\00+)\00\00\00\00b\FB\F6\F1\EC\E7\E2\DD\D8\D3\CE\C9\C4\BF\BA\B5\B0\AB\A6\A1\9C\97\92\8D\88\83~ytoje`[VQLGB=83.)\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\85Z	\00-\84g\86%\00HistacinCHLORPHENIRAMINEHistacin Tablet is used for the treatment, control, prevention, & improvement of the following diseases, conditions and symptoms:    Common cold    Allergy    Hay fever    Watery eyes    Itchy throat/skin    Anaphylactic shock    Histacin Tablet may also be used for purposes not listed here. These side-effects are possible, but do not always occur. Some of the side-effects may be rare but serious. Consult your doctor if you observe any of the following side-effects, especially if they do not go away.    Feeling nervous    Tightness in chest    Stomach pain    Drowsiness    Muscular weakness    Ringing in ears    Histacin Tablet may also cause side-effects not listed here. \00\00\00\00\00\00\00\00@\00\00\84g\00\00HistacinHistacin Tablet is used for the treatment, control, prevention, & improvement of the following diseases, conditions and symptoms:    Common cold    Allergy    Hay fever    Watery eyes    Itchy throat/skin    Anaphylactic shoc\8A`\00#\85)w\8F\00OmidonDOMPERIDONEOmidon Tablet is used for the treatment, control, prevention, & improvement of the following diseases, conditions and symptoms:    Vomiting    Treatment for symptoms associated with idiopathic or diabetic gastroparesis    Treatment for intractable nausea and vomiting    Omidon Tablet may also be used for purposes not listed hereHeadacheSomnolenceAkathisiaDiarrheaRashPruritus Oral Nausea and vomiting Adult: 10-20 mg 3-4 times daily. Max: 80 mg/day. Child: â‰¤12 yr <35 kg: 250-500 mcg/kg 3-4 times daily. Max: â‰¤2.4 mg/kg (80 mg/day). >12 yr â‰¥35 kg: Same as adult dose. Elderly: No dosage adjustment needed. Renal impairment: Mild to moderate: No dosage adjustment needed. Severe: Reduce dosing to 1-2 times daily w/ prolonged treatment. Hepatic impairment: No dosage adjustment needed. Oral Gastrointestinal motility disorders Adult: 10 mg 3-4 times daily. Max: 20 mg 3-4 times daily. Last dose to be taken at bedtime. Elderly: No dosage adjustment needed. Renal impairment: Mild to moderate: No dosage adjustment needed. Severe: Reduce dosing to 1-2 times daily w/ prolonged treatment.Hepatic impairment: No dosage adjustment needed. Rectal Nausea and vomiting Adult: 60 mg bid. Child: â‰¤12 yr >15 kg: 30 mg bid; >12 yr â‰¥35 kg: Same as adult dose. Elderly: No dosage adjustment needed. More: http://www.ndrugs.com/?s=omidon\8BH\00#\85\89\88]\00NapaParacetamolNapaÂ® (Paracetamol) is a fast acting and safe analgesic with marked antipyretic property.It is recommended for the treatment of most painful and febrile conditions, such as headache, toothache, backache, rheumatic and muscle pains, dysmenorrhoea, sore throat, and for relieving the fever, aches and pains of colds and flu.Rare:Bloody or black, tarry stools bloody or cloudy urine fever with or without chills (not present before treatment and not caused by the condition being treated) pain in the lower back and/or side (severe and/or sharp) pinpoint red spots on the skin skin rash, hives, or itching More: http://www.ndrugs.com/?s=napa-extend&t=side%20effectsSymptoms of overdose: Diarrhea increased sweating loss of appetite nausea or vomiting stomach cramps or pain swelling, pain, or tenderness in the upper abdomen or stomach area More: http://www.ndrugs.com/?s=napa-extend&t=side%20effectsTablet:Adults: 1-2 tablets 3-4 times dailySyrup/Suspension:Adults: 4-8 Measuring spoonful 3-4 times daily;Children: 6-12 years: 2- 4 measuring spoonful 3-4 times daily, 1-5 years: 1-2 Measuring spoonful 3-4 times daily, Up to 1 year: 1/2 -1 Measuring spoonful 3-4 times dailyPaediatric drops:Neonates & Children: 0-3 months: 0.5 \00\00\00`C\00\00\00]A\00\00\00\?\00\00\00[>\00\00\00Z=\00\00\00Y<\00\00\00X;\00\00\00V:\00\00\00U9\00\00\00S8\00\00\00Q5\00\00\00P4\00\00\00O3\00\00\00N2\00\00\00I0\00\00\00L/\00\00\00K.\00\00\00H-\00\00\00D*\00\00\00>(\00\00\00<#\00\00\00;"\00\00\00:!\00\00\008 \00\00\00\00\00\00\00\00\00,\00\00\00.\00\00\00/\00\00\00-\00\00\00+\00\00\00)\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00	\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\F3\00\F3\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00tblWordD\00\00\00\8A\00V\8A\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\8A>\00-\84g\86%\89OHistacinCHLORPHENIRAMINEHistacin Tablet is use\89\00!!\85U\83o\88_RanitidineRanitidineRanitidine is used to treat several conditions, including: intestinal and stomach ulcers gastroesophageal reflux disease (GERD) erosive esophagitis conditions where your stomach makes too much acid, such as Zollinger-Ellison syndrome.Ranitidine may be used as part of a combination therapy. This means you may need to take it with other medications.headache (may be severe);drowsiness, dizziness;sleep problems (insomnia);decreased sex drive, impotence, or difficulty having an orgasm; or.swollen or tender breasts (in men);nausea, vomiting, stomach pain; or.diarrhea or constipation.The information is not a substitute for medical advice. Always consult your doctor or pharmacist.Form: oral tabletStrengths: 75 mg, 150 mg, 300 mgForm: oral capsuleStrengths: 150 mg, 300 mgForm: oral syrupStrength: 75 mg/5 mLBrand: ZantacForm: oral tabletStrengths: 150 mg, 300 mgAdult dosage (ages 17â€“64 years)Treatment of an active intestinal ulcer: 150 mg taken twice per day or 300 mg \89I\00!!\85U\83o\88_eRanitidineRanitidineRanitidine is used to treat several conditions, including: intestinal and stomach ulcers gastroesophageal reflux disease (GERD) erosive esophagitis conditions where your stomach makes too much acid, such as Zollinger-Ellison syndrome.Ranitidine may be used as part of a combination therapy. This means you may need to take it with other medications.headache (may be severe);drowsiness, dizziness;sleep problems (insomnia);decreased sex drive, impotence, or difficulty having an orgasm; or.swollen or tender breasts (in men);nausea, vomiting, stomach pain; or.diarrhea or constipation.The information is not a substitute for medical advice. Always consult your doctor or pharmacist.Form: oral tabletStrengths: 75 mg, 150 mg, 300 mgForm: oral capsuleStrengths: 150 mg, 300 mgForm: oral syrupStrength: 75 mg/5 mLBrand: ZantacForm: oral tabletStrengths: 150 mg, 300 mgAdult dosage (ages 17â€“64 years)Treatment of an active intestinal ulcer: 150 mg taken twice per day or 300 mg taken once per day. If you take one dose, take it after your evening meal or at bedtime.Maintenance therapy: 150 mg taken once per day at bedtimeZantac, Zantac 150, Zantac 300, Acid Reducer\8B'\00-\84g\86%\8BHistacinCHLORPHENIRAMINEHistacin Tablet is used for the treatment, control, prevention, & improvement of the following diseases, conditions and symptoms:    Common cold    Allergy    Hay fever    Watery eyes    Itchy throat/skin    Anaphylactic shock    Histacin Tablet may also be used for purposes not listed here. These side-effects are possible, but do not always occur. Some of the side-effects may be rare but serious. Consult your doctor if you observe any of the following side-effects, especially if they do not go away.    Feeling nervous    Tightness in chest    Stomach pain    Drowsiness    Muscular weakness    Ringing in ears    Histacin Tablet may also cause side-effects not listed here. The information is not a substitute for medical advice. Always consult your doctor or pharmacist.Adults and children over 12 years: 4 mg (1 tablet or 10 ml liquid medicine) every 4-6 hours. Do not take more than six doses (24 mg) a day if you are under 65 years of age, or more than a total of three doses (12 mg) a day if you are over 65 years. Children aged 6-11 years: 2 mg (5 ml liquid medicine) every 4-6 hours. Do not take more than a total of six doses (12 mg) a day.Children aged 2-5 years: 1 mg (2.5 ml liquid medicine) every 4-6 hours. Do not take more than a total of six doses (6 mg) a day.Children 1 year-23 months: 1 mg (2.5 ml liquid medicine) twice daily, preferably morning and evening.Histacin\00\00\00\00	\CF\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\8BH\00#\85)w\90UOmidonDOMPERIDONEOmidon Tablet is used for the treatment, control, prevention, & improvement of the following diseases, conditions and symptoms:    Vomiting    Treatment for symptoms associated with idiopathic or diabetic gastroparesis    Treatment for intractable nausea and vomiting    Omidon Tablet may also be used for purposes not listed hereHeadacheSomnolenceAkathisiaDiarrheaRashPruritus The information is not a substitute for medical advice. Always consult your doctor or pharmacist.Oral Nausea and vomiting Adult: 10-20 mg 3-4 times daily. Max: 80 mg/day. Child: â‰¤12 yr <35 kg: 250-500 mcg/kg 3-4 times daily. Max: â‰¤2.4 mg/kg (80 mg/day). >12 yr â‰¥35 kg: Same as adult dose. Elderly: No dosage adjustment needed. Renal impairment: Mild to moderate: No dosage adjustment needed. Severe: Reduce dosing to 1-2 times daily w/ prolonged treatment. Hepatic impairment: No dosage adjustment needed. Oral Gastrointestinal motility disorders Adult: 10 mg 3-4 times daily. Max: 20 mg 3-4 times daily. Last dose to be taken at bedtime. Elderly: No dosage adjustment needed. Renal impairment: Mild to moderate: No dosage adjustment needed. Severe: Reduce dosing to 1-2 times daily w/ prolonged treatment.Hepatic impairment: No dosage adjustment needed. Rectal Nausea and vomiting Adult: 60 mg bid. Child: â‰¤12 yr >15 kg: 30 mg bid; >12 yr â‰¥35 kg: Same as adult dose. Elderly: No dosage adjustment needed. More: http://www.ndrugs.com/?s=omidonOmidon\8C.\00#\85\89\8A!NapaParacetamolNapaÂ® (Paracetamol) is a fast acting and safe analgesic with marked antipyretic property.It is recommended for the treatment of most painful and febrile conditions, such as headache, toothache, backache, rheumatic and muscle pains, dysmenorrhoea, sore throat, and for relieving the fever, aches and pains of colds and flu.Rare:Bloody or black, tarry stools bloody or cloudy urine fever with or without chills (not present before treatment and not caused by the condition being treated) pain in the lower back and/or side (severe and/or sharp) pinpoint red spots on the skin skin rash, hives, or itching More: http://www.ndrugs.com/?s=napa-extend&t=side%20effectsSymptoms of overdose: Diarrhea increased sweating loss of appetite nausea or vomiting stomach cramps or pain swelling, pain, or tenderness in the upper abdomen or stomach area More: http://www.ndrugs.com/?s=napa-extend&t=side%20effectsThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.Tablet:Adults: 1-2 tablets 3-4 times dailySyrup/Suspension:Adults: 4-8 Measuring spoonful 3-4 times daily;Children: 6-12 years: 2- 4 measuring spoonful 3-4 times daily, 1-5 years: 1-2 Measuring spoonful 3-4 times daily, Up to 1 year: 1/2 -1 Measuring spoonful 3-4 times dailyPaediatric drops:Neonates & Children: 0-3 months: 0.5 ml, 4-11 months: 1ml, 12-23 months: 1.5 ml, 2-3 years: 2 ml, 4-5 years: 3 ml four times daily or as directed by physicians.Suppositories:Children: 1-5 years: 125- 250 mg, 6-12 years: 250-500 mg up to 4 times dailyNapa\00\00\00\D3\00\D3I\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\AC\00'a\8A)\941\B8-IAcetaminophenAc\ABs\00'a\8A)\941\B8-AcetaminophenAcetaminophen (oral) (a SEET a MIN oh fen)This combination medication is used to treat attention deficit hyperactivity disorder - ADHD. It works by changing the amounts of certain natural substances in the brain. Amphetamine/dextroamphetamine belongs to a class of drugs known as stimulants. It can help increase your ability to pay attention, stay focused on an activity, and control behavior problems. It may also help you to organize your tasks and improve listening skills.This drug is also used to treat a certain sleeping disorder (narcolepsy) to help you stay awake during the day. It should not be used to treat tiredness or to hold off sleep in people who do not have a sleep disorder.Get emergency medical help if you have signs of an allergic reaction to Adderall: hives; difficult breathing; swelling of your face, lips, tongue, or throat.Call your doctor at once if you have:    signs of heart problems - chest pain, trouble breathing, feeling like you might pass out;    signs of psychosis\A1!\00'a\8A)\941\A0!\82uAcetaminophenAcetaminophen (oral) (a SEET a MIN oh fen)This combination medication is used to treat attention deficit hyperactivity disorder - ADHD. It works by changing the amounts of certain natural substances in the brain. Amphetamine/dextroamphetamine belongs to a class of drugs known as stimulants. It can help increase your ability to pay attention, stay focused on an act\94*\00!\84m\81w\A1YSecloOmeprazoleSeclo Capsule is used for the treatment, control, prevention, & improvement of the following diseases, conditions and symptoms:Abdominal painGastroesophageal reflux diseaseHeartburnBitter fluid into stomachAcidic stomachFood pipe healingSeclo Capsule may also be used for purposes not listed here.HeadacheHypersensitivity reactionsWarmthSensation of whirling and loss of balanceDeficiency of vitamin b12NauseaThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.Usual Adult Dose for Duodenal Ulcer: 20 mg orally once a day before a meal. Most patients heal within 4 to 8 weeks. Usual Adult Dose for  Helicobacter pylori Infection: Dual therapy: Seclo 40 mg orally once a day in the morning plus clarithromycin 500 mg orally 3 times a day on days 1 to 14. Beginning on day 15, Seclo 20 mg orally once a day in the morning on days 15 to 28. Triple therapy: Seclo 20 mg plus clarithromycin 500 mg plus amoxicillin 1000 mg all given orally twice a day for 10 days. If an ulcer is present at the initiation of therapy, continue Seclo 20 mg orally once a day for an additional 18 days. Study - Canadian Adult Dyspepsia Empiric Treatment-Helicobacter pylori positive (CADET-Hp): Seclo 20 mg, metronidazole 500 mg, and clarithromycin 500 mg, twice daily for 7 days. Usual Adult Dose for Gastric Ulcer: 40 mg orally once a day before a meal for 4 to 8 weeks. Usual Adult Dose for Erosive Esophagitis: 20 mg orally once a day before a meal. This dosage may be increased to 40 mg per day based on desired clinical response and patient tolerance. Studies have been completed up to 12 months for maintenance therapy of erosive esophagitis. Usual Adult Dose for Zollinger-Ellison Syndrome: Initial: 60 mg orally once a day. Dosage should be individualized to patient's needs. Maintenance: doses up to 120 mg 3 times a day have been administered. Daily doses greater than 80 mg should be divided. Usual Adult Dose for Gastroesophageal Reflux Disease: Initial: 20 mg orally once a day before a meal for 4 to 8 weeks. This dosage may be increased to 40 mg per day if needed. Maintenance: long-term treatment with doses of 10 to 20 mg per day may be required for maintenance therapy of refractory disease and appears to be safe. Usual Adult Dose for Multiple Endocrine Adenomas: Initial: 60 mg orally once a day before a meal. This dosage may be titrated based on desired clinical response and patient tolerance. Maintenance: doses up to 120 mg 3 times a day have been administered. Daily doses greater than 80 mg should be divided.Seclo\00\00\00\00\DB\00\00\DB sweating, shivering, fast heart rate, muscle stiffness, twitching, loss of coordination, nausea, vomiting, or diarrhea.Adderall can affect growth in children. Tell your doctor if your child is not growing a\9E"\00'a\82g\941\A1e\82uAcetaminophenAcetaminophen (oral) (a SEET a MIN oh fen)This drug is used to treat mild to moderate pain (from headaches, menstrual periods, toothaches, backaches, osteoarthritis, or cold/flu aches and pains) and to reduce fever.Get emergency medical help if you have signs of an allergic reaction to Adderall: hives; difficult breathing; swelling of your face, lips, tongue, or throat.Call your doctor at once if you have:    signs of heart problems - chest pain, trouble breathing, feeling like you might pass out;    signs of psychosis - hallucinations (seeing or hearing things that are not real), new behavior problems, aggression, hostility, paranoia;    signs of circulation problems - numbness, pain, cold feeling, unexplained wounds, or skin color changes (pale, red, or blue appearance) in your fingers or toes;    a seizure (convulsions);    muscle twitches (tics); or    changes in your vision.Seek medical attention right away if you have symptoms of serotonin syndrome, such as: agitation, hallucinations, fever, sweating, shivering, fast heart rate, muscle stiffness, twitching, loss of coordination, nausea, vomiting, or diarrhea.Adderall can affect growth in children. Tell your doctor if your child is not growing at a normal rate while using this medicine.Common Adderall side effects may include:    stomach pain, loss of appetite;    weight loss;    mood changes, feeling nervous;    fast heart rate;    headache, dizziness;    sleep problems (insomnia); or    dry mouth.The information is not a substitute for medical advice. Always consult your doctor or pharmacist.Usual Adult Dose for Fever:Parenteral:Weight 50 kg or greater: 1000 mg IV every 6 hours OR 650 mg IV every 4 hoursMaximum Single Dose: 1000 mgMinimum Dosing Interval: every 4 hoursMaximum Dose: 4000 mg per 24 hoursWeight less than 50 kg: 15 mg/kg IV every 6 hours OR 12.5 mg/kg IV every 4 hoursMaximum Single Dose: 15 mg/kgMinimum Dosing Interval: every 4 hoursMaximum Dose: 75 mg/kg per 24 hoursOral:Immediate-release: 325 mg to 1 g orally every 4 to 6 hoursMinimum Dosing Interval: every 4 hoursMaximum Single Dose: 1000 mgMaximum Dose: 4 g per 24 hoursExtended-Release: 1300 mg orally every 8 hoursMaximum dose: 3900 mg per 24 hoursRectal:650 mg rectally every 4 to 6 hoursMaximum dose: 3900 mg per 24 hoursComments:-Maximum daily dose is based on all routes of administration and all products containing acetaminophen.-Maximum daily dose and dosing recommendations may differ by product; some manufacturers have decreased the maximum daily dose to protect consumers from inadvertent overdoses.-For IV administration, verify the dose in mg and mL to ensure the dose is correct; verify that infusion pumps are properly programmedUses:-For the management of mild to moderate pain and the management of moderate to severe pain with adjunctive opioid analgesics.-For the reduction of fever.Usual Adult Dose for Pain:Parenteral:Weight 50 kg or greater: 1000 mg IV every 6 hours OR 650 mg IV every 4 hoursMaximum Single Dose: 1000 mgMinimum Dosing Interval: every 4 hoursMaximum Dose: 4000 mg per 24 hoursWeight less than 50 kg: 15 mg/kg IV every 6 hours OR 12.5 mg/kg IV every 4 hoursMaximum Single Dose: 15 mg/kgMinimum Dosing Interval: every 4 hoursMaximum Dose: 75 mg/kg per 24 hoursOral:Immediate-release: 325 mg to 1 g orally every 4 to 6 hoursMinimum Dosing Interval: every 4 hoursMaximum Single Dose: 1000 mgMaximum Dose: 4 g per 24 hoursExtended-Release: 1300 mg orally every 8 hoursMaximum dose: 3900 mg per 24 hoursRectal:650 mg rectally every 4 to 6 hoursMaximum dose: 3900 mg per 24 hoursActamin, Anacin AF, Apra, Bromo Seltzer, Children's Tylenol, Elixsure Fever/Pain, Mapap, Medi-Tabs, Q-Pap, Silapap Childrens, Tactinal, Tempra Quicklets, Tycolene, Tylenol, Vitapap\00\00\00\00nically warranted, titration may proceed more rapidly, provided the patient is assessed frequently.Use:-Alone or in combination with other antihypertensive agents to treat hypertensionUsual Adult Dose of Amlodipine for Angina Pectoris:Maintenance dose: 5 to 10 mg orally once a dayMaximum dose: 10 mg/dayComments:-In clinical studies, most patients with angina or coronary artery disease (CAD) required 10 mg orally once a day.-The dosage should be adjusted according to patient response. In general, titration should proceed over 7 to 14 days. If clinically warranted, titration may proceed more rapidly, provided the patient is assessed frequently.Uses:-Alone or in combination with other antianginal agents for the symptomatic treatment of chronic stable angina-Alone or in combination with other antianginal agents for the treatment of confirmed/suspected vasospastic angina-To reduce the risk of hospitalization for angina and to reduce the risk of a coronary revascularization procedure in patients with recently documented CAD by angiography and without heart failure or an ejection fraction less than 40%Usual Adult Dose of Amlodipine for Coronary Artery Disease:Maintenance dose: 5 to 10 mg orally once a dayMaximum dose: 10 mg/dayComments:-In clinical studies, most patients with angina or coronary artery disease (CAD) required 10 mg orally once a day.-The dosage should be adjusted according to patient response. In general, titration should proceed over 7 to 14 days. If clinically warranted, titration may proceed more rapidly, provided the patient is assessed frequently.Uses:-Alone or in combination with other antianginal agents for the symptomatic treatment of chronic stable angina-Alone or in combination with other antianginal agents for the treatment of confirmed/suspected vasospastic angina-To reduce the risk of hospitalization for angina and to reduce the risk of a coronary revascularization procedure in patients with recently documented CAD by angiography and without heart failure or an ejection fraction less than 40%Usual Geriatric Dose of Amlodipine for Hypertension:Initial dose: 2.5 mg orally once a dayMaintenance dose: 2.5 to 10 mg orally once a dayMaximum dose: 10 mg/dayComment:-The dosage should be adjusted according to patient response. In general, titration should proceed over 7 to 14 days. If clinically warranted, titration may proceed more rapidly, provided the patient is assessed frequently.Use:-Alone or in combination with other antihypertensive agents to treat hypertensionUsual Geriatric Dose of Amlodipine for Angina Pectoris:Initial dose: 5 mg orally once a dayMaintenance dose: 5 to 10 mg orally once a dayMaximum dose: 10 mg/dayComments:-In clinical studies, most patients with angina or coronary artery disease (CAD) required 10 mg orally once a day.-The dosage should be adjusted according to patient response. In general, titration should proceed over 7 to 14 days. If clinically warranted, titration may proceed more rapidly, provided the patient is assessed frequently.Uses:-Alone or in combination with other antianginal agents for the symptomatic treatment of chronic stable angina-Alone or in combination with other antianginal agents for the treatment of confirmed/suspected vasospastic angina-To reduce the risk of hospitalization for angina and to reduce the risk of a coronary revascularization procedure in patients with recently documented CAD by angiography and without heart failure or an ejection fraction less than 40%Usual Pediatric Dose of Amlodipine for Hypertension:6 to 17 years:-Maintenance dose: 2.5 to 5 mg orally once a day-Maximum dose: 5 mg/dayComments:-Doses higher than 5 mg have not been studied in pediatric patients.The dosage should be adjusted according to patient response. In general, titration should proceed over 7 to 14 days. If clinically warranted, titration may proceed more rapidly, provided the patient is assessed frequently.Use:-Alone or in combination with other antihypertensive agents to treat hypertensionNorvasc\00\00\00\00-taking behavior;    confusion, agitation, hostility, hallucinations;    uncontrolled muscle movements, tremor, seizure (convulsions); or    pounding heartbeats or fluttering in your chest.Common alprazolam side effects may include:    drowsiness, feeling tired;    slurred speech, lack of balance or coordination;    memory problems; or    feeling anxious early in the morning.This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.The information is not a substitute for medical advice. Always consult your doctor or pharmacist.Usual Adult Dose for Anxiety:Immediate-release tablets, orally disintegrating tablets, oral concentrate:Initial dose: 0.25 to 0.5 mg orally 3 times a dayThis dose may be gradually increased every 3 to 4 days if needed and tolerated.Maintenance dose: May increase up to maximum daily dose of 4 mg in divided dosesUsual Adult Dose for Panic Disorder:Immediate-release tablets, orally disintegrating tablets:Initial dose: 0.5 mg orally 3 times a dayThis dose may be gradually increased every 3 to 4 days if needed and tolerated.Maintenance dose: 1 to 10 mg per day in divided dosesMean dose employed: 5 to 6 mg per day in divided dosesExtended-release tablets:Initial dose: 0.5 to 1 mg once a dayThe daily dose may be gradually increased by no more than 1 mg every 3 to 4 days if needed and tolerated.Maintenance dose: 1 to 10 mg once a dayMean dose employed: 3 to 6 mg once a dayUsual Adult Dose for Depression:Immediate-release tablets, orally disintegrating tablets, oral concentrate:Initial dose: 0.5 mg orally 3 times a dayThe daily dose may be gradually increased by no more than 1 mg every 3 to 4 days.Average Dose: Studies in the treatment of depression have reported an average effective dose of 3 mg orally daily in divided dosesMaximum Dose: Studies in the treatment of depression have reported to have used 4.5 mg orally daily in divided doses as a maximum.Usual Geriatric Dose for Anxiety:Immediate-release tablets, orally disintegrating tablets, oral concentrate:Initial dose: 0.25 mg orally 2 to 3 times a day in elderly or debilitated patientsThis dose may be gradually increased if needed and tolerated.Because of increased sensitivity to benzodiazepines in elderly patients, alprazolam at daily doses greater than 2 mg meets the Beers criteria as a medication that is potentially inappropriate for use in older adults. Smaller doses may be effective as well as safer. Total daily doses should rarely exceed suggested maximums.Usual Geriatric Dose for Depression:Immediate-release tablets, orally disintegrating tablets, oral concentrate:Initial dose: 0.25 mg orally 2 to 3 times a day in elderly or debilitated patientsThis dose may be gradually increased if needed and tolerated.Because of increased sensitivity to benzodiazepines in elderly patients, alprazolam at daily doses greater than 2 mg meets the Beers criteria as a medication that is potentially inappropriate for use in older adults. Smaller doses may be effective as well as safer. Total daily doses should rarely exceed suggested maximums.Usual Geriatric Dose for Panic Disorder:Immediate-release tablets, orally disintegrating tablets:Initial dose: 0.25 mg orally 2 to 3 times a day in elderly or debilitated patientsThis dose may be gradually increased if needed and tolerated.Extended-release tablets:Initial dose: 0.5 mg once a day preferably in the morningThis dose may be gradually increased if needed and tolerated.Because of increased sensitivity to benzodiazepines in elderly patients, alprazolam at daily doses greater than 2 mg meets the Beers criteria as a medication that is potentially inappropriate for use in older adults. Smaller doses may be effective as well as safer. Total daily doses should rarely exceed suggested maximums.Niravam, Xanax, Xanax XRnsomnia, anorexia) appear.-Narcolepsy rarely occurs in children under 12 years of age.Adderall, Adderall XR, Mydayis\00\94\00\94ills.This drug is also used to treat a certain sleeping disorder (narcolepsy) to help you stay awake during the day. It should not be used to treat tiredness or to hold off sleep in people who do not have a sleep disorder.Get emergency medical help if you have signs of an allergic reaction to Adderall: hives; difficult breathing; swelling of your face, lips, tongue, or throat.Call your\ACd\00O\8A)\941\B9qIAdderallAmphetamine and dextroamphetamineThis combination medication is used to treat attention deficit hyperactivity disorder - ADHD. It works by changing the amounts of certain natural substances in the brain. Amphetamine/dextroamphetamine belongs to a class of drugs known as stimulants. It can help increase your ability to pay attention, stay focused on an activity, and control behavior problems. It may also help you to organize your tasks and improve listening skills.This drug is also used to treat a certain sleeping disorder (narcolepsy) to help you stay awake during the day. It should not be used to treat tiredness or to hold off sleep in people who do not have a sleep disorder.Get emergency medical help if you have signs of an allergic reaction to Adderall: hives; difficult breathing; swelling of your face, lips, tongue, or throat.Call your doctor at once if you have:    signs of heart problems - chest pain, trouble breathing, feeling like you might pass out;    signs of psychosis - hallucinations (seeing or hearing things that are not real), new behavior problems, aggression, hostility, paranoia;    signs of circulation problems - numbness, pain, cold feeling, unexplained wounds, or skin color changes (pale, red, or blue appearance) in your fingers or toes;    a seizure (convulsions);    muscle twitches (tics); or    changes in your vision.Seek medical attention right away if you have symptoms of serotonin syndrome, such as: agitation, hallucinations, fever, sweating, shivering, fast heart rate, muscle stiffness, twitching, loss of coordination, nausea, vomiting, or diarrhea.\00\00\000\00\00\00!E\84M\8B3\B3/=AlprazolamAlprazolam (al PRAY zoe lam)Alprazolam is used to treat anxiety and panic disorders. It belongs to a class of medications called benzodiazepines which act on the brain and nerves (central nervous system) to produce a calming effect. It works by enhancing the effects of a certain natural chemical in the body (GABA).Call your doctor at once if you have:    depressed mood, thoughts of suicide or hurting yourself;    racing thoughts, increased energy, unusual risk\00\00\00\00\00\00O\8A)\941\B8-IAdderallAmphetamine and dextroamphetamineThis combination medication is used to treat attention deficit hyperactivity disorder - ADHD. It works by changing the amounts of certain natural substances in the brain. Amphetamine/dextroamphetamine belongs to a class of drugs known as stimulants. It can help increase your ability to pay attention, stay focused on an activity, and control behavior problems. It may also help you to organize your tasks and improve listening skills.This drug is also used to treat a certain sleeping disorder (narcolepsy) to help you stay awake during the day. It should not be used to treat tiredness or to hold off sleep in people who do not have a sleep disorder.Get emergency medical help if you have signs of an allergic reaction to Adderall: hives; difficult breathing; swelling of your face, lips, tongue, or throat.Call your doctor at once if you have:    signs of heart problems - chest pain, trouble breathing, feeling like you might pass out;    signs of psychosis - hallucinations (seeing or \A2o\00!E\84M\8B3\B4s=AlprazolamAlprazolam (al PRAY zoe lam)Alprazolam is used to treat anxiety and panic disorders. It belongs to a class of medications called benzodiazepines which act on the brain and nerves (central nervous system) to produce a calming effect. It works by enhancing the effects of a certain natural chemical in the body (GABA).Call your doctor at once if you have:    depressed mood, thoughts of suicide or hurting yourself;    racing thoughts, increased energy, unusual risk\00\00\00	\00\00\00y\00y\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\9B	\00'Q\86?\95q\98];AmitriptylineAmitriptyline (a mee TRIP ti leen)This medication is used to treat mental/mood problems such as depression. It may help improve mood and feelings of well-being, relieve anxiety and tension, help you sleep better, and increase your energy level. This medication belongs to a class of medications called tricyclic antidepressants. It works by affecting the balance of certain natural chemicals (neurotransmitters such as serotonin) in the brain.Get emergency medical help if you have signs of an allergic reaction to amitriptyline: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.Report any new or worsening symptoms to your doctor, such as: mood or behavior changes, anxiety, panic attacks, trouble sleeping, or if you feel impulsive, irritable, agitated, hostile, aggressive, restless, hyperactive (mentally or physically), more depressed, or have thoughts about suicide or hurting yourself.Call your doctor at once if you have:    unusual thoughts or behavior;    a light-headed feeling, like you might pass out;    chest pain or pressure, pain spreading to your jaw or shoulder, nausea, sweating;    pounding heartbeats or fluttering in your chest;    confusion, hallucinations;    a seizure (convulsions);    painful or difficult urination;    severe constipation;    easy bruising, unusual bleeding; or    sudden weakness or ill feeling, fever, chills, sore throat, mouth sores, red or swollen gums, trouble swallowing.Common amitriptyline side effects may include:    constipation, diarrhea;    nausea, vomiting, upset stomach;    mouth pain, unusual taste, black tongue;    appetite or weight changes;    urinating less than usual;    itching or rash;    breast swelling (in men or women); or    decreased sex drive, impotence, or difficulty having an orgasm.The information is not a substitute for medical advice. Always consult your doctor or pharmacist.Usual Adult Dose for Depression:Outpatients:Usual dose: 75 mg orally per day in divided doses; this may be increased to a total of 150 mg per day if neededAlternate dose: 40 to 100 mg orally as a single dose at bedtime; this may be increased by 25 or 50 mg as needed at bedtime to a total of 150 mg per dayMaximum dose: 150 mg orally per dayInpatients:Initial dose: 100 mg orally per dayMaintenance dose: 40 to 100 mg orally as a single dose at bedtimeMaximum dose: 300 mg orally per dayComments:-Dosage should be reduced to the lowest amount that will maintain relief of symptoms, when satisfactory improvement has been obtained.-Dose increases should preferably be made in the late afternoon or at bedtime due to the sedative effect.-The full therapeutic effect may take as long as 30 days to develop.-Maintenance therapy should be continued for 3 months or longer to lessen the possibility of relapse.Use: Relief of symptoms of depressionUsual Geriatric Dose for Depression:10 mg orally 3 times a day with 20 mg at bedtimeComments:-The full therapeutic effect may take as long as 30 days to develop.-Elderly patients should be monitored carefully and serum levels obtained as clinically appropriate.-Dose adjustments should be made according to clinical response.Use: Relief of symptoms of depressionUsual Pediatric Dose for Depression:12 years or older:10 mg orally 3 times a day with 20 mg at bedtimeUse: Relief of symptoms of depressionVanatrip, Elavil, Endep\00\00\00\00\00\00\00\00\00\001\00\00\002\00\00\003\00\00\004\00\00\005condition being treated.-Current guidelines should be consulted for additional information.Usual Adult Dose for Lyme Disease - Erythema Chronicum MigransInfectious Diseases Society of America (IDSA) recommendations: 500 mg orally 3 times a day for 14 to 28 daysComments:-Duration of treatment depends upon severity of condition being treated.-Current guidelines should be consulted for additional information.Usual Adult Dose for Lyme DiseaseInfectious Diseases Society of America (IDSA) recommendations: 500 mg orally 3 times a day for 14 to 28 daysComments:-Duration of treatment depends upon severity of condition being treated.-Current guidelines should be consulted for additional information.Usual Adult Dose for PneumoniaImmediate-release:-Mild, moderate, or severe infection: 500 mg orally every 8 hours or 875 mg every 12 hoursUse: For the treatment of infections of the lower respiratory tract due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) S pneumoniae, Staphylococcus species, and H influenzaeIDSA and American Thoracic Society (ATS) recommendations:Pneumonia:-Immediate-release: 1 g orally 3 times a dayComments:-Patients should be treated for a minimum of 5 days, be afebrile for 48 to 72 hours, and have no more than 1 community-acquired pneumonia (CAP)-associated sign of clinical instability before discontinuing therapy.-Used in combination with other medications.-Current guidelines should be consulted for additional information.Use: For outpatient empirical treatment of community-acquired pneumoniaUsual Adult Dose for BronchitisImmediate-release:-Mild, moderate, or severe infection: 500 mg orally every 8 hours or 875 mg every 12 hoursUse: For the treatment of infections of the lower respiratory tract due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) S pneumoniae, Staphylococcus species, and H influenzaeIDSA and American Thoracic Society (ATS) recommendations:Pneumonia:-Immediate-release: 1 g orally 3 times a dayComments:-Patients should be treated for a minimum of 5 days, be afebrile for 48 to 72 hours, and have no more than 1 community-acquired pneumonia (CAP)-associated sign of clinical instability before discontinuing therapy.-Used in combination with other medications.-Current guidelines should be consulted for additional information.Use: For outpatient empirical treatment of community-acquired pneumoniaUsual Adult Dose for SinusitisImmediate-release:-Mild to moderate infection: 250 mg orally every 8 hours or 500 mg every 12 hours-Severe infection: 500 mg orally every 8 hours or 875 mg every 12 hoursComments: Dosing for infections caused by bacteria that are intermediate in their susceptibility should follow recommendations for severe infections.Uses: For the treatment of infections of the ear, nose and throat due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) Streptococcus pneumoniae, Staphylococcus species, or Haemophilus influenzae; for the treatment of infections of the genitourinary tract due to susceptible (only beta lactamase negative) isolates of Escherichia coli, Proteus mirabilis, or Enterococcus faecalis; and for the treatment of infections of the skin and structure due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) S pneumoniae, Staphylococcus species, and H influenzaeUsual Adult Dose for Urinary Tract InfectionImmediate-release:-Mild to moderate infection: 250 mg orally every 8 hours or 500 mg every 12 hours-Severe infection: 500 mg orally every 8 hours or 875 mg every 12 hoursComments: Dosing for infections caused by bacteria that are intermediate in their susceptibility should follow recommendations for severe infections.Uses: For the treatment of infections of the ear, nose and throat due to susceptible (only beta l\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\AFc\00!!\8AC\8D;\C7#AmlodipineAmlodipineAmlodipine is used with or without other medications to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. Amlodipine belongs to a class of drugs known as calcium channel blockers. It works by relaxing blood vessels so blood can flow more easily.Amlodipine is also used to prevent certain types of chest pain (angina). It may help to increase your ability to exercise and decrease the frequency of angina attacks. It should not be used to treat attacks of chest pain when they occur. Use other medications (such as sublingual nitroglycerin) to relieve attacks of chest pain as directed by your doctor.Get emergency medical help if you have signs of an allergic reaction to amlodipine: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.In rare cases, when you first start taking amlodipine, your angina may get worse or you could have a heart attack. Seek emergency medical attention or call your doctor right away if you have symptoms such as: chest pain or pressure, pain spreading to your jaw or shoulder, nausea, sweating.Call your doctor at once if you have:    pounding heartbeats or fluttering in your chest;    worsening chest pain;    swelling in your feet or ankles;    severe drowsiness; or    a light-headed feeling, like you might pass out.Common amlodipine side effects may include:    dizziness;    feeling tired;    stomach pain, nausea; or    flushing (warmth, redness, or tingly feeling).The information is not a substitute for medical advice. Always consult your doctor or pharmacist.Usual Adult Dose of Amlodipine for Hypertension:Initial dose: 5 mg orally once a dayMaintenance dose: 5 to 10 mg orally once a dayMaximum dose: 10 mg/dayComments:-Patients who are small or fragile may be started on 2.5 mg orally once a day.-The dosage should be adjusted according to patient response. In general, titration should proceed over 7 to 14 days. If cli\00\00\00\00\00\006neumonia6 months and older:Immediate-release: 10 mg/kg (maximum: 500 mg/dose) orally on day 1, followed by 5 mg/kg (250 mg/dose) orally once a day on days 2 to 5Extended-release:-Patients less than 34 kg: 60 mg/kg (maximum dose: 2 g/dose) orally as a single dose-Patients 34 kg or greater: 2 g orally as a single dose16 years and older:Parenteral: 500 mg IV once a day as a single dose for at least 2 days, followed by 500 mg (immediate-release formulation) orally to complete a 7- to 10-day course of therapyComment: Extended-release formulations should be taken on an empty stomach.Uses:-Treatment of mild to moderate community acquired pneumonia due to C pneumoniae, H influenzae, M pneumonia, or S pneumoniae in patients appropriate for oral therapy-Treatment of community-acquired pneumonia due to C pneumoniae, H influenzae, L pneumophila, M catarrhalis, M pneumoniae, or S pneumoniae in patients who require initial IV therapyIDSA and Pediatric Infectious Disease Society (PIDS) Recommendations:3 months to less than 5 years:Parenteral: 10 mg/kg on days 1 and 2 of treatment, transitioning to oral treatment when possibleOral: 10 mg/kg orally on day 1, then 5 mg/kg/day orally once a day on days 2 to 55 years and older:Oral: 10 mg/kg (maximum: 500 mg/day) orally on day 1, followed by 5 mg/kg/day (maximum: 250 mg/day) orally on days 2 to 5Comments:-Oral therapy may be used in patients with mild infections and/or as outpatient empiric therapy for patients with presumed atypical pneumonia.-Beta lactam antibiotics may be added to inpatients with presumed atypical pneumonia if diagnosis is in doubt.Uses:-Treatment of community-acquired pneumonia caused by M pneumoniae, C trachomatis, or C pneumoniae-Treatment of presumed atypical pneumonia in outpatient and inpatient settingsUsual Pediatric Dose for Tonsillitis/Pharyngitis2 years and older:Immediate-release: 12 mg/kg (maximum: 500 mg/dose) orally once a day for 5 daysUse: Treatment of mild to moderate pharyngitis/tonsillitis caused by S pyogenes as an alternative to first-line therapy in patients who cannot use first-line therapyUsual Pediatric Dose for Sinusitis6 months and older:Immediate-release: 10 mg/kg (maximum: 500 mg/dose) once a day for 3 days16 years and older:Extended-release:-Patients less than 34 kg: 60 mg/kg (maximum dose: 2 g/dose) orally as a single dose-Patients 34 kg or greater: 2 g orally as a single doseComment: The effectiveness of a 1- or 5-day treatment has not been established.Use: Treatment of mild to moderate acute bacterial sinusitis due to H influenza, M catarrhalis, or S pneumoniaeUsual Pediatric Dose for Pelvic Inflammatory Disease16 years and older:Parenteral: 500 mg IV once a day for 1 or 2 days, followed by 250 mg orally once a day to complete a 7-day course of therapyComment: Antimicrobial drugs with anaerobic activity should be used concurrently if anaerobic microorganisms are suspected in contributing to the infection.Use: Treatment of pelvic inflammatory disease due to C trachomatis, N gonorrhoeae, or M hominisUsual Pediatric Dose for Bacterial InfectionAmerican Academy of Pediatrics (AAP) Recommendations:Immediate-release:Less than 1 month:-IV: 10 mg/kg IV every 24 hours-Oral: 10 to 20 mg/kg orally every 24 hours1 month or older:-Mild to moderate infections: 5 to 12 mg/kg orally once a day-Severe infections: 10 mg/kg IV once a dayComments:-The single or total course dose for adult oral therapy is 1.5 to 2 g.-Current guidelines should be consulted for additional information.Usual Pediatric Dose for Skin and Structure InfectionIDSA Recommendations:Immediate-release:Patients greater than 45 kg: 500 mg orally on day 1, then 250 mg orally once a day on days 2 through 5Patients less than 45 kg: 10 mg/kg orally on day 1, then 5 mg/kg orally once a day for 4 additional daysUse: Treatment of bacillary angiomatosis and cat scratch diseaseUsual Pediatric Dose for Gonococcal Infection - UncomplicatedUS CDC Recommendations:Immediate-release:Adolescents:-Recommended regimen:\00\00\00\00r at once if you have:    severe drowsiness;    thoughts of suicide or hurting yourself;    unusual changes in mood or behavior;    confusion, aggression, hallucinations;    worsened sleep problems;    sudden restless feeling or excitement;    muscle weakness, drooping eyelids, trouble swallowing;    vision changes; or    upper stomach pain, dark urine, jaundice (yellowing of the skin or eyes).Common Ativan side effects may include:    dizziness, drowsiness;    weakness;    slurred speech, lack of balance or coordination;    memory problems; or    feeling unsteady.The information is not a substitute for medical advice. Always consult your doctor or pharmacist.Usual Adult Dose of Ativan for Anxiety:Tablets:Initial dose: 2 to 3 mg orally per day administered 2 to 3 times per dayMaintenance dose: 1 to 2 mg orally 2 to 3 times a dayParenteral:IV: 2 mg total, or 0.044 mg/kg, whichever is smallerComments:-The daily dosage may vary from 1 to 10 mg per day.-The dosage should be increased gradually when needed to help avoid adverse effects.-When higher dosage is indicated, the evening dose should be increased before the daytime doses.Use: Management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptomsUsual Adult Dose for Light Anesthesia:IM: 0.05 mg/kg up to a maximum of 4 mgIV: 2 mg total, or 0.044 mg/kg, whichever is smallerComments:-Doses of other injectable central-nervous-system depressant drugs should be reduced.-For optimum effect, intramuscular drug should be administered at least 2 hours before the anticipated operative procedure.-Narcotic analgesics should be administered at their usual preoperative time.-IV: This dose should not ordinarily be exceeded in patients over 50 years of age.-IV: Larger doses as high as 0.05 mg/kg up to a total of 4 mg may be administered.-For optimum effect, intravenous drug should be administered 15 to 20 minutes before the anticipated operative procedure.Use:-Preanesthetic medication for adult patients, producing sedation (sleepiness or drowsiness), relief of anxiety, and a decreased ability to recall events related to the day of surgeryUsual Adult Dose for Status Epilepticus:0.1 mg/kg IV up to 4 mg per dose; may repeat in 5 to 10 minutesMaximum dose: 8 mgComments:-Vital signs should be monitored, an unobstructed airway should be maintained, and artificial ventilation equipment should be available.-When an intravenous port is not available, the IM route may prove useful.Use: Treatment of status epilepticusUsual Adult Dose for Insomnia:2 to 4 mg orally administered at bedtimeComments:-The dosage should be increased gradually when needed to help avoid adverse effects.Use: Management of insomniaUsual Geriatric Dose for Anxiety:Elderly or debilitated patients:1 to 2 mg orally per day in divided dosesComments:-The dosage should be increased gradually when needed to help avoid adverse effects.Use: Management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptomsUsual Pediatric Dose for Anxiety:12 years or older:Initial dose: 2 to 3 mg orally per day administered 2 to 3 times per dayMaintenance dose: 1 to 2 mg orally 2 to 3 times a dayComments:-The daily dosage may vary from 1 to 10 mg per day.-The dosage should be increased gradually when needed to help avoid adverse effects.-When higher dosage is indicated, the evening dose should be increased before the daytime doses.Use: Management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptomsUsual Pediatric Dose for Insomnia:12 years or older:2 to 4 mg orally administered at bedtimeComments:-For elderly or debilitated patients, an initial dosage of 1 to 2 mg/day in divided doses is recommended.-The dosage should be increased gradually when needed to help avoid adverse effects.Use: Management of insomniaAtivannfection:4 months \00\00\00for 3 daysOR10 mg/kg (maximum: 500 mg/dose) orally on day 1, followed by 5 mg/kg (maximum: 250 mg/dose) orally once a day on days 2 to 5Comment: The safety of a re-dosing a 30 mg/kg dose in a patient who vomits has not been established.Use: Treatment of mild to moderate acute otitis media caused by H influenza, M catarrhalis, or S pneumoniaeUsual Pediatric Dose for Legionella Pneumonia6 months and older:Immediate-release: 10 mg/kg (maximum: 500 mg/dose) orally on day 1, followed by 5 mg/kg (250 mg/dose) orally once a day on days 2 to 5Extended-release:-Patients less than 34 kg: 60 mg/kg (maximum dose: 2 g/dose) orally as a single dose-Patients 34 kg or greater: 2 g orally as a single dose16 years and older:Parenteral: 500 mg IV once a day as a single dose for at least 2 days, followed by 500 mg (immediate-release formulation) orally to complete a 7- to 10-day course of therapyComment: Extended-release formulations should be taken on an empty stomach.Uses:-Treatment of mild to moderate community acquired pneumonia due to C pneumoniae, H influenzae, M pneumonia, or S pneumoniae in patients appropriate for oral therapy-Treatment of community-acquired pneumonia due to C pneumoniae, H influenzae, L pneumophila, M catarrhalis, M pneumoniae, or S pneumoniae in patients who require initial IV therapyIDSA and Pediatric Infectious Disease Society (PIDS) Recommendations:3 months to less than 5 years:Parenteral: 10 mg/kg on days 1 and 2 of treatment, transitioning to oral treatment when possibleOral: 10 mg/kg orally on day 1, then 5 mg/kg/day orally once a day on days 2 to 55 years and older:Oral: 10 mg/kg (maximum: 500 mg/day) orally on day 1, followed by 5 mg/kg/day (maximum: 250 mg/day) orally on days 2 to 5Comments:-Oral therapy may be used in patients with mild infections and/or as outpatient empiric therapy for patients with presumed atypical pneumonia.-Beta lactam antibiotics may be added to inpatients with presumed atypical pneumonia if diagnosis is in doubt.Uses:-Treatment of community-acquired pneumonia caused by M pneumoniae, C trachomatis, or C pneumoniae-Treatment of presumed atypical pneumonia in outpatient and inpatient settingsUsual Pediatric Dose for Mycoplasma Pneumonia6 months and older:Immediate-release: 10 mg/kg (maximum: 500 mg/dose) orally on day 1, followed by 5 mg/kg (250 mg/dose) orally once a day on days 2 to 5Extended-release:-Patients less than 34 kg: 60 mg/kg (maximum dose: 2 g/dose) orally as a single dose-Patients 34 kg or greater: 2 g orally as a single dose16 years and older:Parenteral: 500 mg IV once a day as a single dose for at least 2 days, followed by 500 mg (immediate-release formulation) orally to complete a 7- to 10-day course of therapyComment: Extended-release formulations should be taken on an empty stomach.Uses:-Treatment of mild to moderate community acquired pneumonia due to C pneumoniae, H influenzae, M pneumonia, or S pneumoniae in patients appropriate for oral therapy-Treatment of community-acquired pneumonia due to C pneumoniae, H influenzae, L pneumophila, M catarrhalis, M pneumoniae, or S pneumoniae in patients who require initial IV therapyIDSA and Pediatric Infectious Disease Society (PIDS) Recommendations:3 months to less than 5 years:Parenteral: 10 mg/kg on days 1 and 2 of treatment, transitioning to oral treatment when possibleOral: 10 mg/kg orally on day 1, then 5 mg/kg/day orally once a day on days 2 to 55 years and older:Oral: 10 mg/kg (maximum: 500 mg/day) orally on day 1, followed by 5 mg/kg/day (maximum: 250 mg/day) orally on days 2 to 5Comments:-Oral therapy may be used in patients with mild infections and/or as outpatient empiric therapy for patients with presumed atypical pneumonia.-Beta lactam antibiotics may be added to inpatients with presumed atypical pneumonia if diagnosis is in doubt.Uses:-Treatment of community-acquired pneumonia caused by M pneumoniae, C trachomatis, or C pneumoniae-Treatment of presumed atypical pneumonia in outpatient and inpatient settingsUsual Pediatric Dose for P\00\00\00e prophylaxis for HCT recipients, regardless of vaccination status-Prophylaxis against bacterial infectionsUsual Adult Dose for PertussisAmerican Society for Blood and Marrow Transplantation (ASBMT) and IDSA Recommendations:Immediate-release:Immunization against pertussis:-Alternative treatment: 250 mg orally once a dayPostexposure prophylaxis: 500 mg orally once on day 1, then 250 mg orally once a day for 4 daysComments:-Patients should receive the acellular pertussis vaccine after hematopoietic cell transplantation (HCT).-Treatment with this drug may be given to patients with an incomplete vaccination series.Uses:-Immunization against pertussis for adult recipients after HCT-Postexposure prophylaxis for HCT recipients, regardless of vaccination status-Prophylaxis against bacterial infectionsUsual Adult Dose for Lyme Disease - Erythema Chronicum MigransIDSA Recommendations:Immediate-release:Early Lyme disease: 500 mg orally once a day for 7 to 10 daysComment: Use should be reserved for patients who are intolerant or should not take amoxicillin, doxycycline, and cefuroxime axetil.Use: Alternative treatment for early Lyme diseaseUsual Adult Dose for BabesiosisIDSA Recommendations:Immediate-release: 500 to 1000 mg orally once on day 1, followed by 250 mg orally once a day for a total of 7 to 10 daysComments:-This drug should be taken in combination with atovaquone.-Immunocompromised patients may be given 600 to 1000 mg orally on day 1.Use: Treatment of babesiosisUsual Adult Dose for Bacterial Endocarditis ProphylaxisAHA and IDSA Recommendations:Immediate-release: 500 mg orally as a single dose 30 to 60 minutes prior to the procedureUse: Prevention of infective endocarditis in patients allergic to penicillins/ampicillinUsual Adult Dose for ToxoplasmosisNIH Recommendations:Immediate-release: 900 to 1200 mg orally once a day plus pyrimethamine and leucovorin-Duration of therapy: At least 6 weeks; longer treatment may be required if clinical/radiologic disease is extensive or response is incomplete at 6 weeksComments:-This drug is recommended as an alternative regimen.-Patients should continue chronic maintenance therapy once acute treatment is complete.Use: Treatment of Toxoplasma gondii encephalitisUsual Adult Dose for Campylobacter GastroenteritisNIH Recommendations:Immediate-release:Campylobacteriosis:-Mild to moderate disease: 500 mg orally once a day for 5 daysShigellosis:-Alternative therapy: 500 mg orally once a day for 5 daysComment: This drug should not be used to treat Shigella or Campylobacter bacteremia.Uses:-Treatment of gastroenteritis caused by Shigella infection-Treatment of mild to moderate campylobacteriosisUsual Adult Dose for ShigellosisNIH Recommendations:Immediate-release:Campylobacteriosis:-Mild to moderate disease: 500 mg orally once a day for 5 daysShigellosis:-Alternative therapy: 500 mg orally once a day for 5 daysComment: This drug should not be used to treat Shigella or Campylobacter bacteremia.Uses:-Treatment of gastroenteritis caused by Shigella infection-Treatment of mild to moderate campylobacteriosisUsual Adult Dose for Upper Respiratory Tract InfectionASBMT and IDSA Recommendations:Immediate-release:Bacterial infections within the first 100 days of HCT:-Alternative treatment: 250 mg orally once a dayUse: Prevention of bacterial infections for HCT patients with anticipated neutropenic periods of at least 7 daysUsual Adult Dose for Syphilis - EarlyNIH Recommendations:Immediate-release:-Alternative treatment: 2 g orally as a single doseComments:-This drug may be given to patients with penicillin allergies.-Use should be avoided in men who have sex with men or pregnant patients.Use: Alternative therapy for the treatment of early stage syphilis, including primary, secondary, and early latent stage syphilisUsual Pediatric Dose for Otitis Media6 months and older:Immediate-release: 30 mg/kg (maximum: 1500 mg/dose) orally as a single doseOR10 mg/kg (maximum: 500 mg/dose) orally once a day \00\00\00e Pulmonary Disease - AcuteImmediate-release: 500 mg orally once a day for 3 days OR 500 mg orally as a single dose on day 1, followed by 250 mg orally once a day on days 2 to 5Uses:-Mild to moderate acute bacterial exacerbations of COPD-Treatment of mild to moderate acute bacterial exacerbations of chronic bronchitis due to H influenzae, M catarrhalis, or S pneumoniaeUsual Adult Dose for BronchitisImmediate-release: 500 mg orally once a day for 3 days OR 500 mg orally as a single dose on day 1, followed by 250 mg orally once a day on days 2 to 5Uses:-Mild to moderate acute bacterial exacerbations of COPD-Treatment of mild to moderate acute bacterial exacerbations of chronic bronchitis due to H influenzae, M catarrhalis, or S pneumoniaeUsual Adult Dose for Mycobacterium avium-intracellulare - ProphylaxisImmediate-release:1200 mg orally once a weekComment: This drug may be given with rifabutin.Use: Prevention of disseminated Mycobacterium avium-intracellulare complex (MAC) diseaseNIH, IDSA, and ATS Recommendations:Immediate-release:Patients with AIDS and CD4 counts less than 50 cells/mcL:-Primary prophylaxis: 1200 mg orally once a week OR 600 mg orally 2 times a weekComment: Primary prophylaxis may be discontinued when the CD3 count is greater than 100 cells/mm3 for at least 3 months in response to antiretroviral therapy.Use: Preventing the first episode of disseminated MAC diseaseUsual Adult Dose for Mycobacterium avium-intracellulare - TreatmentImmediate-release:600 mg orally once a day plus ethambutolUse: Treatment of disseminated MAC infectionsNIH, IDSA, and ATS Recommendations:Immediate-release:-Initial treatment of nodular/bronchiectatic disease: 500 mg orally 3 times a week plus rifampin and ethambutol-Initial treatment of fibrocavitary MAC pulmonary or severe nodular/bronchiectatic disease: 250 mg orally once a day plus ethambutol and rifampin, with/without streptomycin or amikacin-Advanced/severe or previously treated MAC disease: 250 to 300 mg orally once a day plus ethambutol-Treatment of disseminated MAC disease: 250 mg orally once a day plus ethambutol---Some experts recommend: 500 to 600 mg orally once a day plus ethambutolComments:-Patients with severe/advanced disease should be treated until culture negative (e.g., 1 year).-Patients with disseminated MAC disease may discontinue treatment when symptoms resolve and cell-mediated immune function resumes.-Treatment of disseminated MAC disease is preferred when drug interactions/intolerance preclude use of clarithromycin.Use: Alternative treatment of MAC pulmonary diseaseUsual Adult Dose for Granuloma InguinaleUS CDC Recommendations:Immediate-release: 1 g orally once a week OR 500 mg orally once a day for at least 3 weeks and until all lesions have completely healedComments:-Patients diagnosed with granuloma inguinale should be tested for HIV.-Patients should be monitored until all signs/symptoms have resolved.-The patient's sexual partner(s) during the 60 days preceding the onset of symptoms should be evaluated and offered treatment.Use: Treatment of granuloma inguinale/donovanosis caused by Klebsiella granulomatisUsual Adult Dose for STD ProphylaxisUS CDC Recommendations:Immediate-release: 1 g orally once as a single dose, in conjunction with ceftriaxone plus (metronidazole or tinidazole)Use: Postexposure prophylaxis of sexually transmitted diseases in survivors of sexual assaultUsual Adult Dose for Pertussis ProphylaxisAmerican Society for Blood and Marrow Transplantation (ASBMT) and IDSA Recommendations:Immediate-release:Immunization against pertussis:-Alternative treatment: 250 mg orally once a dayPostexposure prophylaxis: 500 mg orally once on day 1, then 250 mg orally once a day for 4 daysComments:-Patients should receive the acellular pertussis vaccine after hematopoietic cell transplantation (HCT).-Treatment with this drug may be given to patients with an incomplete vaccination series.Uses:-Immunization against pertussis for adult recipients after HCT-Postexposur\00\00\00 as a single dose on day 1, followed by 250 mg orally once a day on days 2 to 5Use: Treatment of mild to moderate uncomplicated skin and skin structure infections due to Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus agalactiaeIDSA and NIH Recommendations:Immediate-release:Patients greater than 45 kg: 500 mg orally on day 1, then 250 mg orally once a day on days 2 through 5Patients less than 45 kg: 10 mg/kg orally on day 1, then 5 mg/kg orally once a day for 4 additional daysAlternative therapy for Bartonella infections (not endocarditis or central nervous system infections): 500 mg orally once a day for at least 3 monthsUses:-Treatment of bacillary angiomatosis and cat scratch disease-Alternative therapy for Bartonella infectionsUsual Adult Dose for Gonococcal Infection - UncomplicatedGonococcal urethritis and cervicitis:Immediate-release: 2 g orally onceUse: Treatment of mild to moderate urethritis and cervicitis due to Neisseria gonorrhoeaeUS Centers for Disease Control and Prevention (CDC) Recommendations:Immediate-release:-Recommended regimen: 1 g orally once as a single dose plus ceftriaxone-Alternative regimen: 1 g orally once as a single dose plus cefiximeComments:-The alternative regimen may be used for uncomplicated infections if ceftriaxone is unavailable.-Arthritis and arthritis-dermatitis syndrome may be treated with 1 g orally once plus cefotaxime OR ceftizoxime.Uses:-Uncomplicated gonococcal infections of the pharynx, cervix, urethra, and rectum-Treatment of gonococcal conjunctivitis-Treatment of arthritis and arthritis-dermatitis syndrome caused by disseminated gonococcal infection-Treatment of gonococcal meningitis and endocarditisUsual Adult Dose for Nongonococcal UrethritisNon-gonococcal urethritis and cervicitis:-Immediate-release: 1 g orally onceComment: A 1 g oral dose given once a week for 3 weeks may be effective in the treatment of lymphogranuloma venereum due to Chlamydia trachomatis.Uses:-Treatment of mild to moderate urethritis and cervicitis due to C trachomatis-Treatment of nongonococcal urethritis, cervicitis, and chlamydial infectionsUsual Adult Dose for Chlamydia InfectionNon-gonococcal urethritis and cervicitis:-Immediate-release: 1 g orally onceComment: A 1 g oral dose given once a week for 3 weeks may be effective in the treatment of lymphogranuloma venereum due to Chlamydia trachomatis.Uses:-Treatment of mild to moderate urethritis and cervicitis due to C trachomatis-Treatment of nongonococcal urethritis, cervicitis, and chlamydial infectionsUsual Adult Dose for CervicitisNon-gonococcal urethritis and cervicitis:-Immediate-release: 1 g orally onceComment: A 1 g oral dose given once a week for 3 weeks may be effective in the treatment of lymphogranuloma venereum due to Chlamydia trachomatis.Uses:-Treatment of mild to moderate urethritis and cervicitis due to C trachomatis-Treatment of nongonococcal urethritis, cervicitis, and chlamydial infectionsUsual Adult Dose for ChancroidImmediate-release: 1 g orally onceComments:-The efficacy of this drug in female patients with chancroid has not been established.-The patient's sexual partner(s) during the 10 days preceding the onset of symptoms should be evaluated/treated.-Patients should be tested for HIV infection when chancroid is diagnosed and a serologic test for HIV and syphilis should be performed 3 months after diagnosis in patients with negative initial HIV test results.Use: Treatment of genital ulcer disease in men due to Haemophilus ducreyi (chancroid)Usual Adult Dose for Pelvic Inflammatory Disease500 mg IV once a day for 1 or 2 days, followed by 250 mg (immediate-release formulation) orally once a day to complete a 7-day course of therapyComment: Antimicrobial drugs with anaerobic activity should be used concurrently if anaerobic microorganisms are suspected in contributing to the infection.Use: Treatment of pelvic inflammatory disease due to C trachomatis, N gonorrhoeae, or Mycoplasma hominisUsual Adult Dose for Chronic Obstructiv\00\00\00\00\00\00\81\81\DBc\00##\847\92\83\A0MAmoxicillinAmoxicillinAmoxicillin is used to treat a wide variety of bacterial infections. This medication is a penicillin-type antibiotic. It works by stopping the growth of bacteria.This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu).Get emergency medical help if you have any of these signs of an allergic reaction to amoxicillin: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.Call your doctor at once if you have:    diarrhea that is watery or bloody;    fever, swollen gums, painful mouth sores, pain when swallowing, skin sores, cold or flu symptoms, cough, trouble breathing;    swollen glands, rash or itching, joint pain, or general ill feeling;    pale or yellowed skin, yellowing of the eyes, dark colored urine, fever, confusion or weakness;    severe tingling, numbness, pain, muscle weakness;    easy bruising, unusual bleeding (nose, mouth, vagina, or rectum), purple or red pinpoint spots under your skin; or    severe skin reaction--fever, sore throat, swelling in your face or tongue, burning in your eyes, skin pain, followed by a red or purple skin rash that spreads (especially in the face or upper body) and causes blistering and peeling.Common amoxicillin side effects may include:    stomach pain, nausea, vomiting, diarrhea;    vaginal itching or discharge;    headache; or    swollen, black, or "hairy" tongue.The information is not a substitute for medical advice. Always consult your doctor or pharmacist.Usual Adult Dose for Bacterial Endocarditis ProphylaxisAmerican Heart Association (AHA) recommendations:-Immediate-release: 2 g orally as a single dose 30 to 60 minutes prior to procedureComments:-Prophylaxis should be used for patients at high risk of adverse outcomes from endocarditis with underlying cardiac conditions who undergo any dental procedure that involves manipulation of gingival tissue or periapical region of a tooth and for those procedures that perforate oral mucosa.-Prophylaxis should also be used for patients at high risk of adverse outcomes from endocarditis who undergo invasive respiratory tract procedures.-Current guidelines should be consulted for additional information.Usual Adult Dose for Chlamydia InfectionUS CDC recommendations: 500 mg orally 3 times a day for 7 days in pregnant patients as an alternative to azithromycinComments:-Women less than 25 years and those at an increased risk for chlamydia should be re-screened during the third trimester of pregnancy to prevent maternal postnatal complications and chlamydial infection in the infant.-Current guidelines should be consulted for additional information.Usual Adult Dose for Helicobacter pylori InfectionImmediate-release:-Dual Therapy: 1 g orally every 8 hours for 14 days in combination with lansoprazole-Triple Therapy: 1 g orally every 12 hours for 14 days in combination with clarithromycin and lansoprazoleComments: Refer to clarithromycin and lansoprazole for full prescribing information.Usual Adult Dose for Lyme Disease - ArthritisInfectious Diseases Society of America (IDSA) recommendations: 500 mg orally 3 times a day for 14 to 28 daysComments:-Duration of treatment depends upon severity of condition being treated.-Current guidelines should be consulted for additional information.Usual Adult Dose for Lyme Disease - CarditisInfectious Diseases Society of America (IDSA) recommendations: 500 mg orally 3 times a day for 14 to 28 daysComments:-Duration of treatment d\00\00\00W\A3R\00-\84C\8C\B6AtivanLorazepam (oral)This medication is used to treat anxiety. Lorazepam belongs to a class of drugs known as benzodiazepines which act on the brain and nerves (central nervous system) to produce a calming effect. This drug works by enhancing the effects of a certain natural chemical in the body (GABA).Get emergency medical help if you have signs of an allergic reaction to Ativan: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.Call your docto\00\00\00\00\00\00and peeling.Call your doctor right away if a baby taking azithromycin becomes irritable or vomits while eating or nursing.Older adults may be more likely to have side effects on heart rhythm, including a life-threatening fast heart rate.Common azithromycin side effects may include:    diarrhea;    nausea, vomiting, stomach pain; or    headache.The information is not a substitute for medical advice. Always consult your doctor or pharmacist.     Usual Adult Dose for Legionella PneumoniaCommunity-acquired pneumonia:Oral:-Immediate-release: 500 mg orally as a single dose on day 1, followed by 250 mg orally once a day on days 2 to 5-Extended-release: 2 g orally once as a single doseParenteral: 500 mg IV once a day as a single dose for at least 2 days, followed by 500 mg (immediate-release formulation) orally to complete a 7- to 10-day course of therapyComment: Extended-release formulations should be taken on an empty stomach.Uses:-Treatment of mild community acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy-Treatment of community-acquired pneumonia due to C pneumoniae, H influenzae, Legionella pneumophila, Moraxella catarrhalis, M pneumoniae, or S pneumoniae in patients who require initial IV therapyUsual Adult Dose for Mycoplasma PneumoniaCommunity-acquired pneumonia:Oral:-Immediate-release: 500 mg orally as a single dose on day 1, followed by 250 mg orally once a day on days 2 to 5-Extended-release: 2 g orally once as a single doseParenteral: 500 mg IV once a day as a single dose for at least 2 days, followed by 500 mg (immediate-release formulation) orally to complete a 7- to 10-day course of therapyComment: Extended-release formulations should be taken on an empty stomach.Uses:-Treatment of mild community acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy-Treatment of community-acquired pneumonia due to C pneumoniae, H influenzae, Legionella pneumophila, Moraxella catarrhalis, M pneumoniae, or S pneumoniae in patients who require initial IV therapyUsual Adult Dose for PneumoniaCommunity-acquired pneumonia:Oral:-Immediate-release: 500 mg orally as a single dose on day 1, followed by 250 mg orally once a day on days 2 to 5-Extended-release: 2 g orally once as a single doseParenteral: 500 mg IV once a day as a single dose for at least 2 days, followed by 500 mg (immediate-release formulation) orally to complete a 7- to 10-day course of therapyComment: Extended-release formulations should be taken on an empty stomach.Uses:-Treatment of mild community acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy-Treatment of community-acquired pneumonia due to C pneumoniae, H influenzae, Legionella pneumophila, Moraxella catarrhalis, M pneumoniae, or S pneumoniae in patients who require initial IV therapyUsual Adult Dose for Tonsillitis/PharyngitisImmediate-release: 500 mg orally as a single dose on day 1, followed by 250 mg orally once a day on days 2 to 5Use: Treatment of pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in patients who cannot use first-line therapyIDSA Recommendations:Immediate-release:Individuals with penicillin allergy: 12 mg/kg orally once a day-Maximum dose: 500 mg/day-Duration of therapy: 5 daysUse: Treatment of Group A streptococcal pharyngitisUsual Adult Dose for SinusitisImmediate-release: 500 mg orally once a day for 3 daysExtended-release: 2 g orally once as a single doseComment: Extended-release formulations should be taken on an empty stomach.Use: Treatment of mild to moderate acute bacterial sinusitis due to H influenzae, M catarrhalis, or S pneumoniaeUsual Adult Dose for Skin and Structure InfectionImmediate-release: 500 mg orally\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\98~\00%%\84?\8Ew\9EAtorvastatinAtorvastatinAtorvastatin is used along with a proper diet to help lower "bad" cholesterol and fats (such as LDL, triglycerides) and raise "good" cholesterol (HDL) in the blood. It belongs to a group of drugs known as "statins." It works by reducing the amount of cholesterol made by the liver.Get emergency medical help if you have signs of an allergic reaction to atorvastatin: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.In rare cases, atorvastatin can cause a condition that results in the breakdown of skeletal muscle tissue, leading to kidney failure. Call your doctor right away if you have unexplained muscle pain, tenderness, or weakness especially if you also have fever, unusual tiredness, and dark colored urine.Also call your doctor at once if you have:    pain or burning when you urinate;    liver problems - upper stomach pain, weakness, tired feeling, loss of appetite, dark urine, jaundice (yellowing of the skin or eyes); or    kidney problems - little or no urinating, swelling in your feet or ankles, feeling tired or short of breath.Common atorvastatin side effects may include:    joint pain;    stuffy nose, sore throat;    diarrhea; or    pain in your arms or legs.The information is not a substitute for medical advice. Always consult your doctor or pharmacist.Usual Adult Dose for Prevention of Cardiovascular Disease:Initial dose: 10 mg to 80 mg orally once a day.The initial dosage recommended for the prevention of cardiovascular disease is 10 mg to 80 mg orally once a day. The dose may be administered at any time of the day without regard for meals.Dose adjustments should be made at intervals of 2 to 4 weeks.Studies have demonstrated that treatment with atorvastatin is associated with significant reductions in the risk of cardiovascular endpoints and stroke in various patient populations for both primary and secondary prevention.For primary prevention, atorvastatin treatment was effective in hypertensive patients with normal or mildly elevated cholesterol levels as well as in patients with type II diabetes. Patients had relatively low cholesterol levels at baseline in both trials; however, treatment with this medicine still resulted in significant reductions in cardiovascular outcomes and stroke.For secondary prevention, intensive lipid lowering therapy with doses of 80 mg/day were associated with significant incremental clinical benefit beyond therapy with 10 mg/day in patients with stable coronary heart disease. It was also shown to significantly reduce the risk of clinical outcomes in coronary heart disease patients versus usual medical care.Usual Adult Dose for Hyperlipidemia:Initial dose: 10, 20 or 40 mg orally once a day. The 40 mg starting dose is recommended for patients who require a reduction in LDL-cholesterol of more than 45%.Dose adjustments should be made at intervals of 2 to 4 weeks.Maintenance dose: 10 to 80 mg orally once a day.Usual Pediatric Dose for Heterozygous Familial Hypercholesterolemia:10 to 17 years:10 mg per day (max dose is 20 mg per day). Adjustments should be made at intervals of 4 weeks or more.Lipitor\00\00\00\00n\00z\00n\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\AE\00/\84\8AS\CC+QBactrobanMupirocin topicalMupirocin is an antibiotic. Mupirocin topical prevents bacteria from growing on your skin. Mupirocin topical is used to treat infections of the skin such as impetigo. Mupirocin topical may also be used for purposes other than those listed in this medication guide.Get emergency medical help if you have signs of an allergic reaction to Bactroban: hives; dizziness, fast or pounding heartbeats; wheezing, difficult breathing; swelling of your face, lips, tongue, or throat.Call your doctor at once if you have:    severe stomach pain, diarrhea that is watery or bloody;    severe itching, rash, or other irritation of treated skin;    unusual skin blistering or peeling; or    any signs of a new skin infection.Common Bactroban side effects may include:    burning, stinging;    itching; or    pain.This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.The information is not a substitute for medical advice. Always consult your doctor or pharmacist.Usual Adult Dose for Secondary Cutaneous Bacterial InfectionsTopical cream: Apply a small amount to the affected area 3 times a day for 10 days.Use: For the treatment of secondarily infected traumatic skin lesions (up to 10 cm in length or 100 cm2 in area) due to susceptible strains of Staphylococcus aureus and Streptococcus pyogenesUsual Adult Dose for Nasal Carriage of Staphylococcus aureusNasal ointment: Apply about one-half of the tube contents into 1 nostril and the other half into the other nostril twice a day (morning and evening).Duration of therapy: 5 daysUse: For the eradication of nasal colonization with methicillin-resistant S aureus (MRSA) in patients and healthcare workers as part of a comp\00\00\00\91\00O\84g\94\87yaBactrimSulfamethoxazole and trimethoprimThis medication is a combination of two antibiotics: sulfamethoxazole and trimethoprim. It is used to treat a wide variety of bacterial infections (such as middle ear, urine, respiratory, and intestinal infections). It is also used to prevent and treat a certain type of pneumonia (pneumocystis-type).Get emergency medical help if you have any of these signs of an allergic reaction to Bactrim: hives; difficult breathing; swelling of your face, lips, tongue, or throat.Call your doctor at once if you have:    diarrhea that is watery or bloody;    pale skin, feeling light-headed or short of breath, rapid heart rate, trouble concentrating;    sudden weakness or ill feeling, fever, chills, sore throat, new or worsening cough;    cold or flu symptoms, swollen gums, painful mouth sores, pain when swallowing, skin sores;    low levels of sodium in the body--headache, confusion, slurred speech, severe weakness, vomiting, loss of coordination, feeling unsteady;    liver problems--upper stomach pain, tired feeling, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes); or    severe skin reaction--fever, sore throat, swelling in your face or tongue, burning in your eyes, skin pain, followed by a red or purple skin rash that spreads (especially in the face or upper body) and causes blistering and peeling.Common Bactrim side effects may include:    nausea, vomiting, loss of appetite; or    mild itching or rash.This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. The information is not a substitute for medical advice. Always consult your doctor or pharmacist.Bactrim tablets are white and round and contain 80 milligrams (mg) of trimethoprim and 400 mg of sulfamethoxazole.Bactrim DS tablets are white and oval, containing 160 mg of trimethoprim and 800 mg of sulfamethoxazole.Take the medication as directed by your doctor until you finish the prescription, even if you feel better.Failure to do so may help create bacteria that are resistant to treatment.Bactrim, Bactrim DS, Septra DS, SMZ-TMP DS\00\00\00\00e recommended starting dose for Effexor is 75 mg/day, administered in two or three divided doses, taken with food. Depending on tolerability and the need for further clinical effect, the dose may be increased to 150 mg/day. If needed, the dose should be further increased up to 225 mg/day. When increasing the dose, increments of up to 75 mg/day should be made at intervals of no less than 4 days. In outpatient settings there was no evidence of usefulness of doses greater than 225 mg/day for moderately depressed patients, but more severely depressed inpatients responded to a mean dose of 350 mg/day. Certain patients, including more severely depressed patients, may therefore respond more to higher doses, up to a maximum of 375 mg/day, generally in three divided doses (see PRECAUTIONS, General, Use in Patients with Concomitant Illness).Special PopulationsTreatment of Pregnant Women During the Third TrimesterNeonates exposed to Effexor, other SNRIs, or SSRIs, late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding (see PRECAUTIONS). When treating pregnant women with Effexor during the third trimester, the physician should carefully consider the potential risks and benefits of treatment. The physician may consider tapering Effexor in the third trimester.Dosage for Patients with Hepatic ImpairmentGiven the decrease in clearance and increase in elimination half-life for both venlafaxine and ODV that is observed in patients with hepatic cirrhosis and mild and moderate hepatic impairment compared to normal subjects (see CLINICAL PHARMACOLOGY), it is recommended that the total daily dose be reduced by 50% in patients with mild to moderate hepatic impairment. Since there was much individual variability in clearance between subjects with cirrhosis, it may be necessary to reduce the dose even more than 50%, and individualization of dosing may be desirable in some patients.Dosage for Patients with Renal ImpairmentGiven the decrease in clearance for venlafaxine and the increase in elimination half-life for both venlafaxine and ODV that is observed in patients with renal impairment (GFR = 10 to 70 mL/min) compared to normals (see CLINICAL PHARMACOLOGY), it is recommended that the total daily dose be reduced by 25% in patients with mild to moderate renal impairment. It is recommended that the total daily dose be reduced by 50% in patients undergoing hemodialysis. Since there was much individual variability in clearance between patients with renal impairment, individualization of dosing may be desirable in some patients.Dosage for Elderly PatientsNo dose adjustment is recommended for elderly patients on the basis of age. As with any antidepressant, however, caution should be exercised in treating the elderly. When individualizing the dosage, extra care should be taken when increasing the dose.Maintenance TreatmentIt is generally agreed that acute episodes of major depressive disorder require several months or longer of sustained pharmacological therapy beyond response to the acute episode. In one study, in which patients responding during 8 weeks of acute treatment with Effexor XR were assigned randomly to placebo or to the same dose of Effexor XR (75, 150, or 225 mg/day, qAM) during 26 weeks of maintenance treatment as they had received during the acute stabilization phase, longer-term efficacy was demonstrated. A second longer-term study has demonstrated the efficacy of Effexor in maintaining an antidepressant response in patients with recurrent depression who had responded and continued to be improved during an initial 26 weeks of treatment and were then randomly assigned to placebo or Effexor for periods of up to 52 weeks on the same dose (100 to 200 mg/day, on a b.i.d. schedule) (see CLINICAL TRIALS). Based on these limited data, it is not known whether or not the dose of Effexor/Effexor XR needed for maintenance treatment is identical to the dose needed to achieve an initial response. Patients should be periodically reassEffexor XR, Effexor\00\00\00c\00c\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\95\00\84G\89!\9C/EffientPrasugrelPrasugrel is used with aspirin by patients with heart disease (recent heart attack, unstable angina) who undergo a certain heart procedure (angioplasty). This medication helps to prevent other serious heart/blood vessel problems (such as heart attacks, strokes, blood clots in stents).Check with your doctor immediately if any of the following side effects occur while taking prasugrel:More common    Blurred vision    dizziness    headache    nervousness    pounding in the ears    slow or fast heartbeatLess common    Black, tarry stools    bloating or swelling of the face, arms, hands, lower legs, or feet    chest pain or discomfort    chills    cough    difficult or labored breathing    fainting    fever    irregular heartbeat    lightheadedness, dizziness, or fainting    painful or difficult urination    rapid weight gain    sore throatThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.nitiate Effient treatment as a single 60-mg oral loading dose and then continue at 10-mg orally once daily. Patients taking Effient should also take aspirin (75-mg to 325-mg) daily. Effient may be administered with or without food.Timing of Loading DoseIn the clinical trial that established the efficacy and safety of Effient, the loading dose of Effient was not administered until coronary anatomy was established in UA/NSTEMI patients and in STEMI patients presenting more than 12 hours after symptom onset. In STEMI patients presenting within 12 hours of symptom onset, the loading dose of Effient was administered at the time of diagnosis, although most received Effient at the time of PCI . For the small fraction of patients that required urgent CABG after treatment with Effient, the risk of significant bleeding was substantial.Although it is generally recommended that antiplatelet therapy be administered promptly in the management of ACS because many cardiovascular events occur within hours of initial presentation, in a trial of 4033 NSTEMI patients, no clear benefit was observed when Effient loading dose was administered prior to diagnostic coronary angiography compared to at the time of PCI; however, risk of bleeding was increased with early administration in patients undergoing PCI or early CABG.Dosing in Low Weight PatientsCompared to patients weighing â‰¥60 kg, patients weighing <60 kg have an increased exposure to the active metabolite of prasugrel and an increased risk of bleeding on a 10-mg once daily maintenance dose. Consider lowering the maintenance dose to 5-mg in patients <60 kg. The effectiveness and safety of the 5-mg dose have not been prospectively studied.Effient\00\00\00\00o 9 mg orally per dayParenteral:-Initial dose: 0.5 mg to 9 mg IV or IM per day in divided doses every 12 hoursMaintenance dose: After a favorable initial response, dose should be decreased in small amounts to the lowest dose that maintains an adequate clinical response; if a positive response is not achieved after a reasonable period of time, alternative therapy should be sought.Comments:-Lower doses, including doses lower than recommended doses, may suffice in less severe disease; doses in excess of recommended doses may be required in severe disease; in life-threatening situations, doses exceeding multiples of the oral dose may be justified.-When oral therapy is not feasible IV or IM therapy in doses ranging from one-third to one-half the oral dose may be given every 12 hours.-Patients should be closely monitored for signs requiring dose adjustments; if therapy is to be stopped after more than a few days, it should be gradually withdrawn.Uses: For use as a potent anti-inflammatory agent in managing disorders, diseases, and conditions affecting many organ systems including endocrine, dermatologic, ophthalmic, nervous. gastrointestinal, respiratory, musculoskeletal, and hematologic.Usual Adult Dose for ImmunosuppressionDosing should be individualized on the basis of disease and patient responseOral:-Initial dose: 0.75 mg to 9 mg orally per dayParenteral:-Initial dose: 0.5 mg to 9 mg IV or IM per day in divided doses every 12 hoursMaintenance dose: After a favorable initial response, dose should be decreased in small amounts to the lowest dose that maintains an adequate clinical response; if a positive response is not achieved after a reasonable period of time, alternative therapy should be sought.Comments:-Lower doses, including doses lower than recommended doses, may suffice in less severe disease; doses in excess of recommended doses may be required in severe disease; in life-threatening situations, doses exceeding multiples of the oral dose may be justified.-When oral therapy is not feasible IV or IM therapy in doses ranging from one-third to one-half the oral dose may be given every 12 hours.-Patients should be closely monitored for signs requiring dose adjustments; if therapy is to be stopped after more than a few days, it should be gradually withdrawn.Uses: For use as a potent anti-inflammatory agent in managing disorders, diseases, and conditions affecting many organ systems including endocrine, dermatologic, ophthalmic, nervous. gastrointestinal, respiratory, musculoskeletal, and hematologic.Usual Adult Dose for Brain/Intracranial Tumor2 mg oral/IV/IM 2 to 3 times a dayUse: For palliative management of recurrent or inoperable brain tumors.Usual Adult Dose for Allergic ReactionFirst day: 4 to 8 mg IM onceSecond and third day: 1.5 mg orally twice per dayFourth day: 0.75 mg orally twice per dayFifth and sixth day: 0.75 mg orally once a daySeventh day: No treatmentEighth day: ReassessmentComments: This dosing schedule is designed to ensure adequate therapy during an acute episode while minimizing the risk of overdose in chronic cases.Use: For the treatment of acute, self-limited allergic disorder or exacerbation of chronic allergic disorder.Usual Adult Dose for BursitisSuggested doses:Large joints: 2 to 4 mgSmall joints: 0.8 to 1 mgBursae: 2 to 4 mgTendon Sheaths: 0.4 to 1 mgInjections may be repeated from once every 3 to 5 days to once every 2 to 3 weeksComments:-Dose will vary according to the degree of inflammation and the size and location of the affected site.-Intrasynovial and soft tissue injections should be limited to 1 or 2 sites; frequent intra-articular injections may cause damage to joint tissue.Use: As adjunctive therapy for an acute episode or exacerbation of synovitis of osteoarthritis, rheumatoid arthritis, acute and subacute bursitis, acute gouty arthritis, epicondylitis, acute nonspecific tenosynovitis, and posttraumatic osteoarthritis.Baycadron, Dexamethasone Intensol, DexPak 10 Day Taperpak, DexPak 13 DayTaperpak, DexPak 6 DayTaperpak\00\00\00\00rehensive infection control program to reduce risk of MRSA infection among high-risk patients during institutional outbreaks of MRSA infectionsUsual Adult Dose for ImpetigoTopical ointment: Apply a small amount to the affected area 3 times a day.Use: For the topical treatment of impetigo due to S aureus and S pyogenesUsual Pediatric Dose for Secondary Cutaneous Bacterial Infections3 months or older:Topical cream: Apply a small amount to the affected area 3 times a day for 10 days.Use: For the treatment of secondarily infected traumatic skin lesions (up to 10 cm in length or 100 cm2 in area) due to susceptible strains of S aureus and S pyogenesUsual Pediatric Dose for Nasal Carriage of Staphylococcus aureus12 years or older:Nasal ointment: Apply about one-half of the tube contents into 1 nostril and the other half into the other nostril twice a day (morning and evening).Duration of therapy: 5 daysUse: For the eradication of nasal colonization with MRSA in patients and healthcare workers as part of a comprehensive infection control program to reduce risk of MRSA infection among high-risk patients during institutional outbreaks of MRSA infectionsUsual Pediatric Dose for Impetigo2 months or older:Topical ointment: Apply a small amount to the affected area 3 times a day.Use: For the topical treatment of impetigo due to S aureus and S pyogenesRenal Dose AdjustmentsData not availableComments:-The polyethylene glycol-based ointment formulation should not be used in conditions where large amounts of polyethylene glycol may be absorbed, especially in patients with moderate or severe renal dysfunction.Liver Dose AdjustmentsData not availablePrecautionsSafety and efficacy have not been established in patients younger than 2 months (topical ointment), 3 months (topical cream), or 12 years (nasal ointment).Consult WARNINGS section for additional precautions.DialysisData not availableOther CommentsAdministration advice:-Nasal ointment: After application (to spread drug throughout the nares), close nostrils by pressing together and release the sides of the nose repeatedly for about 1 minute; do not apply this product concomitantly with other intranasal products.-Topical cream and ointment: For external use only; may cover treated area by gauze dressing if desired-Do not use the polyethylene glycol-based ointment formulation in conditions where large amounts of polyethylene glycol may be absorbed.Storage requirements:-Nasal ointment: Store at 20C to 25C (68F to 77F); excursions permitted to 15C to 30C (59F to 86F); do not refrigerate.-Topical cream: Store at or below 25C (77F); do not freeze.-Topical ointment: Store at 20C to 25C (68F to 77F).General:-Limitations of use (nasal ointment): Data insufficient to establish safety and efficacy of this product as part of an intervention program to prevent autoinfection of high-risk patients from their own nasal carriage of S aureus; data insufficient to recommend use of this product for general prophylaxis of any infection in any patient population-Nasal ointment: The single-use tube will deliver about 0.25 g of the product per nostril.-Topical cream and ointment: If clinical response is not seen within 3 to 5 days, patients should be reevaluated.Patient advice:-Avoid contact of this drug with the eyes; if it gets in or near the eyes, rinse thoroughly with water.-Stop this drug and consult healthcare provider if sensitization or severe local irritation occurs while using the nasal ointment, or if irritation, severe itching, or rash occurs while using the topical cream or ointment.-Nasal ointment: Wash hands before and after applying this drug; after application, press the sides of the nose together and gently massage to spread the drug throughout the inside of the nostrils. Avoid missing doses and complete the entire course of therapy. Consult the Patient Information Leaflet for additional information.-Topical cream and ointment: Contact healthcare provider if no improvement seen in 3 to 5 days.Bactroban, Centany, Centany AT Kit\00\00\00\00f the elderly who are unable to tolerate more potent agents-Mild cases of parkinsonism in other age groups-Other cases of parkinsonism in combination with centrally acting anticholinergic agentsUsual Adult Dose for InsomniaDiphenhydramine Citrate: 76 mg orally once a day at bedtimeDiphenhydramine Hydrochloride: 50 mg orally once a day at bedtimeComment:-Patients should contact their healthcare provider if symptoms of insomnia persist for more than 2 weeks while receiving treatment.Uses:-As a nighttime sleep aid-To reduce difficulty falling asleep-Relief of occasional sleeplessnessUsual Adult Dose for Motion SicknessOral:-Prescription formulations: 25 to 50 mg orally 3 to 4 times a day, with the first dose given 30 minutes before exposure to motion and repeated before meals and upon retiring throughout the duration of the journey.Parenteral: 10 to 50 mg deep IM or IV as needed, and may increase to 100 mg if required-Maximum dose: 400 mg/dayComment:-IV injection rates should not exceed 25 mg/min.Use:-Active and prophylactic treatment of motion sicknessUsual Pediatric Dose for Allergic RhinitisPrescription formulations:1 month and older:Oral: 12.5 to 25 mg orally 3 to 4 times a day; alternatively, weight-based dosing of 5 mg/kg orally per day OR body surface area dosing of 150 mg/m2 orally per day may be used-Maximum dose: 300 mg/dayParenteral: 1.25 mg/kg deep IM or IV 4 times a day OR 37.5 mg/m2 deep IM or IV 4 times a day-Maximum dose: 300 mg/dayOral Over-the-Counter (OTC) formulations:Diphenhydramine Citrate:6 to 12 years: 19 to 38 mg orally every 4 to 6 hours as needed-Maximum dose: 228 mg/day12 years and older: 38 to 76 mg orally every 4 to 6 hours as needed-Maximum dose: 456 mg/dayDiphenhydramine Hydrochloride:2 to 6 years: 6.25 mg orally every 4 to 6 hours as needed-Maximum dose: 37.5 mg/day6 to 12 years: 12.5 to 25 mg orally every 4 to 6 hours as needed-Maximum dose: 150 mg/day12 years and older: 25 to 50 mg orally every 4 to 6 hours as needed-Maximum dose: 300 mg/dayComments:-IV injection rates should not exceed 25 mg/min.-To prevent motion sickness, the first dose should be given 30 minutes before exposure to motion and should be repeated before meals and upon retiring throughout the duration of the journey.Uses:-Active and prophylactic treatment of motion sickness-Temporary relief of runny nose, itchy, watery eyes, sneezing, and itching of the nose/throat due to hay fever or other upper respiratory allergies-Temporarily relieves runny nose and sneezing due to the common coldUsual Pediatric Dose for Cold SymptomsPrescription formulations:1 month and older:Oral: 12.5 to 25 mg orally 3 to 4 times a day; alternatively, weight-based dosing of 5 mg/kg orally per day OR body surface area dosing of 150 mg/m2 orally per day may be used-Maximum dose: 300 mg/dayParenteral: 1.25 mg/kg deep IM or IV 4 times a day OR 37.5 mg/m2 deep IM or IV 4 times a day-Maximum dose: 300 mg/dayOral Over-the-Counter (OTC) formulations:Diphenhydramine Citrate:6 to 12 years: 19 to 38 mg orally every 4 to 6 hours as needed-Maximum dose: 228 mg/day12 years and older: 38 to 76 mg orally every 4 to 6 hours as needed-Maximum dose: 456 mg/dayDiphenhydramine Hydrochloride:2 to 6 years: 6.25 mg orally every 4 to 6 hours as needed-Maximum dose: 37.5 mg/day6 to 12 years: 12.5 to 25 mg orally every 4 to 6 hours as needed-Maximum dose: 150 mg/day12 years and older: 25 to 50 mg orally every 4 to 6 hours as needed-Maximum dose: 300 mg/dayComments:-IV injection rates should not exceed 25 mg/min.-To prevent motion sickness, the first dose should be given 30 minutes before exposure to motion and should be repeated before meals and upon retiring throughout the duration of the journey.Uses:-Active and prophylactic treatment of motion sickness-Temporary relief of runny nose, itchy, watery eyes, sneezing, and itching of the nose/throat due to hay fever or other upper respiratory allergies-Temporarily relieves runny nose and sneezing due to the common coldBenadryl\00\00\00\00=\00\00=\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\9F@\00%%\8D+\8D]\A1w\81mErythromycinErythromycinErythromycin is used to treat certain infections caused by bacteria, such as infections of the respiratory tract, including bronchitis, pneumonia, Legionnaires' disease (a type of lung infection), and pertussis (whooping cough; a serious infection that can cause severe coughing); diphtheria (a serious infection in the throat); sexually transmitted diseases (STD), including syphilis; and ear, intestine, gynecological, urinary tract, and skin infections. It also is used to prevent recurrent rheumatic fever. Erythromycin is in a class of medications called macrolide antibiotics. It works by stopping the growth of bacteria.Antibiotics such as erythromycin will not work for colds, flu, or other viral infections. Taking antibiotics when they are not needed increases your risk of getting an infection later that resists antibiotic treatment. Check with your doctor immediately if any of the following side effects occur while taking erythromycin:Rare    Blistering, peeling, or loosening of the skin    chills    cough    diarrhea    difficulty with swallowing    dizziness    fast heartbeat    hives or welts    joint or muscle pain    puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue    red, irritated eyes    red skin lesions, often with a purple center    redness of the skin    skin rash    sore throat    sores, ulcers, or white spots in the mouth or on the lips    tightness in the chest    unusual tiredness or weakness    wheezingIncidence not known    Abdominal or stomach cramps or tenderness    bloating    bloody or cloudy urine    chest pain or discomfort    dark urine    diarrhea, watery and severe, which may also be bloody    faintingThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.Usual Adult Dose for Campylobacter GastroenteritisMild to moderate infection: 250 to 500 mg (base, estolate, stearate) or 400 to 800 mg (ethylsuccinate) orally every 6 hours.Severe infection: 1 to 4 g/day IV in divided doses every 6 hours or by continuous infusion.Usual Adult Dose for ChancroidMild to moderate infection: 250 to 500 mg (base, estolate, stearate) or 400 to 800 mg (ethylsuccinate) orally every 6 hours.Severe infection: 1 to 4 g/day IV in divided doses every 6 hours or by continuous infusion.Usual Adult Dose for Lymphogranuloma VenereumMild to moderate infection: 250 to 500 mg (base, estolate, stearate) or 400 to 800 mg (ethylsuccinate) orally every 6 hours.Severe infection: 1 to 4 g/day IV in divided doses every 6 hours or by continuous infusion.Usual Adult Dose for Mycoplasma PneumoniaMild to moderate infection: 250 to 500 mg (base, estolate, stearate) or 400 to 800 mg (ethylsuccinate) orally every 6 hours.Severe infection: 1 to 4 g/day IV in divided doses every 6 hours or by continuous infusion.Usual Adult Dose for Nongonococcal UrethritisMild to moderate infection: 250 to 500 mg (base, estolate, stearate) or 400 to 800 mg (ethylsuccinate) orally every 6 hours.Severe infection: 1 to 4 g/day IV in divided doses every 6 hours or by continuous infusion.Usual Adult Dose for Otitis MediaMild to moderate infection: 250 to 500 mg (base, estolate, stearate) or 400 to 800 mg (ethylsuccinate) orally every 6 hours.Severe infection: 1 to 4 g/day IV in divided doses every 6 hours or by continuous infusion.Usual Adult Dose for PharyngitisMild to moderate infection: 250 to 500 mg (base, estolate, stearate) or 400 to 800 mg (ethylsuccinate) orally every 6 hours.Severe infection: 1 to 4 g/day IV in divided doses every 6 hours or by continuous infusion.Usual Adult Dose for PneumoniaMild to moderate infection: 250 to 500 mg (base, estolate, stearate) or 400 to 800 mg (ethylsuccinate) orally every 6 hours.Severe infection: 1 to 4 g/day IV in divided doses every 6 hours or by continuous infusion.E.E.S. Granules, E.E.S.-400 Filmtab, EryPed 200, EryPed 400, Ery-Tab, Erythrocin Stearate Filmtab, PCE Dispertab\00\00\00\00AL:2 to 10 mg orally 2 to 4 times a dayPARENTERAL:Moderate Anxiety Disorders and Symptoms: 2 to 5 mg IM or IV, repeated in 3 to 4 hours if necessarySevere Anxiety Disorders and Symptoms: 5 to 10 mg IM or IV, repeated in 3 to 4 hours if necessaryComments:-Oral doses should be determined by the severity of symptoms.-Anxiety associated with the stress of everyday life usually does not require treatment with this drug.Use: Management of anxiety disorders and short-term relief of anxiety symptomsUsual Adult Dose for Alcohol WithdrawalORAL:-Initial dose: 10 mg orally 3 to 4 times a day for the first 24 hours-Maintenance dose: 5 mg orally 3 to 4 times a day as neededPARENTERAL:10 mg IM or IV once, then 5 to 10 mg IM or IV in 3 to 4 hours if necessaryUse: Symptomatic relief of acute agitation, tremor, impending/acute delirium tremens, and hallucinations in acute alcohol withdrawalUsual Adult Dose for Muscle SpasmORAL:2 to 10 mg orally 3 to 4 times a dayPARENTERAL:5 to 10 mg IM or IV, then 5 to 10 mg IM or IV in 3 to 4 hours if necessaryComment:-Larger parenteral doses may be necessary for patients with tetanus.Use: Adjunctive treatment for the relief of skeletal muscle spasm due to reflex spasm to local pathology, spasticity caused by upper motor neuron disorders, athetosis, and stiff-man syndrome (e.g., inflammation of the muscles/joints secondary to trauma, cerebral palsy, paraplegia)Usual Adult Dose for SeizuresORAL:2 to 10 mg orally 2 to 4 times a dayRECTAL:-Initial dose: 0.2 mg/kg rectally, rounded upward to the next available dose. A 2.5 mg rectal dose may be given as a partial replacement if patients expel a portion of the initial dose-If necessary, a second dose of 0.2 mg/kg may be given rectally 4 to 12 hours after the first dose.-Maximum Frequency: May be used to treat up to 1 seizure episode every 5 days, and no more than 5 episodes/monthUses:-Management of selected, refractory patients with epilepsy on stable regimens of antiepileptic drugs who require intermittent use of this drug to control bouts of increased seizure activity-Adjunctive treatment for convulsive disordersUsual Adult Dose for Endoscopy or Radiology PremedicationPARENTERAL:Cardioversion: 5 to 15 mg IV once 5 to 10 minutes before the procedureEndoscopic Procedures:IV: Usually less than 10 mg, but some patients require up to 20 mg IV, especially when narcotics are omitted-IV titration: The IV dose should be titrated to desired sedative response (e.g., slurring of speech) with slow administration immediately before the procedure.IM: 5 to 10 mg IM once 30 minutes prior to the procedureComments:-Narcotic dosing should be reduced by approximately 33%, and may be omitted in some patients.-The IV route is preferred, but IM administration may be used if IV administration is not possible.Uses:-Adjunct prior to endoscopic procedures if apprehension, anxiety, or acute stress reactions are present and to diminish recall of the procedures-Prior to cardioversion for the relief of anxiety and tension and to diminish the patient's recall of the procedureUsual Adult Dose for Status EpilepticusPARENTERAL:-Initial dose: 5 to 10 mg IV once, repeated at 10 to 15 minute intervals to a maximum dose of 30 mg if necessaryComments:-The IV route is preferred; however, the IM route may be used if IV administration is impossible.-Treatment may be repeated every 2 to 4 hours, but active metabolites may persist during readministration.-Patients with chronic lung disease or unstable cardiovascular conditions should be given this drug with extreme caution.Use: Adjunct to status epilepticus and severe recurrent convulsive seizuresUsual Adult Dose for Light AnesthesiaPARENTERAL:Preoperative Medication: 10 mg IM once before surgeryComments:-The IM route is preferred when given as a preoperative medication.-Atropine, scopolamine, and other premedications should be administered in separate syringes.Use: Premedication for the relief of anxiety and tension in patients undergoing surgical proceduresValium\00\00\00\00I\00\D8\DF\00I\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\EF\00'5\84c\A2g\81\B5SCCiprofloxacinCiprofloxacin (oral)This medication is used to treat a variety of bacterial infections. Ciprofloxacin belongs to a class of drugs called quinolone antibiotics. It works by stopping the growth of bacteria.This antibiotic treats only bacterial infections. It will not work for virus infections (such as common cold, flu).Get emergency medical help if you have signs of an allergic reaction to ciprofloxacin: hives, or the first sign of a skin rash; fast heartbeat, difficult breathing; swelling of your face, lips, tongue, or throat.Ciprofloxacin may cause your tendons to swell or cause tendon rupture. It can also have serious effects on your nerves, and may cause permanent nerve damage. Stop using this medicine and call your doctor at once if you have:    signs of tendon rupture - sudden pain, swelling, bruising, tenderness, stiffness, movement problems, or a snapping or popping sound in any of your joints (rest the joint until you receive medical care or instructions); or    nerve symptoms - numbness, tingling, burning pain, or being more sensitive to temperature, light touch, or the sense of your body position.Also, stop using this medicine and call your doctor at once if you have:    severe stomach pain, diarrhea that is watery or bloody;    a headache with chest pain and severe dizziness and fast or pounding heartbeats;    the first sign of any skin rash, no matter how mild;    confusion, hallucinations, nightmares, paranoia, depression, thoughts about hurting yourself;    muscle weakness or trouble breathing;    ongoing headaches (sometimes with blurred vision);    tremors, anxiety, trouble sleeping, feeling restless or nervous;    a light-headed feeling, like you might pass out;    increased pressure inside the skull - severe headaches, ringing in your ears, dizziness, vision problems, pain behind your eyes;    liver problems - nausea, vomiting, loss \00\00\00'\81\85a\00\82]\89s\81\FDq}BaclofenBaclofenBaclofen is used to treat muscle spasms caused by certain conditions (such as multiple sclerosis, spinal cord injury/disease). It works by helping to relax the muscles.Get emergency medical help if you have signs of an allergic reaction to baclofen: hives; difficult breathing; swelling of your face, lips, tongue, or throat.Call your doctor at once if you have:    weak or shallow breathing;    confusion, hallucinations; or    a seizure (convulsions).Common baclofen side effects may include:    drowsiness, dizziness, weakness, tired feeling;    headache;    sleep problems (insomnia);    nausea, constipation; or    urinating more often than usual.This is not a complete list of side effects and oth\00\00\00!\82\8A\00\00%%\83U\96	\83\F8\82AzithromycinAzithromycinAzithromycin is used to treat a wide variety of bacterial infections. It is a macrolide-type antibiotic. It works by stopping the growth of bacteria. This medication will not work for viral infections (such as common cold, flu).Get emergency medical help if you have signs of an allergic reaction to azithromycin: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.In rare cases, azithromycin may cause a severe skin reaction that can be fatal if it spreads to other parts of the body. Seek medical treatment if you have a new or worsening skin rash with fever, swollen glands, flu symptoms, or severe tingling or numbness.Call your doctor at once if you have:    severe stomach pain, diarrhea that is watery or bloody;    headache with chest pain and severe dizziness, fainting, fast or pounding heartbeats;    liver problems - nausea, upper stomach pain, itching, tired feeling, loss of appetite, dark urine, clay-colored stools, jaundice                   yellowing of the skin or eyes); or    severe skin reaction - fever, sore throat, swelling in your face or tongue, burning in your eyes, skin pain or swelling, pus-filled   pimples, red or purple skin rash that spreads (especially in the face or upper body) and causes blistering \00\00\00\00\00\00\00ation    black, tarry stools    bleeding gums    blood in urine or stools    blurred vision    burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings    change in consciousness    changes in patterns and rhythms of speech    chest pain or discomfort    chills    cold sweats    coma    confusion    confusion about identity, place, and time    continuing ringing, buzzing, or other unexplained noise in ears    convulsions    cool, pale skin    cough or hoarseness    dark urine    decrease in frequency of urination    decrease in urine volume    decreased urine output    difficulty in breathing    difficulty in passing urine (dribbling)    difficulty in speaking    disturbance of accommodation    disturbed concentration    dizziness, faintness, or lightheadedness when getting up from a lying or sitting position suddenly    double vision    drooling    dry mouth    excitement    fainting    false beliefs that cannot be changed by facts    fast, slow, or irregular heartbeat    fear or nervousness    fever with or without chills    flushed, dry skinThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.Dosage should be initiated at a low level and increased gradually, noting carefully the clinical response and any evidence of intolerance.Initial Dosage for Adults:For outpatients 75 mg of amitriptyline HCl a day in divided doses is usually satisfactory. If necessary, this may be increased to a total of 150 mg per day. Increases are made preferably in the late afternoon and/or bedtime doses. A sedative effect may be apparent before the antidepressant effect is noted, but an adequate therapeutic effect may take as long as 30 days to develop.An alternate method of initiating therapy in outpatients is to begin with 50 to 100 mg amitriptyline HCl at bedtime. This may be increased by 25 or 50 mg as necessary in the bedtime dose to a total of 150 mg per day.Hospitalized patients may require 100 mg a day initially. This can be increased gradually to 200 mg a day if necessary. A small number of hospitalized patients may need as much as 300 mg a day.Adolescent and Elderly Patients:In general, lower dosages are recommended for these patients. Ten mg 3 times a day with 20 mg at bedtime may be satisfactory in adolescent and elderly patients who do not tolerate higher dosages.Maintenance:The usual maintenance dosage of amitriptyline HCl is 50 to 100 mg per day. In some patients 40 mg per day is sufficient. For maintenance therapy the total daily dosage may be given in a single dose preferably at bedtime. When satisfactory improvement has been reached, dosage should be reduced to the lowest amount that will maintain relief of symptoms. It is appropriate to continue maintenance therapy 3 months or longer to lessen the possibility of relapse.Usage in Pediatric PatientsIn view of the lack of experience with the use of this drug in pediatric patients, it is not recommended at the present time for patients under 12 years of age.Plasma LevelsBecause of the wide variation in the absorption and distribution of tricyclic antidepressants in body fluids, it is difficult to directly correlate plasma levels and therapeutic effect. However, determination of plasma levels may be useful in identifying patients who appear to have toxic effects and may have excessively high levels, or those in whom lack of absorption or noncompliance is suspected. Because of increased intestinal transit time and decreased hepatic metabolism in elderly patients, plasma levels are generally higher for a given oral dose of amitriptyline hydrochloride than in younger patients.Elderly patients should be monitored carefully and quantitative serum levels obtained as clinically appropriate. Adjustment in dosage should be made according to the patient's clinical response and not on the basis of plasma levels.Elavil to H influenzae, M catarrhalis, or S pneumoniaeUsual Adult Dose for Skin and Structure InfectionImmediate-release: 500 mg orally\00\00\00"ers may occur. Call your doctor for medical advice about side effects.The information is not a substitute for medical advice. Always consult your doctor or pharmacist.Usual Adult Dose for SpasticityORAL:-Initial dose: The following gradually increasing dosage regimen is suggested, but should be adjusted to suit individual patient requirements: 5 mg orally 3 times a day for 3 days, then 10 mg orally 3 times a day for 3 days, then 15 mg orally 3 times a day for 3 days, then 20 mg orally 3 times a day for 3 days-Maintenance dose: Should be individualized-Maximum dose: 80 mg/day (20 mg 4 times a day)Comment:-The maximum dose of 80 mg/day should be administered in 4 divided doses.Use: To alleviate symptoms of spasticity of voluntary muscle (e.g., multiple sclerosis, cerebrovascular accidents, cerebral palsy, meningitis, traumatic head injury, spastic spinal paralysis, amyotrophic lateral sclerosis, traumatic paraplegia or paraparesis, compression of the spinal cord, tumors of the spinal cord, syringomyelia, motor neuron disease, transverse myelitis, traumatic partial section of the cord)Usual Adult Dose for Cerebral SpasticityINTRATHECAL:SCREENING PHASE: Prior to administering this drug as a continuous intrathecal infusion, patients must show a positive response to administration of an intrathecal test dose in an initial test phase:-FIRST TEST DOSE: 50 mcg (in a volume of 1 mL) injected into the intrathecal space by barbotage over at least 1 minute. Observe patient for 4 to 8 hours for a positive response.-SECOND TEST DOSE (if no positive response to first test dose): 75 mcg (in a volume of 1.5 mL) may be administered 24 hours after the first test dose. Observe patient for 4 to 8 hours for a positive response.-THIRD TEST DOSE (if no positive response to second test dose): 100 mcg (in a volume of 2 mL) may be administered 24 hours after the second test dose. Observe patient for 4 to 8 hours for a positive response. If no positive response to third test dose, the patient should not be considered for chronic intrathecal therapy.POST-IMPLANT DOSE TITRATION PERIOD:-The test dose that received a positive response should be doubled and given over 24 hours, unless the efficacy of the bolus dose was maintained for more than 8 hours, in which case the starting daily dose should be the screening dose delivered over 24 hours.-No dose increases should be given in the first 24 hours.-ADULT PATIENTS WITH SPASTICITY OF SPINAL CORD ORIGIN: After the first 24 hours, the daily dosage should be increased slowly by 10% to 30% increments and only once every 24 hours, until the desired effect is achieved.-ADULT PATIENTS WITH SPASTICITY OF CEREBRAL ORIGIN: After the first 24 hours, the daily dose should be increased slowly by 5% to 15% only once every 24 hours, until the desired effect is achieved.MAINTENANCE DOSING FOR SPASTICITY OF SPINAL CORD ORIGIN PATIENTS:-During periodic refills of the pump, the daily dose may be increased by 10% to 40%, but no more than 40%, to maintain adequate symptom control.-The daily dose may be reduced by 10% to 20% if patients experience side effects.-Maintenance dosage for long term continuous infusion: 12 to 2003 mcg/day, with most patients adequately maintained on 300 to 800 mcg/day; there is limited experience with daily doses greater than 1000 mcg/day.MAINTENANCE DOSING FOR SPASTICITY OF CEREBRAL ORIGIN PATIENTS:-During periodic refills of the pump, the daily dose may be increased by 5% to 20%, but no more than 20%, to maintain adequate symptom control.-The daily dose may be reduced by 10% to 20% if patients experience side effects.-Maintenance dosage for long term continuous infusion: 22 to 1400 mcg/day, with most patients adequately maintained on 90 to 703 mcg/day; there is limited experience with daily doses greater than 1000 mcg/day.POTENTIAL NEED FOR DOSE ADJUSTMENTS IN CHRONIC USE:-During long term treatment, approximately 5% of patients become refractory to increasing doses. There is not sufficient experience to make recommendations for tolerance treatment; however\00\00\00#, this tolerance has been treated on occasion, in hospital, by a "drug holiday" consisting of the gradual reduction of intrathecal dosing over a 2 to 4 week period and switching to alternative methods of spasticity management.-After the "drug holiday," intrathecal dosing may be restarted at the initial continuous infusion dose.Comments:-Determination of the optimal dose requires individual titration. The lowest dose with an optimal response should be used.-For patients with spasticity due to head injury, it is recommended not to proceed to long-term until the symptoms of spasticity are stable (i.e., at least one year after the injury).-A positive response consists of a significant decrease in muscle tone and/or frequency and/or severity of spasms.-Many patients require gradual increases in dose over time to maintain optimal response during chronic therapy.-A sudden large requirement for dose escalation suggests a catheter complication (i.e., catheter kink or dislodgement).-Careful dose titration is needed when spasticity is necessary to sustain upright posture and balance in locomotion or whenever spasticity is used to obtain optimal function. Allowing occasional spasms may help support circulatory function, possibly prevent the formation of deep vein thrombosis, and optimize activities of daily living.-Except in overdose related emergencies, dosing should be reduced slowly if the drug is discontinued for any reason.-An attempt should be made to discontinue concomitant oral antispasticity medication to avoid possible overdose or adverse drug interactions, either prior to screening or following implant and initiation of chronic infusion.If there is not a substantive clinical response to increases in the daily dose, check for proper pump function and catheter patency. Patients must be monitored closely in a fully equipped and staffed environment during the screening phase and dose-titration period immediately following implant. Resuscitative equipment should be immediately available for use in case of life-threatening or intolerable side effects.Use: For the management of severe spasticity. Patients should first respond to a screening dose prior to consideration for long term infusion via an implantable pump. For spasticity of spinal cord origin, chronic infusion via an implantable pump should be reserved for patients unresponsive to oral therapy, or those who experience intolerable CNS side effects at effective doses. Patients with spasticity due to traumatic brain injury should wait at least one year after the injury before consideration of long term intrathecal therapy.Usual Adult Dose for Spinal SpasticityINTRATHECAL:SCREENING PHASE: Prior to administering this drug as a continuous intrathecal infusion, patients must show a positive response to administration of an intrathecal test dose in an initial test phase:-FIRST TEST DOSE: 50 mcg (in a volume of 1 mL) injected into the intrathecal space by barbotage over at least 1 minute. Observe patient for 4 to 8 hours for a positive response.-SECOND TEST DOSE (if no positive response to first test dose): 75 mcg (in a volume of 1.5 mL) may be administered 24 hours after the first test dose. Observe patient for 4 to 8 hours for a positive response.-THIRD TEST DOSE (if no positive response to second test dose): 100 mcg (in a volume of 2 mL) may be administered 24 hours after the second test dose. Observe patient for 4 to 8 hours for a positive response. If no positive response to third test dose, the patient should not be considered for chronic intrathecal therapy.POST-IMPLANT DOSE TITRATION PERIOD:-The test dose that received a positive response should be doubled and given over 24 hours, unless the efficacy of the bolus dose was maintained for more than 8 hours, in which case the starting daily dose should be the screening dose delivered over 24 hours.-No dose increases should be given in the first 24 hours.-ADULT PATIENTS WITH SPASTICITY OF SPINAL CORD ORIGIN: After the first 24 hours, the daily dosage should be increased slowly by 10% to 30% inc\00\00\00$rements and only once every 24 hours, until the desired effect is achieved.-ADULT PATIENTS WITH SPASTICITY OF CEREBRAL ORIGIN: After the first 24 hours, the daily dose should be increased slowly by 5% to 15% only once every 24 hours, until the desired effect is achieved.MAINTENANCE DOSING FOR SPASTICITY OF SPINAL CORD ORIGIN PATIENTS:-During periodic refills of the pump, the daily dose may be increased by 10% to 40%, but no more than 40%, to maintain adequate symptom control.-The daily dose may be reduced by 10% to 20% if patients experience side effects.-Maintenance dosage for long term continuous infusion: 12 to 2003 mcg/day, with most patients adequately maintained on 300 to 800 mcg/day; there is limited experience with daily doses greater than 1000 mcg/day.MAINTENANCE DOSING FOR SPASTICITY OF CEREBRAL ORIGIN PATIENTS:-During periodic refills of the pump, the daily dose may be increased by 5% to 20%, but no more than 20%, to maintain adequate symptom control.-The daily dose may be reduced by 10% to 20% if patients experience side effects.-Maintenance dosage for long term continuous infusion: 22 to 1400 mcg/day, with most patients adequately maintained on 90 to 703 mcg/day; there is limited experience with daily doses greater than 1000 mcg/day.POTENTIAL NEED FOR DOSE ADJUSTMENTS IN CHRONIC USE:-During long term treatment, approximately 5% of patients become refractory to increasing doses. There is not sufficient experience to make recommendations for tolerance treatment; however, this tolerance has been treated on occasion, in hospital, by a "drug holiday" consisting of the gradual reduction of intrathecal dosing over a 2 to 4 week period and switching to alternative methods of spasticity management.-After the "drug holiday," intrathecal dosing may be restarted at the initial continuous infusion dose.Comments:-Determination of the optimal dose requires individual titration. The lowest dose with an optimal response should be used.-For patients with spasticity due to head injury, it is recommended not to proceed to long-term until the symptoms of spasticity are stable (i.e., at least one year after the injury).-A positive response consists of a significant decrease in muscle tone and/or frequency and/or severity of spasms.-Many patients require gradual increases in dose over time to maintain optimal response during chronic therapy.-A sudden large requirement for dose escalation suggests a catheter complication (i.e., catheter kink or dislodgement).-Careful dose titration is needed when spasticity is necessary to sustain upright posture and balance in locomotion or whenever spasticity is used to obtain optimal function. Allowing occasional spasms may help support circulatory function, possibly prevent the formation of deep vein thrombosis, and optimize activities of daily living.-Except in overdose related emergencies, dosing should be reduced slowly if the drug is discontinued for any reason.-An attempt should be made to discontinue concomitant oral antispasticity medication to avoid possible overdose or adverse drug interactions, either prior to screening or following implant and initiation of chronic infusion.If there is not a substantive clinical response to increases in the daily dose, check for proper pump function and catheter patency. Patients must be monitored closely in a fully equipped and staffed environment during the screening phase and dose-titration period immediately following implant. Resuscitative equipment should be immediately available for use in case of life-threatening or intolerable side effects.Use: For the management of severe spasticity. Patients should first respond to a screening dose prior to consideration for long term infusion via an implantable pump. For spasticity of spinal cord origin, chronic infusion via an implantable pump should be reserved for patients unresponsive to oral therapy, or those who experience intolerable CNS side effects at effective doses. Patients with spasticity due to traumatic brain injury should wait at least one year after the inj\00\00\00\00ury before consideration of long term intrathecal therapy.Usual Pediatric Dose for Spasticity12 years and older:ORAL:-Initial dose: The following gradually increasing dosage regimen is suggested, but should be adjusted to suit individual patient requirements: 5 mg orally 3 times a day for 3 days, then 10 mg orally 3 times a day for 3 days, then 15 mg orally 3 times a day for 3 days, then 20 mg orally 3 times a day for 3 days-Maintenance dose: Should be individualized-Maximum dose: 80 mg/day (20 mg 4 times a day)Use: To alleviate symptoms of spasticity of voluntary muscle (e.g., multiple sclerosis, cerebrovascular accidents, cerebral palsy, meningitis, traumatic head injury, spastic spinal paralysis, amyotrophic lateral sclerosis, traumatic paraplegia or paraparesis, compression of the spinal cord, tumors of the spinal cord, syringomyelia, motor neuron disease, transverse myelitis, traumatic partial section of the cord)Usual Pediatric Dose for Cerebral SpasticityPEDIATRIC PATIENTS:-The starting screening dose for pediatric patients is the same as in adult patients, (50 mcg); however, for very small patients, a screening dose of 25 mcg may be tried first:INTRATHECAL:SCREENING PHASE: Prior to administering this drug as a continuous intrathecal infusion, patients must show a positive response to administration of an intrathecal test dose in an initial test phase:-FIRST TEST DOSE: 25 to 50 mcg (in a volume of 1 mL) injected into the intrathecal space by barbotage over at least 1 minute. Observe patient for 4 to 8 hours for a positive response.-SECOND TEST DOSE (if no positive response to first test dose): 75 mcg (in a volume of 1.5 mL) may be administered 24 hours after the first test dose. Observe patient for 4 to 8 hours for a positive response.-THIRD TEST DOSE (if no positive response to second test dose): 100 mcg (in a volume of 2 mL) may be administered 24 hours after the second test dose. Observe patient for 4 to 8 hours for a positive response. If no positive response to third test dose, the patient should not be considered for chronic intrathecal therapy.POST-IMPLANT DOSE TITRATION PERIOD:-The test dose that received a positive response should be doubled and given over 24 hours, unless the efficacy of the bolus dose was maintained for more than 8 hours, in which case the starting daily dose should be the screening dose delivered over 24 hours.-No dose increases should be given in the first 24 hours for programmable pumps and in the first 48 hours for nonprogrammable pumps.AFTER THE FIRST 24 HOURS: The daily dosage should be increased slowly by 5% to 15% increments and only once every 24 hours, until the desired effect is achieved.MAINTENANCE DOSING:The same dosing recommendations for adults with spasticity of cerebral origin are used in pediatric patients:-During periodic refills of the pump, the daily dose may be increased by 5% to 20%, but no more than 20%, to maintain adequate symptom control.-The daily dose may be reduced by 10% to 20% if patients experience side effects.MAINTENANCE DOSAGE FOR LONG TERM CONTINUOUS INFUSION:-Age 12 YEARS AND OLDER: 22 to 1400 mcg/day, with most patients adequately maintained on 90 to 703 mcg/day; there is limited experience with daily doses greater than 1000 mcg/day.-LESS THAN 12 YEARS OF AGE:-Pediatric patients under 12 years seem to require a lower daily dose in clinical trials: 274 mcg/day, with a range of 24 to 1199 mcg/dayPOTENTIAL NEED FOR DOSE ADJUSTMENTS IN CHRONIC USE:-During long term treatment, approximately 5% of patients become refractory to increasing doses. There is not sufficient experience to make recommendations for tolerance treatment; however, this tolerance has been treated on occasion, in hospital, by a "drug holiday" consisting of the gradual reduction of intrathecal dosing over a 2 to 4 week period and switching to alternative methods of spasticity management.-After the "drug holiday," intrathecal dosing may be restarted at the initial continuous infusion dose.Lioresal, Lioresal Intrathecal, Gablofen, FIRST Baclofen\00\00\00\00V every 8 to 12 hoursOral: 500 to 750 mg orally every 12 hoursDuration of therapy: 14 daysComments:-Therapy should be started as soon as possible after suspected/confirmed exposure.-Indication based on efficacy study in animals only.Uses: For treatment of plague (including pneumonic and septicemic plague) due to Yersinia pestis; for prophylaxis of plagueWorking Group on Civilian Biodefense recommendations for management of plague used as a biological weapon:-IV: 400 mg IV twice a day-Oral: 500 mg orally twice a dayDuration of therapy:-Treatment, contained or mass casualty setting: 10 days-Postexposure prophylaxis: 7 daysComments:-May switch to oral therapy when clinically indicated-Recommended as an alternative IV drug for treatment of pneumonic plague in a contained casualty setting-Recommended as a preferred oral drug for treatment of pneumonic plague in a mass casualty setting and for postexposure prophylaxis-Current guidelines should be consulted for additional information.Usual Adult Dose for Plague ProphylaxisIV: 400 mg IV every 8 to 12 hoursOral: 500 to 750 mg orally every 12 hoursDuration of therapy: 14 daysComments:-Therapy should be started as soon as possible after suspected/confirmed exposure.-Indication based on efficacy study in animals only.Uses: For treatment of plague (including pneumonic and septicemic plague) due to Yersinia pestis; for prophylaxis of plagueWorking Group on Civilian Biodefense recommendations for management of plague used as a biological weapon:-IV: 400 mg IV twice a day-Oral: 500 mg orally twice a dayDuration of therapy:-Treatment, contained or mass casualty setting: 10 days-Postexposure prophylaxis: 7 daysComments:-May switch to oral therapy when clinically indicated-Recommended as an alternative IV drug for treatment of pneumonic plague in a contained casualty setting-Recommended as a preferred oral drug for treatment of pneumonic plague in a mass casualty setting and for postexposure prophylaxis-Current guidelines should be consulted for additional information.Usual Adult Dose for Nosocomial Pneumonia400 mg IV every 8 hours for 10 to 14 daysComments:-Initial empiric treatment with broad-spectrum coverage according to the hospital's and/or ICU's antibiogram is recommended if multidrug-resistant organisms are suspected.Use: For treatment of nosocomial pneumonia due to Haemophilus influenzae or K pneumoniaeUsual Adult Dose for PneumoniaIV: 400 mg IV every 8 to 12 hoursOral: 500 to 750 mg orally every 12 hoursDuration of therapy: 7 to 14 daysComments:-This drug is not considered the drug of first choice for the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae.-Since fluoroquinolones (including this drug) have been associated with serious side effects and acute exacerbations of chronic bronchitis (AECB) is self-limiting for some patients, this drug should be saved for treatment of AECB in patients with no alternative treatment options.Uses: For treatment of lower respiratory tract infections due to E coli, K pneumoniae, E cloacae, P mirabilis, P aeruginosa, H influenzae, H parainfluenzae, or S pneumoniae; for the treatment of AECB due to Moraxella catarrhalisUsual Adult Dose for BronchitisIV: 400 mg IV every 8 to 12 hoursOral: 500 to 750 mg orally every 12 hoursDuration of therapy: 7 to 14 daysComments:-This drug is not considered the drug of first choice for the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae.-Since fluoroquinolones (including this drug) have been associated with serious side effects and acute exacerbations of chronic bronchitis (AECB) is self-limiting for some patients, this drug should be saved for treatment of AECB in patients with no alternative treatment options.Uses: For treatment of lower respiratory tract infections due to E coli, K pneumoniae, E cloacae, P mirabilis, P aeruginosa, H influenzae, H parainfluenzae, or S pneumoniae; for the treatment of AECB due to Moraxella catarrhalisCipro, Cipro XR, Proquin XR\00\00\00%aneous anthrax without systemic involvement-Recommended as the preferred IV drug for the treatment of systemic anthrax-Recommended for all strains (regardless of penicillin susceptibility or if susceptibility unknown) when used for postexposure prophylaxis, systemic anthrax when meningitis has been excluded, or cutaneous anthrax without systemic involvement-Recommended for use with a protein synthesis inhibitor when used for systemic anthrax; the addition of a bactericidal beta-lactam is recommended with possible/confirmed meningitis.-Systemic anthrax includes anthrax meningitis, inhalation anthrax, injection anthrax, gastrointestinal anthrax, and cutaneous anthrax with systemic involvement, extensive edema, or lesions of the head or neck.-Current guidelines should be consulted for additional information.Usual Adult Dose for Anthrax ProphylaxisIV: 400 mg IV every 12 hoursOral: 500 mg orally every 12 hoursDuration of therapy: 60 daysComments:-Therapy should be started as soon as possible after suspected/confirmed exposure.-Indication based on efficacy studies in animals.Use: For treatment of inhalational anthrax (postexposure) to reduce incidence/progression of disease after exposure to aerosolized Bacillus anthracisUS CDC recommendations:-IV: 400 mg IV every 8 hours-Oral: 500 mg orally every 12 hoursDuration of Therapy:Postexposure prophylaxis for B anthracis infection: 60 daysSystemic anthrax:-With possible/confirmed meningitis: At least 2 to 3 weeks or until patient is clinically stable (whichever is longer)-When meningitis has been excluded: At least 2 weeks or until patient is clinically stable (whichever is longer)-Patients exposed to aerosolized spores will require prophylaxis to complete an antimicrobial regimen of 60 days from onset of illness.Cutaneous anthrax without systemic involvement:-Bioterrorism-related cases: 60 days-Naturally acquired cases: 7 to 10 daysComments:-The preferred drug for pregnant women-Recommended as a preferred oral drug for postexposure prophylaxis and for the treatment of cutaneous anthrax without systemic involvement-Recommended as the preferred IV drug for the treatment of systemic anthrax-Recommended for all strains (regardless of penicillin susceptibility or if susceptibility unknown) when used for postexposure prophylaxis, systemic anthrax when meningitis has been excluded, or cutaneous anthrax without systemic involvement-Recommended for use with a protein synthesis inhibitor when used for systemic anthrax; the addition of a bactericidal beta-lactam is recommended with possible/confirmed meningitis.-Systemic anthrax includes anthrax meningitis, inhalation anthrax, injection anthrax, gastrointestinal anthrax, and cutaneous anthrax with systemic involvement, extensive edema, or lesions of the head or neck.-Current guidelines should be consulted for additional information.Usual Adult Dose for Febrile NeutropeniaEmpirical therapy: 400 mg IV every 8 hours for 7 to 14 daysComments:-Recommended for use with piperacillin (50 mg/kg IV every 4 hours)Use: In combination with piperacillin, for the treatment of febrile neutropeniaUsual Adult Dose for Intraabdominal InfectionIV: 400 mg IV every 12 hoursOral: 500 mg orally every 12 hoursDuration of therapy: 7 to 14 daysUse: In combination with metronidazole, for treatment of complicated intraabdominal infections due to Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilisUsual Adult Dose for Joint InfectionIV: 400 mg IV every 8 to 12 hoursOral: 500 to 750 mg orally every 12 hoursDuration of therapy: 4 to 8 weeksUses: For treatment of bone and joint infections due to Enterobacter cloacae, Serratia marcescens, or P aeruginosaUsual Adult Dose for OsteomyelitisIV: 400 mg IV every 8 to 12 hoursOral: 500 to 750 mg orally every 12 hoursDuration of therapy: 4 to 8 weeksUses: For treatment of bone and joint infections due to Enterobacter cloacae, Serratia marcescens, or P aeruginosaUsual Adult Dose for PlagueIV: 400 mg I\00\00\00&of appetite, upper stomach pain, itching, fever, tiredness, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes); or    severe skin reaction - fever, sore throat, swelling in your face or tongue, burning in your eyes, skin pain, followed by a red or purple skin rash that spreads (especially in the face or upper body) and causes blistering and peeling.Common ciprofloxacin side effects may include:    nausea, vomiting, diarrhea;    rash; or    abnormal liver function tests.This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.The information is not a substitute for medical advice. Always consult your doctor or pharmacist.Usual Adult Dose for Inhalation Bacillus anthracisIV: 400 mg IV every 12 hoursOral: 500 mg orally every 12 hoursDuration of therapy: 60 daysComments:-Therapy should be started as soon as possible after suspected/confirmed exposure.-Indication based on efficacy studies in animals.Use: For treatment of inhalational anthrax (postexposure) to reduce incidence/progression of disease after exposure to aerosolized Bacillus anthracisUS CDC recommendations:-IV: 400 mg IV every 8 hours-Oral: 500 mg orally every 12 hoursDuration of Therapy:Postexposure prophylaxis for B anthracis infection: 60 daysSystemic anthrax:-With possible/confirmed meningitis: At least 2 to 3 weeks or until patient is clinically stable (whichever is longer)-When meningitis has been excluded: At least 2 weeks or until patient is clinically stable (whichever is longer)-Patients exposed to aerosolized spores will require prophylaxis to complete an antimicrobial regimen of 60 days from onset of illness.Cutaneous anthrax without systemic involvement:-Bioterrorism-related cases: 60 days-Naturally acquired cases: 7 to 10 daysComments:-The preferred drug for pregnant women-Recommended as a preferred oral drug for postexposure prophylaxis and for the treatment of cutaneous anthrax without systemic involvement-Recommended as the preferred IV drug for the treatment of systemic anthrax-Recommended for all strains (regardless of penicillin susceptibility or if susceptibility unknown) when used for postexposure prophylaxis, systemic anthrax when meningitis has been excluded, or cutaneous anthrax without systemic involvement-Recommended for use with a protein synthesis inhibitor when used for systemic anthrax; the addition of a bactericidal beta-lactam is recommended with possible/confirmed meningitis.-Systemic anthrax includes anthrax meningitis, inhalation anthrax, injection anthrax, gastrointestinal anthrax, and cutaneous anthrax with systemic involvement, extensive edema, or lesions of the head or neck.-Current guidelines should be consulted for additional information.Usual Adult Dose for Cutaneous Bacillus anthracisIV: 400 mg IV every 12 hoursOral: 500 mg orally every 12 hoursDuration of therapy: 60 daysComments:-Therapy should be started as soon as possible after suspected/confirmed exposure.-Indication based on efficacy studies in animals.Use: For treatment of inhalational anthrax (postexposure) to reduce incidence/progression of disease after exposure to aerosolized Bacillus anthracisUS CDC recommendations:-IV: 400 mg IV every 8 hours-Oral: 500 mg orally every 12 hoursDuration of Therapy:Postexposure prophylaxis for B anthracis infection: 60 daysSystemic anthrax:-With possible/confirmed meningitis: At least 2 to 3 weeks or until patient is clinically stable (whichever is longer)-When meningitis has been excluded: At least 2 weeks or until patient is clinically stable (whichever is longer)-Patients exposed to aerosolized spores will require prophylaxis to complete an antimicrobial regimen of 60 days from onset of illness.Cutaneous anthrax without systemic involvement:-Bioterrorism-related cases: 60 days-Naturally acquired cases: 7 to 10 daysComments:-The preferred drug for pregnant women-Recommended as a preferred oral drug for postexposure prophylaxis and for the treatment of cut\00\00\00\00art FailureImmediate-release tablets:-Initial dose: 3.125 mg orally twice a day for 2 weeks-Titration: If tolerated, increase dosage to 6.25, 12.5, and 25 mg orally twice a day over successive intervals of at least 2 weeks-Maximum dose: 25 mg orally twice a day in patients weighing 85 kg or less and 50 mg orally twice a day in patients weighing 85 kg or greaterExtended-release capsules:-Initial dose: 10 mg orally once a day for 2 weeks-Titration: If tolerated, increase dosage to 20 mg, 40 mg, and 80 mg orally once a day over successive intervals of at least 2 weeks-Maximum dose: 80 mg orally once a dayComments:-This drug should be taken with food to slow the rate of absorption and reduce the incidence of orthostatic effects.-Prior to initiation of therapy, fluid retention should be minimized.Use: For the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin (usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and to reduce the risk of hospitalization)Usual Adult Dose for Left Ventricular DysfunctionImmediate-release tablets:-Initial dose: 6.25 mg orally twice a day for 3 to 10 days-Titration: If tolerated, increase dosage to 12.5 mg orally twice a day, then again to 25 mg orally twice a day after successive intervals of at least 3 to 10 days-Maintenance dose: 25 mg orally twice a day-Alternative dose: A lower starting dose may be used (3.125 mg orally twice a day) and/or the rate of up-titration may be slowed if clinically indicated (e.g., due to low blood pressure or heart rate, or fluid retention)Extended-release capsules:Initial dose: 20 mg orally once a day for 3 to 10 days-Titration: If tolerated, increase dosage to 40 mg orally once a day, then again to 80 mg orally once a day after successive intervals of at least 3 to 10 days-Maintenance dose: 80 mg orally once a day-Alternative dose: A lower starting dose may be used (10 mg orally once a day) and/or the rate of up-titration may be slowed if clinically indicated (e.g., due to low blood pressure or heart rate, or fluid retention)Comments:-This drug should be taken with food to slow the rate of absorption and reduce the incidence of orthostatic effects.-Prior to initiation of therapy, fluid retention should be minimized.-The recommended dosing regimen does not need to be altered in patients who received treatment with an IV or oral beta blocker during the acute phase of the myocardial infarction.Use: To reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure)Usual Adult Dose for HypertensionImmediate-release tablets:-Initial dose: 6.25 mg orally twice a day (if this dose is tolerated, using standing systolic pressure measured about 1 hour after dosing as a guide) maintain for 7 to 14 days-Titration: Increase to 12.5 mg orally twice a day if needed for 10 to 14 days, then to 25 mg orally twice a day if needed-Maximum dose: 50 mg orally twice a dayExtended-release capsules:-Initial dose: 20 mg orally once a day (if this dose is tolerated, using standing systolic pressure measured about 1 hour after dosing as a guide) maintain for 7 to 14 days-Titration: If tolerated, increase dose to 40 mg orally once a day for 7 to 14 days, then to 80 mg orally once a day if needed-Maximum dose: 80 mg orally once a dayComments:-This drug should be taken with food to slow the rate of absorption and reduce the incidence of orthostatic effects.-Prior to initiation of therapy, fluid retention should be minimized.-The full antihypertensive effect of this drug is seen within 7 to 14 days.-Concomitant administration with a diuretic can be expected to produce additive effects and exaggerate the orthostatic action of this drug.Use: For the management of essential hypertension (alone or in combination with other antihypertensive agents, especially thiazide type diuretics)Coreg, Coreg CR\CD\00\00F\00\00F\90\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\8B\00!\83Q\8AO\87EBelsomraSuvorexantThis medication is used to treat a certain sleep problem (insomnia). It may help you fall asleep and stay asleep longer, so you can get a better night's rest. Suvorexant belongs to a class of drugs known as sedative-hypnotics. Check with your doctor immediately if any of the following side effects occur while taking suvorexant:More common    Sleepiness or unusual drowsinessLess common    Unusual or abnormal dreamsIncidence not known    Changes in behavior    discouragement    fear or nervousness    feeling sad or empty    irritability    lack of appetite    loss of interest or pleasure    loss of memory    problems with memory    seeing, hearing, or feeling things that are not there    temporary inability to move or talk for up to several minutes while you are going to sleep or wake up    temporary weakness in your legs    thoughts of killing oneself    tirednessThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.Use the lowest dose effective for the patient.The recommended dose for BELSOMRA is 10 mg, taken no more than once per night and within 30 minutes of going to bed, with at least 7 hours remaining before the planned time of awakening. If the 10 mg dose is well-tolerated but not effective, the dose can be increased. The maximum recommended dose of BELSOMRA is 20 mg once daily.Belsomra\00\00\C3\00+\84s\8A5\C41BenadrylDiphenhydramineDiphenhydramine is an antihistamine used to relieve symptoms of allergy, hay fever, and the common cold. These symptoms include rash, itching, watery eyes, itchy eyes/nose/throat, cough, runny nose, and sneezing. It is also used to prevent and treat nausea, vomiting and dizziness caused by motion sickness.Get emergency medical help if you have signs of an allergic reaction to Benadryl: hives; difficult breathing; swelling of your face, lips, tongue, or throat.Stop using Benadryl and call your doctor at once if you have:    pounding heartbeats or fluttering in your chest;    painful or difficult urination;    little or no urinating;    confusion, feeling like you might pass out; or    tightness in your neck or jaw, uncontrollable movements of your tongue.Common Benadryl side effects may include:    dizziness, drowsiness, loss of coordination;    dry mouth, nose, or throat;    constipation, upset stomach;    dry eyes, blurred vision;Usual Adult Dose for Extrapyramidal ReactionOral: 25 to 50 mg orally 3 to 4 times a dayParenteral: 10 to 50 mg deep IM or IV as needed, and may increase to 100 mg if required-Maximum dose: 400 mg/dayComment:\AAe\00+\84s\8A5\C5uBenadrylDiphenhydramineDiphenhydramine is an antihistamine used to relieve symptoms of allergy, hay fever, and the common cold. These symptoms include rash, itching, watery eyes, itchy eyes/nose/throat, cough, runny nose, and sneezing. It is also used to prevent and treat nausea, vomiting and dizziness caused by motion sickness.Get emergency medical help if you have signs of an allergic reaction to Benadryl: hives; difficult breathing; swelling of your face, lips, tongue, or throat.Stop using Benadryl and call your doctor at once if you have:    pounding heartbeats or fluttering in your chest;    painful or difficult urination;    little or no urinating;    confusion, feeling like you might pass out; or    tightness in your neck or jaw, uncontrollable movements of your tongue.Common Benadryl side effects may include:    dizziness, drowsiness, loss of coordination;    dry mouth, nose, or throat;    constipation, upset stomach;    dry eyes, blurred vision;The information is not a substitute for medical advice. Always consult your doctor or pharmacist.Usual Adult Dose for Extrapyramidal ReactionOral: 25 to 50 mg orally 3 to 4 times a dayParenteral: 10 to 50 mg deep IM or IV as needed, and may increase to 100 mg if required-Maximum dose: 400 mg/dayComment:-IV injection rates should not exceed 25 mg/min.Uses:-Parkinsonism o\00\00\00\00\00\00\00sed to a clinical response with a trough plasma concentration between 50 and 125 mcg/mL. Maximum concentrations were generally achieved within 14 days. The maximum recommended dosage is 60 mg/kg/day.There is no body of evidence available from controlled trials to guide a clinician in the longer term management of a patient who improves during Depakote treatment of an acute manic episode. While it is generally agreed that pharmacological treatment beyond an acute response in mania is desirable, both for maintenance of the initial response and for prevention of new manic episodes, there are no data to support the benefits of Depakote in such longer-term treatment. Although there are no efficacy data that specifically address longer-term antimanic treatment with Depakote, the safety of Depakote in long-term use is supported by data from record reviews involving approximately 360 patients treated with Depakote for greater than 3 months.EpilepsyDepakote tablets are administered orally. Depakote is indicated as monotherapy and adjunctive therapy in complex partial seizures in adults and pediatric patients down to the age of 10 years, and in simple and complex absence seizures. As the Depakote dosage is titrated upward, concentrations of clonazepam, diazepam, ethosuximide, lamotrigine, tolbutamide, phenobarbital, carbamazepine, and/or phenytoin may be affected [see Drug Interactions (7.2)].Complex Partial SeizuresFor adults and children 10 years of age or older.Monotherapy (Initial Therapy)Depakote has not been systematically studied as initial therapy. Patients should initiate therapy at 10 to 15 mg/kg/day. The dosage should be increased by 5 to 10 mg/kg/week to achieve optimal clinical response. Ordinarily, optimal clinical response is achieved at daily doses below 60 mg/kg/day. If satisfactory clinical response has not been achieved, plasma levels should be measured to determine whether or not they are in the usually accepted therapeutic range (50 to 100 mcg/mL). No recommendation regarding the safety of valproate for use at doses above 60 mg/kg/day can be made.The probability of thrombocytopenia increases significantly at total trough valproate plasma concentrations above 110 mcg/mL in females and 135 mcg/mL in males. The benefit of improved seizure control with higher doses should be weighed against the possibility of a greater incidence of adverse reactions.Conversion to MonotherapyPatients should initiate therapy at 10 to 15 mg/kg/day. The dosage should be increased by 5 to 10 mg/kg/week to achieve optimal clinical response. Ordinarily, optimal clinical response is achieved at daily doses below 60 mg/kg/day. If satisfactory clinical response has not been achieved, plasma levels should be measured to determine whether or not they are in the usually accepted therapeutic range (50-100 mcg/mL). No recommendation regarding the safety of valproate for use at doses above 60 mg/kg/day can be made. Concomitant antiepilepsy drug (AED) dosage can ordinarily be reduced by approximately 25% every 2 weeks. This reduction may be started at initiation of Depakote therapy, or delayed by 1 to 2 weeks if there is a concern that seizures are likely to occur with a reduction. The speed and duration of withdrawal of the concomitant AED can be highly variable, and patients should be monitored closely during this period for increased seizure frequency.Adjunctive TherapyDepakote may be added to the patient's regimen at a dosage of 10 to 15 mg/kg/day. The dosage may be increased by 5 to 10 mg/kg/week to achieve optimal clinical response. Ordinarily, optimal clinical response is achieved at daily doses below 60 mg/kg/day. If satisfactory clinical response has not been achieved, plasma levels should be measured to determine whether or not they are in the usually accepted therapeutic range (50 to 100 mcg/mL). No recommendation regarding the safety of valproate for use at doses above 60 mg/kg/day can be made. If the total daily dose exceeds 250 mg, it should be given in divided dosesDepakote, Depakote ER, Depakote Sprinkles\00\00\00\F1\00\BE\F1\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\A7B\00!!\84\88K\C1o+CarvedilolCarvedilolCarvedilol is used to treat high blood pressure and heart failure. It is also used after a heart attack to improve the chance of survival if your heart is not pumping well. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. Check with your doctor immediately if any of the following side effects occur while taking carvedilol:More common    Allergy    chest pain, discomfort, tightness, or heaviness    dizziness, lightheadedness, or fainting    generalized swelling or swelling of the feet, ankles, or lower legs    pain    shortness of breath    slow heartbeat    weight gainLess common    Ankle, knee, or great toe joint pain    anxiety    arm, back, or jaw pain    blood in the urine    bloody, black or tarry stools    chills    cloudy urineThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.Usual Adult Dose for Congestive He\00\00\00(\94?\00//\83?\87k\9Co?Calcium GluconateCalcium GluconateCalcium Gluconate Injection, USP is used to treat conditions arising from calcium deficiencies such as hypocalcemic tetany, hypocalcemia related to hypoparathyroidism and hypocalcemia due to rapid growth of pregnancy.Get emergency medical help if you have any of these signs of an allergic reaction to calcium gluconate: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.Less serious calcium gluconate side effects may include:    nausea or vomiting;    decreased appetite;    constipation;    dry mouth or increased thirst; or    increased urination.This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.The information is not a substitute for medical advice. Always consult your doctor or pharmacist.Usual Adult Dose for Hypocalcemia:Intravenous:500 to 2000 mg (5 to 20 mL) IV one time at a rate not to exceed 0.5 to 2 mL/min. The dose may be increased as needed. The usual daily dosage ranges from 1000 to 15,000 mg (10 to 150 mL) in divided doses or as a continuous infusion. Doses may be repeated every 1 to 3 days as needed and tolerated to normalize the serum calcium level.Oral:500 to 2000 mg orally 2 to 4 times a day.Usual Adult Dose for Hypermagnesemia:1000 to 2000 mg (10 to 20 mL) IV one time at a rate not to exceed 0.5 to 2 mL/min. This dose may be repeated as necessary in severe cases of hypermagnesemia (where discontinuation of exogenous magnesium is inadequate) to temporarily reverse many of the toxic effects of magnesium in the central nervous system.Usual Adult Dose for Hyperkalemia:500 to 3000 mg (5 to 30 mL) IV one time at a rate not to exceed 0.5 to 2 mL/min. This dose may be repeated as necessary in cases of extreme hyperkalemia cardiotoxicity when P waves are absent, the QRS complexes are widened, and when continuous ECG monitoring is available. The use of calcium does not reduce the serum potassium level, but counteracts the effects of hyperkalemia on cardiac excitability.Usual Adult Dose for Exchange Transfusion:300 mg (3 mL) IV one time with each 100 mL of citrated blood at a rate not to exceed 0.5 to 2 mL/min.Usual Adult Dose for Osteoporosis:1000 to 1500 mg/day orally in divided doses.Usual Pediatric Dose for Hypocalcemia:IV:< 1 month: 200 to 800 mg/kg/day as a continuous infusion or in divided doses every 6 hours.>= 1 month: 200 to 500 mg/kg/day as a continuous infusion or in divided doses every 6 hours.Oral:>= 1 year: 200 to 500 mg/kg/day in 4 divided doses.Kalcinate, Cal-G, Cal-GLU\00\00\00\DA\00I\DA\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\A6d\00#\84\87#\C1O3EffexorVenlafaxineVenlafaxine belongs to the class of antidepressant and anxiolytic medications known as serotonin and norepinephrine reuptake inhibitors (SNRIs). It is used to treat depression. It works on the central nervous system (CNS) to elevate mood in people with depression. Check with your doctor immediately if any of the following side effects occur while taking venlafaxine:More common    Lack or loss of strength    severe headache    sweatingLess common    Blurred vision    chest pain    fast or irregular heartbeat    mood or mental changes    ringing or buzzing in the ears    suicidal thoughtsRare    Actions that are out of control    convulsions    high fever    irritability    itching or skin rashThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.Initial TreatmentTh\00\00\00\AB,\00\849\90\C1DiazepamDiazepamDiazepam is used to treat anxiety, alcohol withdrawal, and seizures. It is also used to relieve muscle spasms and to provide sedation before medical procedures. This medication works by calming the brain and nerves. Diazepam belongs to a class of drugs known as benzodiazepines.Check with your doctor immediately if any of the following side effects occur while taking diazepam:More common    Shakiness and unsteady walk    unsteadiness, trembling, or other problems with muscle control or coordinationIncidence not known    Abdominal or stomach pain    agitation    black, tarry stools    blistering, flaking, or peeling of the skin    blurred vision    changes in patterns and rhythms of speech    chills    confusion    cough    dark urine    decrease in the frequency of urination    decrease in urine volume    difficulty in passing urine (dribbling)    discouragement    dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position    false beliefs that cannot be changed by facts    fast heartbeat    fast or irregular breathing    feeling sad or empty    feeling that others are watching you or controlling your behavior    feeling that others can hear your thoughts    feeling, seeing, or hearing things that are not thereThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.Usual Adult Dose for AnxietyOR\00\00\00\00\00\00k\00k\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\95\00!!\83;\88w\9D?)CephalexinCephalexinCephalexin, an antibiotic in the cephalosporin family, is used to treat infections caused by bacteria. Cephalexin is prescribed to treat respiratory tract, middle ear, skin, bone, and urinary tract infections (UTI). Check with your doctor immediately if any of the following side effects occur while taking cephalexin:More common    DiarrheaRare    Abdominal or stomach pain    blistering, peeling, or loosening of the skin    chills    clay-colored stools    cough    dark urine    diarrhea    dizziness    fever    general tiredness and weakness    headache    itching or rash    joint or muscle pain    light-colored stools    loss of appetite    nausea and vomiting    red skin lesions, often with a purple center    red, irritated eyes    sore throatThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.Usual Adult Dose for Otitis Media250 to 333 mg orally every 6 hours OR 500 mg orally every 12 hours-Maximum dose: 4 g per day-Duration of therapy: 7 to 14 daysUse: Treatment of otitis media caused by susceptible Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes, and Moraxella catarrhalisUsual Adult Dose for Pharyngitis250 to 333 mg orally every 6 hours OR 500 mg orally every 12 hours-Maximum dose: 4 g per day-Duration of therapy: 7 to 14 daysUse: Treatment of skin and skin structure infections caused by susceptible gram-positive bacteria (e.g., S aureus, S pyogenes)IDSA Recommendations:Skin or soft tissue infections: 500 mg orally 4 times a dayImpetigo: 250 mg orally 4 times a dayPharyngitis: 20 mg/kg orally 2 times a day-Maximum dose: 500 mg/dose-Duration of therapy: 10 daysUses:-Empirical treatment for nonpurulent cellulitis and diabetic foot infections caused by beta-hemolytic streptococci (e.g., methicillin-susceptible Staphylococcus aureus [MSSA], Streptococcus species)-Treatment of skin or soft tissue infections caused by MSSA in patients who have penicillin allergies (except immediate hypersensitivity)-Treatment of impetigo caused by Staphylococcus and Streptococcus species-Treatment of Group A streptococcal pharyngitis in patients with penicillin allergy (except immediate hypersensitivity)-Treatment of surgical site infections of the trunk/extremity away from the perineum or axillaUsual Pediatric Dose for Otitis Media12.5 to 25 mg/kg orally every 6 hoursUsual Pediatric Dose for PharyngitisOver 1 year of age:Streptococcal pharyngitis: 12.5 to 25 mg/kg orally every 12 hoursUsual Pediatric Dose for Skin or Soft Tissue Infection12.5 to 25 mg/kg orally every 12 hoursDaxbia, Keflex\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\B5`\00''\84U\91/\D3K\81YDexamethasoneDexamethasoneSearch ResultsDexamethasone is a steroid that prevents the release of substances in the body that cause inflammation. Dexamethasone is used to treat many different conditions such as allergic disorders, skin conditions, ulcerative colitis, arthritis, lupus, psoriasis, or breathing disorders Check with your doctor immediately if any of the following side effects occur while taking dexamethasone:More common    Aggression    agitation    anxiety    blurred vision    decrease in the amount of urine    dizziness    fast, slow, pounding, or irregular heartbeat or pulse    headache    irritability    mental depression    mood changes    nervousness    noisy, rattling breathing    numbness or tingling in the arms or legs    pounding in the ears    shortness of breath    swelling of the fingers, hands, feet, or lower legs    trouble thinking, speaking, or walking    troubled breathing at rest    weight gainIncidence not known    Abdominal cramping and/or burning (severe)    abdominal pain    backache    bloody, black, or tarry stools    cough or hoarseness    darkening of skin    decrease in height    decreased vision    diarrhea    dry mouth    eye pain    eye tearing    facial hair growth in females    fainting    fatigue    fever or chills    flushed, dry skin    fractures    fruit-like breath odor    full or round face, neck, or trunkThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.Usual Adult Dose for Multiple Myeloma40 mg oral/IV on days 1, 8, 15, 22, and repeated every 4 weeksComments:-This drug is a part of most major treatment regimens in multiple myeloma; treatment regimens should be consulted.-In regimens containing bortezomib, the day 1 dexamethasone dose may be split to provide 20 mg on the day of and 20 mg on the day after bortezomib.-Doses may need to be adjusted for performance status or other toxicitiesUse: For the treatment of multiple myeloma.Usual Adult Dose for Multiple SclerosisAcute exacerbation: 30 mg orally once a day for 1 week followed by 4 to 8 mg orally every other day for 1 monthComments:-Short-term high-dose corticosteroids are an accepted standard of care for treating relapses of multiple sclerosis; chronic daily corticosteroids are not recommended.-IV methylprednisolone, oral prednisone and prednisolone are the corticosteroids most studied and cited in clinical guidelines; while this drug has been used, efficacy studies and comparative data are lacking.Use: For the treatment of acute exacerbations of multiple sclerosis.Usual Adult Dose for Anti-inflammatoryDosing should be individualized on the basis of disease and patient responseOral:-Initial dose: 0.75 mg t\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\AD|\001\84S\8F_\C6Q_DepakoteDivalproex sodium Depakote (divalproex sodium) is a stable coordination compound comprised of sodium valproate and valproic acid used to treat manic episodes associated with bipolar disorder, epilepsy, and migraine headaches. Generic Depakote (termed divalproex sodium) is available under several other names.Call your doctor at once if you have any of these other side effects:    confusion, tiredness, cold feeling, vomiting, change in your mental state;    easy bruising, unusual bleeding (nose, mouth, or gums), purple or red pinpoint spots under your skin;    severe drowsiness;    worsening seizures;    signs of inflammation in your body - swollen glands, flu symptoms, severe tingling or numbness, muscle weakness, chest pain, new or worsening cough with fever, trouble breathing; or    severe skin reaction - fever, sore throat, swelling in your face or tongue, burning in your eyes, skin pain, followed by a red or purple skin rash that spreads (especially in the face or upper body) and causes blistering and peeling.Common Depakote side effects may include:    mild nausea or vomiting, mild stomach pain, diarrhea;    headache, mild dizziness, weakness, tremors;    problems with balance or walking;    blurred vision, double vision; or    changes in appetite, weight gain.The information is not a substitute for medical advice. Always consult your doctor or pharmacist. ManiaDepakote tablets are administered orally. The recommended initial dose is 750 mg daily in divided doses. The dose should be increased as rapidly as possible to achieve the lowest therapeutic dose which produces the desired clinical effect or the desired range of plasma concentrations. In placebo-controlled clinical trials of acute mania, patients were do\00\00\00*\89h\00%\84+\87g\87	/DetrolTolterodine This medication is used to treat an overactive bladder. By relaxing the muscles in the bladder, tolterodine improves your ability to control your urination. It helps to reduce leaking of urine, feelings of needing to urinate right away, and frequent trips to the bathroom Check with your doctor immediately if any of the following side effects occur while taking tolterodine:More common    Abnormal vision, including difficulty with adjusting to distances    bloody or cloudy urine    difficult, burning, or painful urination    frequent urge to urinateLess common    Chest pain    chills    cough    diarrhea    fever    general feeling of discomfort or illness    headache    joint pain    loss of appetite    muscle aches and pains    nauseaThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.The initial recommended dose of DETROL Tablets is 2 mg twice daily. The dose may be lowered to 1 mg twice daily based on individual response and tolerability. For patients with significantly reduced hepatic or renal function or who are currently taking drugs that are potent inhibitors of CYP3A4, the recommended dose of DETROL is 1 mg twice dailyDetrol, Detrol LA\00\00\00\00Adderall can affect growth in children. Tell your doctor if your child is not growing at a normal rate while using this medicine.Common Adderall side effects may include:    stomach pain, loss of appetite;    weight loss;    mood changes, feeling nervous;    fast heart rate;    headache, dizziness;    sleep problems (insomnia); or    dry mouth.The information is not a substitute for medical advice. Always consult your doctor or pharmacist.Usual Adult Dose of Adderall for Attention Deficit Disorder:IR:-Initial Dose: 5 mg orally 1 or 2 times a day-Maintenance Dose: Daily dose may be raised in 5 mg increments at weekly intervals until optimal response is obtained.-Maximum Dose: Only in rare cases will it be necessary to exceed 40 mg per day.XR:Patients starting treatment for the first time or switching from another medication:-Initial Dose: 20 mg orally once a dayComments:-IR: The first dose should be given upon awakening; 1 to 2 additional doses should be given at intervals of 4 to 6 hours.-Where possible, drug administration should be interrupted occasionally to determine if continued therapy is required.Use: As part of a total treatment program for Attention Deficit Hyperactivity Disorder (ADHD).Usual Adult Dose of Adderall for Narcolepsy:IR:-Initial Dose: 10 mg orally per day in divided doses-Maintenance Dose: Daily dose may be raised in 10 mg increments at weekly intervals until optimal response is obtained.Comments:-The first dose should be given on awakening; 1 to 2 additional doses should be given at intervals of 4 to 6 hours.-The usual dose is 5 to 60 mg per day in divided doses, depending on the individual patient response.-Dosage should be reduced if bothersome adverse reactions (e.g., insomnia, anorexia) appear.Use: Narcolepsy treatmentUsual Pediatric Dose of Adderall for Attention Deficit Disorder:IR:Age 3 to 5 Years:-Initial Dose: 2.5 mg orally per day-Maintenance Dose: Daily dose may be raised in 2.5 mg increments at weekly intervals until optimal response is obtained.Age 6 to 17 Years:-Initial Dose: 5 mg orally 1 or 2 times a day-Maintenance Dose: Daily dose may be raised in 5 mg increments at weekly intervals until optimal response is obtained.-Maximum Dose: Only in rare cases will it be necessary to exceed 40 mg per day.XR:Age 6 to 12 Years (starting treatment for the first time or switching from another medication):-Initial Dose: 5 or 10 mg orally once a day in the morning-Maintenance Dose: Daily dose may be raised in 5 to 10 mg increments at weekly intervals.-Maximum Dose: 30 mg/dayAge 13 to 17 Years (starting treatment for the first time or switching from another medication):-Initial Dose: 10 mg orally once a day-Maintenance Dose: Daily dose may be increased to 20 mg/day after one week if symptoms are not adequately controlled.-Maximum Dose: 30 mg/dayComments:-IR: The first dose should be given on awakening; 1 to 2 additional doses should be given at intervals of 4 to 6 hours.-Where possible, drug administration should be interrupted occasionally to determine if continued therapy is required.Use: As part of a total treatment program for Attention Deficit Hyperactivity Disorder (ADHD).Usual Pediatric Dose of Adderall for Narcolepsy:IR:Age 6 to 11 Years:-Initial Dose: 5 mg orally per day in divided doses-Maintenance Dose: Daily dose may be raised in 5 mg increments at weekly intervals until optimal response is obtained.Age 12 Years and Older:-Initial Dose: 10 mg orally per day in divided doses-Maintenance Dose: Daily dose may be raised in 10 mg increments at weekly intervals until optimal response is obtained.Comments:-The first dose should be given on awakening; 1 to 2 additional doses should be given at intervals of 4 to 6 hours.-The usual dose is 5 to 60 mg per day in divided doses, depending on the individual patient response.-Dosage should be reduced if bothersome adverse reactions (e.g., insomnia, anorexia) appear.-Narcolepsy rarely occurs in children under 12 years of age.Adderall, Adderall XR, Mydayis\00\00\002actamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) Streptococcus pneumoniae, Staphylococcus species, or Haemophilus influenzae; for the treatment of infections of the genitourinary tract due to susceptible (only beta lactamase negative) isolates of Escherichia coli, Proteus mirabilis, or Enterococcus faecalis; and for the treatment of infections of the skin and structure due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) S pneumoniae, Staphylococcus species, and H influenzaeUsual Adult Dose for Tonsillitis/PharyngitisExtended-release: 775 mg orally once a day within 1 hour after a meal for 10 daysComments: The full 10-day course of treatment should be completed in order to be effective.Uses: For the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenesIDSA recommendations:Immediate-release: 1000 mg orally once a day or 500 mg orally twice a dayUse: For the treatment of Group A Streptococcal pharyngitisUsual Adult Dose for Skin and Structure InfectionImmediate-release:-Mild to moderate infection: 250 mg orally every 8 hours or 500 mg every 12 hours-Severe infection: 500 mg orally every 8 hours or 875 mg every 12 hoursComments: Dosing for infections caused by bacteria that are intermediate in their susceptibility should follow recommendations for severe infections.Use: For the treatment of infections of the skin and structure due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) S pneumoniae, Staphylococcus species, and H influenzaeIDSA recommendations:-Immediate-release: 500 mg orally 3 times a day for 7 to 10 daysUse: For the treatment of erysipeloidUsual Adult Dose for Cutaneous Bacillus anthracisUS CDC Recommendations: 1 g orally every 8 hoursDuration of prophylaxis: 60 daysComments:-Recommended as an alternative oral regimen for postexposure prophylaxis and cutaneous anthrax without systemic involvement; recommended for penicillin-susceptible strains-Current guidelines should be consulted for additional information.Usual Adult Dose for Anthrax ProphylaxisUS CDC Recommendations: 1 g orally every 8 hoursDuration of prophylaxis: 60 daysComments:-Recommended as an alternative oral regimen for postexposure prophylaxis and cutaneous anthrax without systemic involvement; recommended for penicillin-susceptible strains-Current guidelines should be consulted for additional information.Usual Pediatric Dose for Bacterial Endocarditis ProphylaxisAHA recommendations:Children:-Immediate-release: 50 mg/kg orally as a single dose 30 to 60 minutes prior to procedure; maximum of 2 g/doseComments:-Prophylaxis should be used for patients at high risk of adverse outcomes from endocarditis with underlying cardiac conditions who undergo any dental procedure that involves manipulation of gingival tissue or periapical region of a tooth and for those procedures that perforate oral mucosa.-Prophylaxis should also be used for patients at high risk of adverse outcomes from endocarditis who undergo invasive respiratory tract procedures.-Current guidelines should be consulted for additional information.Usual Pediatric Dose for SinusitisImmediate-Release Formulations:Mild, Moderate, or Severe Infection:3 months or younger: Up to 30 mg/kg/day orally in divided doses every 12 hoursComments:-Treatment should be continued for a minimum of 48 to 72 hours beyond the time the patient becomes asymptomatic or evidence of bacterial eradication occurs.-At least 10 days of treatment for any infection caused by Streptococcus pyogenes is recommended to prevent the occurrence of acute rheumatic fever.Immediate-Release Formulations:Mild to Moderate Infection:4 months or older:-Less than 40 kg: 20 mg/kg/day orally in divided doses every 8 hours or 25 mg/kg/day in divided doses every 12 hours-At least 40 kg: 250 mg orally every 8 hours or 500 mg every 12 hoursSevere Infection:4 months \00\00\003or older:-Less than 40 kg: 40 mg/kg/day orally in divided doses every 8 hours or 45 mg/kg/day in divided doses every 12 hours-At least 40 kg: 500 mg orally every 8 hours or 875 mg every 12 hoursComments: Dosing for infections caused by bacteria that are intermediate in their susceptibility should follow recommendations for severe infections.Uses: For the treatment of infections of the ear, nose and throat due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) Streptococcus pneumoniae, Staphylococcus species, or Haemophilus influenzae; for the treatment of infections of the genitourinary tract due to susceptible (only beta lactamase negative) isolates of Escherichia coli, Proteus mirabilis, or Enterococcus faecalis; and for the treatment of infections of the skin and structure due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) S pneumoniae, Staphylococcus species, and H influenzaeUsual Pediatric Dose for Skin or Soft Tissue InfectionImmediate-Release Formulations:Mild, Moderate, or Severe Infection:3 months or younger: Up to 30 mg/kg/day orally in divided doses every 12 hoursComments:-Treatment should be continued for a minimum of 48 to 72 hours beyond the time the patient becomes asymptomatic or evidence of bacterial eradication occurs.-At least 10 days of treatment for any infection caused by Streptococcus pyogenes is recommended to prevent the occurrence of acute rheumatic fever.Immediate-Release Formulations:Mild to Moderate Infection:4 months or older:-Less than 40 kg: 20 mg/kg/day orally in divided doses every 8 hours or 25 mg/kg/day in divided doses every 12 hours-At least 40 kg: 250 mg orally every 8 hours or 500 mg every 12 hoursSevere Infection:4 months or older:-Less than 40 kg: 40 mg/kg/day orally in divided doses every 8 hours or 45 mg/kg/day in divided doses every 12 hours-At least 40 kg: 500 mg orally every 8 hours or 875 mg every 12 hoursComments: Dosing for infections caused by bacteria that are intermediate in their susceptibility should follow recommendations for severe infections.Uses: For the treatment of infections of the ear, nose and throat due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) Streptococcus pneumoniae, Staphylococcus species, or Haemophilus influenzae; for the treatment of infections of the genitourinary tract due to susceptible (only beta lactamase negative) isolates of Escherichia coli, Proteus mirabilis, or Enterococcus faecalis; and for the treatment of infections of the skin and structure due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) S pneumoniae, Staphylococcus species, and H influenzaeUsual Pediatric Dose for Urinary Tract InfectionImmediate-Release Formulations:Mild, Moderate, or Severe Infection:3 months or younger: Up to 30 mg/kg/day orally in divided doses every 12 hoursComments:-Treatment should be continued for a minimum of 48 to 72 hours beyond the time the patient becomes asymptomatic or evidence of bacterial eradication occurs.-At least 10 days of treatment for any infection caused by Streptococcus pyogenes is recommended to prevent the occurrence of acute rheumatic fever.Immediate-Release Formulations:Mild to Moderate Infection:4 months or older:-Less than 40 kg: 20 mg/kg/day orally in divided doses every 8 hours or 25 mg/kg/day in divided doses every 12 hours-At least 40 kg: 250 mg orally every 8 hours or 500 mg every 12 hoursSevere Infection:4 months or older:-Less than 40 kg: 40 mg/kg/day orally in divided doses every 8 hours or 45 mg/kg/day in divided doses every 12 hours-At least 40 kg: 500 mg orally every 8 hours or 875 mg every 12 hoursComments: Dosing for infections caused by bacteria that are intermediate in their susceptibility should follow recommendations for severe infections.Uses: For the treatment of infe\00\00\004ctions of the ear, nose and throat due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) Streptococcus pneumoniae, Staphylococcus species, or Haemophilus influenzae; for the treatment of infections of the genitourinary tract due to susceptible (only beta lactamase negative) isolates of Escherichia coli, Proteus mirabilis, or Enterococcus faecalis; and for the treatment of infections of the skin and structure due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) S pneumoniae, Staphylococcus species, and H influenzaeUsual Pediatric Dose for PneumoniaImmediate-Release Formulations:Mild, Moderate, or Severe infection:3 months or younger: Up to 30 mg/kg/day orally in divided doses every 12 hours4 months or older:-Less than 40 kg: 40 mg/kg/day orally in divided doses every 8 hours or 45 mg/kg/day in divided doses every 12 hours-At least 40 kg: 500 mg orally every 8 hours or 875 mg every 12 hoursUse: For the treatment of infections of the lower respiratory tract due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) S pneumoniae, Staphylococcus species, and H influenzaeIDSA and the Pediatric Infectious Diseases Society recommendations:Immediate-release formulations:4 months or older:-Empiric therapy for presumed bacterial pneumonia: 90 mg/kg/day orally in 2 divided doses; maximum 4 g/day-Streptococcus pneumoniae (penicillin minimum inhibitory concentration of 2 mcg/mL or less): 90 mg/kg/day orally in 2 divided doses or 45 mg/kg/day in 3 divided doses-Group A Streptococcus: 50 to 75 mg/kg/day orally in 2 divided doses-Haemophilus influenza typeable (A to F) or nontypeable: 75 to 100 mg/kg/day orally in 3 divided dosesComments: Current guidelines should be consulted for additional information.Use: For the management of community-acquired pneumoniaUsual Pediatric Dose for BronchitisImmediate-Release Formulations:Mild, Moderate, or Severe infection:3 months or younger: Up to 30 mg/kg/day orally in divided doses every 12 hours4 months or older:-Less than 40 kg: 40 mg/kg/day orally in divided doses every 8 hours or 45 mg/kg/day in divided doses every 12 hours-At least 40 kg: 500 mg orally every 8 hours or 875 mg every 12 hoursUse: For the treatment of infections of the lower respiratory tract due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) S pneumoniae, Staphylococcus species, and H influenzaeIDSA and the Pediatric Infectious Diseases Society recommendations:Immediate-release formulations:4 months or older:-Empiric therapy for presumed bacterial pneumonia: 90 mg/kg/day orally in 2 divided doses; maximum 4 g/day-Streptococcus pneumoniae (penicillin minimum inhibitory concentration of 2 mcg/mL or less): 90 mg/kg/day orally in 2 divided doses or 45 mg/kg/day in 3 divided doses-Group A Streptococcus: 50 to 75 mg/kg/day orally in 2 divided doses-Haemophilus influenza typeable (A to F) or nontypeable: 75 to 100 mg/kg/day orally in 3 divided dosesComments: Current guidelines should be consulted for additional information.Use: For the management of community-acquired pneumoniaUsual Pediatric Dose for Tonsillitis/Pharyngitis12 years or older:-Extended-release: 775 mg orally once a day within 1 hour after a meal for 10 daysComments: The full 10-day course of treatment should be completed in order to be effective.Uses: For the treatment of tonsillitis and/or pharyngitis secondary to S pyogenesIDSA recommendations:Immediate-release: 50 mg/kg (maximum 1000 mg) orally once a day or 25 mg/kg (maximum 500 mg) twice a dayUse: For the treatment of Group A Streptococcal pharyngitisUsual Pediatric Dose for Lyme DiseaseIDSA recommendations:Children:-Immediate-release: 50 mg/kg/day orally in 3 divides doses for 14 to 28 days; maximum single dose of 500 mgComments:-Duration of treatment depends upon sever\00\00\005ity of condition being treated.-Current guidelines should be consulted for additional information.Usual Pediatric Dose for Otitis MediaAmerican Academy of Pediatrics (AAP) and American Academy of Family Physicians (AAFP) recommendations:-Immediate-release: 80 to 90 mg/kg/day orally in 2 divided doses; some experts recommend 90 mg/kg orally in 2 divided doses as initial therapyComments:-Optimal duration of treatment uncertain; however, for young children and children with severe disease at any age, a 10 day course is recommended; children 6 years or older with mild or moderate disease should find a duration of 5 to 7 days appropriate.-Current guidelines should be consulted for additional information.Use: For the treatment of acute otitis mediaUsual Pediatric Dose for Inhalation Bacillus anthracisAAP Recommendations:Up to 1 week of age:-Gestational age 32 to 37 weeks: 50 mg/kg orally in divided doses every 12 hours-Term neonate: 75 mg/kg orally in divided doses every 8 hours1 to 4 weeks:-Gestational age 32 to 37 weeks: 75 mg/kg orally in divided doses every 8 hours-Term neonate: 75 mg/kg/day orally in divided doses every 8 hours1 month or older: 75 mg/kg/day orally in divided doses every 8 hours; not to exceed 1 g/doseDuration of Therapy:Postexposure prophylaxis for B anthracis infection: 60 days after exposureCutaneous anthrax without systemic involvement:-Bioterrorism-related cases: To complete an antimicrobial regimen of up to 60 days from onset of illness-Naturally-acquired cases: 7 to 10 daysFollow-up for severe anthrax:-To complete a regimen of 10 to 14 days or longer (up to 4 weeks of age) or to complete a regimen of 14 days or longer (1 month or older)-Patients may require prophylaxis to complete an antimicrobial regimen of up to 60 days from onset of illness.Comments:-Recommended as an alternative regimen for postexposure prophylaxis, the treatment of cutaneous anthrax without systemic involvement, and oral follow-up therapy for severe anthrax-Recommended as an alternative for penicillin-susceptible strains-Recommended for use with a protein synthesis inhibitor when used for follow-up therapy for severe anthrax (includes anthrax meningitis, inhalation anthrax, injection anthrax, gastrointestinal anthrax, and cutaneous anthrax with systemic involvement, extensive edema, or lesions of the head or neck).-Current guidelines should be consulted for additional information.Usual Pediatric Dose for Cutaneous Bacillus anthracisAAP Recommendations:Up to 1 week of age:-Gestational age 32 to 37 weeks: 50 mg/kg orally in divided doses every 12 hours-Term neonate: 75 mg/kg orally in divided doses every 8 hours1 to 4 weeks:-Gestational age 32 to 37 weeks: 75 mg/kg orally in divided doses every 8 hours-Term neonate: 75 mg/kg/day orally in divided doses every 8 hours1 month or older: 75 mg/kg/day orally in divided doses every 8 hours; not to exceed 1 g/doseDuration of Therapy:Postexposure prophylaxis for B anthracis infection: 60 days after exposureCutaneous anthrax without systemic involvement:-Bioterrorism-related cases: To complete an antimicrobial regimen of up to 60 days from onset of illness-Naturally-acquired cases: 7 to 10 daysFollow-up for severe anthrax:-To complete a regimen of 10 to 14 days or longer (up to 4 weeks of age) or to complete a regimen of 14 days or longer (1 month or older)-Patients may require prophylaxis to complete an antimicrobial regimen of up to 60 days from onset of illness.Comments:-Recommended as an alternative regimen for postexposure prophylaxis, the treatment of cutaneous anthrax without systemic involvement, and oral follow-up therapy for severe anthrax-Recommended as an alternative for penicillin-susceptible strains-Recommended for use with a protein synthesis inhibitor when used for follow-up therapy for severe anthrax (includes anthrax meningitis, inhalation anthrax, injection anthrax, gastrointestinal anthrax, and cutaneous anthrax with systemic involvement, extensive edema, or lesions of the head or neck).-Current gu\00\00\00\00idelines should be consulted for additional information.Usual Pediatric Dose for Anthrax ProphylaxisAAP Recommendations:Up to 1 week of age:-Gestational age 32 to 37 weeks: 50 mg/kg orally in divided doses every 12 hours-Term neonate: 75 mg/kg orally in divided doses every 8 hours1 to 4 weeks:-Gestational age 32 to 37 weeks: 75 mg/kg orally in divided doses every 8 hours-Term neonate: 75 mg/kg/day orally in divided doses every 8 hours1 month or older: 75 mg/kg/day orally in divided doses every 8 hours; not to exceed 1 g/doseDuration of Therapy:Postexposure prophylaxis for B anthracis infection: 60 days after exposureCutaneous anthrax without systemic involvement:-Bioterrorism-related cases: To complete an antimicrobial regimen of up to 60 days from onset of illness-Naturally-acquired cases: 7 to 10 daysFollow-up for severe anthrax:-To complete a regimen of 10 to 14 days or longer (up to 4 weeks of age) or to complete a regimen of 14 days or longer (1 month or older)-Patients may require prophylaxis to complete an antimicrobial regimen of up to 60 days from onset of illness.Comments:-Recommended as an alternative regimen for postexposure prophylaxis, the treatment of cutaneous anthrax without systemic involvement, and oral follow-up therapy for severe anthrax-Recommended as an alternative for penicillin-susceptible strains-Recommended for use with a protein synthesis inhibitor when used for follow-up therapy for severe anthrax (includes anthrax meningitis, inhalation anthrax, injection anthrax, gastrointestinal anthrax, and cutaneous anthrax with systemic involvement, extensive edema, or lesions of the head or neck).-Current guidelines should be consulted for additional information.Renal Dose AdjustmentsExtended-release Tablets:-Severe renal dysfunction (CrCl less than 30 mL/min): Not recommended.Immediate-release formulations:Mild to moderate renal dysfunction: No adjustment recommended.Severe renal dysfunction:-GFR 10 to 30 mL/min: 250 or 500 mg orally every 12 hours, depending on severity of infection-GFR less than 10 mL/min: 250 or 500 mg orally every 24 hours, depending on severity of infectionComments: Patients with severe renal dysfunction (CrCl less than 30 mL/min) should not receive the 875 mg tablets.Liver Dose AdjustmentsData not availablePrecautionsExtended-release tablets: Safety and efficacy have not been established in patients younger than 12 years.Consult WARNINGS section for additional precautions.DialysisHemodialysis:-Extended-release Tablets: Not recommended.-Immediate-release: 250 or 500 mg orally every 24 hours, depending on severity of infection; patients should receive an additional dose both during and at the end of dialysisOther CommentsAdministration advice:-Extended-release tablets: Do not crush or chew; take with food.-Oral suspension: Shake well before use; after reconstitution, the required amount of suspension should be placed directly on patient's tongue and swallowed; alternatively, may add to milk, fruit juice, water, ginger ale, or cold drinks and taken immediately.Storage requirements:-Dispense in a tight container.-Oral suspension: Keep bottle tightly closed; refrigeration preferable but not required; discard after 14 days.Reconstitution/preparation techniques:-Oral suspension: The manufacturer product information should be consulted.General:-To reduce the development of drug-resistant bacteria and maintain efficacy, this drug should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.-When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy; in absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.Patient advice:-Seek medical attention immediately if an allergic reaction occurs.-Contact your healthcare provider if watery and bloody stools develop.-The full course of therapy should be completed.Moxatag\00\00\007 1 g orally once as a single dose plus ceftriaxone-Alternative regimen: 1 g orally once as a single dose plus cefiximeComments:-The alternative regimen may be used for uncomplicated infections if ceftriaxone is unavailable.-Arthritis and arthritis-dermatitis syndrome may be treated with 1 g orally once plus cefotaxime OR ceftizoxime.Uses:-Uncomplicated gonococcal infections of the pharynx, cervix, urethra, and rectum-Treatment of gonococcal conjunctivitis-Treatment of arthritis and arthritis-dermatitis syndrome caused by disseminated gonococcal infection-Treatment of gonococcal meningitis and endocarditisUsual Pediatric Dose for Nongonococcal UrethritisUS CDC Recommendations:Immediate-release:30 days or younger:-Ophthalmia neonatorum: 20 mg/kg orally (oral suspension) once a day for 3 days1 to 3 months:-Infant pneumonia: 20 mg/kg orally (oral suspension) once a day for 3 daysChildren less than 8 years who weigh 45 kg or more, and patients 8 years or older: 1 g orally as a single doseComments:-Neonates should be monitored for signs/symptoms of hypertrophic pyloric stenosis.-Healthcare providers should follow-up to determine whether treatment was effective.Uses:-Alternative treatment of ophthalmia neonatorum caused by C trachomatis-Alternative treatment of chlamydial pneumonia in infants-Treatment of chlamydial infections in childrenUsual Pediatric Dose for Chlamydia InfectionUS CDC Recommendations:Immediate-release:30 days or younger:-Ophthalmia neonatorum: 20 mg/kg orally (oral suspension) once a day for 3 days1 to 3 months:-Infant pneumonia: 20 mg/kg orally (oral suspension) once a day for 3 daysChildren less than 8 years who weigh 45 kg or more, and patients 8 years or older: 1 g orally as a single doseComments:-Neonates should be monitored for signs/symptoms of hypertrophic pyloric stenosis.-Healthcare providers should follow-up to determine whether treatment was effective.Uses:-Alternative treatment of ophthalmia neonatorum caused by C trachomatis-Alternative treatment of chlamydial pneumonia in infants-Treatment of chlamydial infections in childrenUsual Pediatric Dose for CervicitisUS CDC Recommendations:Immediate-release:30 days or younger:-Ophthalmia neonatorum: 20 mg/kg orally (oral suspension) once a day for 3 days1 to 3 months:-Infant pneumonia: 20 mg/kg orally (oral suspension) once a day for 3 daysChildren less than 8 years who weigh 45 kg or more, and patients 8 years or older: 1 g orally as a single doseComments:-Neonates should be monitored for signs/symptoms of hypertrophic pyloric stenosis.-Healthcare providers should follow-up to determine whether treatment was effective.Uses:-Alternative treatment of ophthalmia neonatorum caused by C trachomatis-Alternative treatment of chlamydial pneumonia in infants-Treatment of chlamydial infections in childrenUsual Pediatric Dose for ChancroidUS CDC Recommendations:Immediate-release:Adolescents: 1 g orally onceComments:-The efficacy of this drug in female patients with chancroid has not been established.-The patient's sexual partner(s) during the 10 days preceding the onset of symptoms should be evaluated/treated.-Patients should be tested for HIV infection when chancroid is diagnosed and a serologic test for HIV and syphilis should be performed 3 months after diagnosis in patients with negative initial HIV test results.Use: Treatment of genital ulcer disease in men due to H ducreyi (chancroid)Usual Pediatric Dose for Mycobacterium avium-intracellulare - ProphylaxisNIH and IDSA Recommendations:Immediate-release:CHILDREN:Primary prophylaxis of MAC disease:-First choice: 20 mg/kg orally once a week (max 1200 mg/week)-Alternative choice: 5 mg/kg orally once a day (max 250 mg/day)Secondary prophylaxis/chronic suppressive therapy):-Alternative choice: 5 mg/kg (maximum: 250 mg) orally once a day plus ethambutol with/without rifabutinADOLESCENTS:Patients with AIDS and CD4 counts less than 50 cells/mcL:-Primary prophylaxis: 1200 mg orally once a week OR 600 mg orally 2 tim\00\00\00\00es a weekComments:-Primary prophylaxis may be discontinued when the CD3 count is greater than 100 cells/mm3 for at least 3 months in response to antiretroviral therapy (ART).-Secondary prophylaxis is usually continued for life; however, discontinuation may be considered in patients with sustained immune recovery in response to ART.Use: Preventing the first episode of disseminated MAC diseaseUsual Pediatric Dose for Mycobacterium avium-intracellulare - TreatmentNIH and IDSA Recommendations:Immediate-release:CHILDREN:-Alternative: 10 to 12 mg/kg (maximum: 500 mg/day) orally once a day plus ethambutol with/without rifabutin for at least 12 monthsADOLESCENTS:-Initial treatment of nodular/bronchiectatic disease: 500 mg orally 3 times a week plus rifampin and ethambutol-Initial treatment of fibrocavitary MAC pulmonary or severe nodular/bronchiectatic disease: 250 mg orally once a day plus ethambutol and rifampin, with/without streptomycin or amikacin-Advanced/severe or previously treated MAC disease: 250 to 300 mg orally once a day plus ethambutol-Treatment of disseminated MAC disease: 250 mg orally once a day plus ethambutol---Some experts recommend: 500 to 600 mg orally once a day plus ethambutolComments:-Patients with severe/advanced disease should be treated until culture negative (e.g., 1 year).-Patients with disseminated MAC disease may discontinue treatment when symptoms resolve and cell-mediated immune function resumes.-Treatment of disseminated MAC disease is preferred when drug interactions/intolerance preclude use of clarithromycin.-Once patients are treated, chronic suppressive therapy/secondary prophylaxis should be considered.Use: Alternative treatment of MAC pulmonary diseaseUsual Pediatric Dose for STD ProphylaxisUS CDC Recommendations:Immediate-release:Adolescents: 1 g orally once as a single dose, in conjunction with ceftriaxone plus (metronidazole or tinidazole)Use: Postexposure prophylaxis of sexually transmitted diseases in survivors of sexual assaultUsual Pediatric Dose for Pertussis ProphylaxisASBMT and IDSA Recommendations:Immediate-release:Immunization against pertussis:-Alternative treatment: 5 mg/kg orally once a dayPostexposure prophylaxis: 10 mg/kg orally (as a loading dose), then 5 mg/kg orally once a day for 4 daysComments:-Patients should receive the acellular pertussis vaccine after hematopoietic cell transplantation (HCT).-Treatment with this drug may be given to patients with an incomplete vaccination series.Uses:-Immunization against pertussis for adult HCT recipients-Postexposure prophylaxis for HCT recipients, regardless of vaccination statusUsual Pediatric Dose for PertussisASBMT and IDSA Recommendations:Immediate-release:Immunization against pertussis:-Alternative treatment: 5 mg/kg orally once a dayPostexposure prophylaxis: 10 mg/kg orally (as a loading dose), then 5 mg/kg orally once a day for 4 daysComments:-Patients should receive the acellular pertussis vaccine after hematopoietic cell transplantation (HCT).-Treatment with this drug may be given to patients with an incomplete vaccination series.Uses:-Immunization against pertussis for adult HCT recipients-Postexposure prophylaxis for HCT recipients, regardless of vaccination statusUsual Pediatric Dose for Lyme Disease - Erythema Chronicum MigransIDSA Recommendations:Immediate-release:Early Lyme disease: 10 mg/kg orally once a day-Maximum dose: 500 mg/dayComment: Use should be reserved for patients who are intolerant or should not take amoxicillin, doxycycline, and cefuroxime axetil.Use: Alternative treatment for early Lyme diseaseUsual Pediatric Dose for BabesiosisIDSA Recommendations:Immediate-release:10 mg/kg (maximum: 500 mg/dose) orally once on day 1, followed by 5 mg/kg (maximum: 250 mg/dose) orally once a day for a total of 7 to 10 daysComment: This drug should be given with atovaquone.Use: Treatment of babesiosisAzithromycin 3 Day Dose Pack, Azithromycin 5 Day Dose Pack, Zithromax, Zithromax TRI-PAK, Zithromax Z-Pak, Zmax, Zithromax IV\00\00\00\EA\00\EA\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\B4 \00!!\84S\90\D1q\81eFamotidineFamotidineFamotidine a histamine-2 blockers. Famotidine works by decreasing the amount of acid the stomach produces. Famotidine is used to treat and prevent ulcers in the stomach and intestines. It also treats conditions in which the stomach produces too much acid, such as Zollinger-Ellison syndrome. Check with your doctor immediately if any of the following side effects occur while taking famotidine:Rare    Bleeding gums    blistering, peeling, or loosening of the skin    blood in the urine or stools    bloody, black, or tarry stools    chest pain    chills    cough or hoarseness    diarrhea    fever    fever with or without chills    general feeling of tiredness or weakness    high fever    itching    joint or muscle pain    lower back or side pain    painful or difficult urination    pale skin    pinpoint red spots on the skin    red, irritated eyes    red skin lesions, often with a purple center    shortness of breath    sore throat    sores, ulcers, or white spots on the lips or in the mouth    swollen glands    unusual bleeding or bruising    unusual tiredness or weaknessIncidence not known    Abdominal or stomach pain    anxiety    burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings    clay-colored stools    dark urineThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.Usual Adult Dose for Duodenal UlcerOral:-Usual dose: 40 mg orally once a day at bedtime OR 20 mg orally 2 times a day-Maintenance dose: 20 mg orally once a day at bedtime-Duration of therapy: 4 weeksParenteral:-Usual dose: 20 mg IV every 12 hoursComments:-Most patients who received oral formulations healed within 4 weeks, with few patients requiring treatment for 6 to 8 weeks; there are no safety data for the treatment of uncomplicated active duodenal ulcer beyond 8 weeks. Studies have not been conducted in patients receiving oral maintenance therapy for longer than 1 year.-Parenteral treatment should be limited to patients who cannot tolerate oral formulations.Uses:-Short-term treatment of active duodenal ulcer-Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer-Hospitalized patients with intractable ulcers, or as an alternative to the oral dosage forms for short-term use in patients who are unable to take oral medication for active duodenal ulcers-Alternative to the oral dosage forms for short-term use in specific hospitalized patients who are unable to take oral medic\00\00\009\A2a\00'\84Y\94+\ACElavilAmitriptylineThis medication is used to treat mental/mood problems such as depression. It may help improve mood and feelings of well-being, relieve anxiety and tension, help you sleep better, and increase your energy level. This medication belongs to a class of medications called tricyclic antidepressants.Check with your doctor immediately if any of the following side effects occur while taking amitriptyline:Incidence not known    Abdominal or stomach pain    agit\00\00\00 \00\00\00\00ation for duodenal ulcer maintenance therapyUsual Adult Dose for Peptic UlcerOral:-Usual dose: 40 mg orally once a day at bedtime OR 20 mg orally 2 times a day-Maintenance dose: 20 mg orally once a day at bedtime-Duration of therapy: 4 weeksParenteral:-Usual dose: 20 mg IV every 12 hoursComments:-Most patients who received oral formulations healed within 4 weeks, with few patients requiring treatment for 6 to 8 weeks; there are no safety data for the treatment of uncomplicated active duodenal ulcer beyond 8 weeks. Studies have not been conducted in patients receiving oral maintenance therapy for longer than 1 year.-Parenteral treatment should be limited to patients who cannot tolerate oral formulations.Uses:-Short-term treatment of active duodenal ulcer-Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer-Hospitalized patients with intractable ulcers, or as an alternative to the oral dosage forms for short-term use in patients who are unable to take oral medication for active duodenal ulcers-Alternative to the oral dosage forms for short-term use in specific hospitalized patients who are unable to take oral medication for duodenal ulcer maintenance therapyUsual Pediatric Dose for Peptic Ulcer1 TO 16 YEARS:Oral:-Usual dose: 0.5 mg/kg orally once a day at bedtime OR 0.25 mg/kg orally 2 times a day-Maximum dose: 40 mg/dayParenteral:-Initial dose: 0.25 mg/kg IV injected over at least 2 minutes OR infused over 15 minutes every 12 hours-Maximum dose: 40 mg/day16 YEARS AND OLDER:Oral:-Usual dose: 40 mg orally once a day at bedtime OR 20 mg orally 2 times a day-Maintenance dose: 20 mg orally once a day at bedtime-Duration of therapy: 4 weeksParenteral:-Usual dose: 20 mg IV every 12 hoursComments:-Uncontrolled clinical trials have used oral doses up to 1 mg/kg in patients 1 to 16 years of age.-Gastric acid suppression occurred at IV doses of 0.5 mg/kg every 12 hours.Uses:-Short-term treatment of active duodenal ulcer-Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer-Hospitalized patients with intractable ulcers, or as an alternative to the oral dosage forms for short-term use in patients who are unable to take oral medication for active duodenal ulcers-Alternative to the oral dosage forms for short-term use in specific hospitalized patients who are unable to take oral medication for duodenal ulcer maintenance therapyUsual Pediatric Dose for Gastroesophageal Reflux DiseaseLESS THAN 3 MONTHS:Oral:-Initial dose: 0.5 mg/kg orally once a day-Duration of therapy: Up to 8 weeks3 MONTHS TO LESS THAN 1 YEAR:Oral:-Initial dose: 0.5 mg/kg orally 2 times a day-Duration of therapy: Up to 8 weeks1 YEAR TO 16 YEARS:Oral:-Usual dose: 0.5 mg/kg/day orally 2 times a day-Maximum dose: Up to 40 mg/doseParenteral:-Initial dose: 0.25 mg/kg IV injected over at least 2 minutes OR infused over 15 minutes every 12 hours-Maximum dose: 40 mg/day16 YEARS AND OLDER:Oral:-Usual dose: 20 mg orally 2 times day-Duration of therapy: Up to 6 weeksParenteral:-Usual dose: 20 mg IV every 12 hoursComments:-The concomitant use of conservative measures (e.g., thickened feedings) should be considered during treatment.-Parenteral treatment should be limited to patients who cannot tolerate oral formulations.-Uncontrolled clinical trials have used oral doses up to 2 mg/kg in patients 1 to 16 years of age with gastroesophageal reflux disease (GERD) with/without esophagitis (including erosions ad ulcerations).-Oral dissolving tablets may be used in patients 6 years and older, but should be taken as an intact tablet.Uses:-Short-term treatment of esophagitis due to gastroesophageal reflux disease, including erosive/ulcerative disease diagnosed by endoscopy-Alternative to the oral dosage forms for short-term use in specific hospitalized patients who are unable to take oral medication for GERDHeartburn Relief, Pepcid, Pepcid AC, Pepcid AC Maximum Strength, Pepcid RPD, Mylanta AR, Leader Acid Reducer\00\00\00\EE\00\EE\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\92!\00'\83\92=\8E9FarxigaDapagliflozinFarxiga (dapagliflozin) is a sodium-glucose co-transporter 2 (SGLT2) inhibitor used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Check with your doctor immediately if any of the following side effects occur while taking dapagliflozin:More common    Anxiety    bladder pain    bloody or cloudy urine    blurred vision    chills    cold sweats    coma    confusion    cool, pale skin    decreased frequency or amount of urine    depression    difficult, burning, or painful urination    dizziness    fast heartbeat    frequent urge to urinate    headache    increased hunger    increased thirst    itching of the vagina or genitals    loss of appetite    lower back or side pain    nausea    nightmares    seizures    shakiness    slurred speech    swelling of the face, fingers, or lower legs    thick, white vaginal discharge with mild or no odor    troubled breathing    unusual tiredness or weakness    vomiting    weight gainLess common    Foul smelling discharge from the penis    pain in the skin around the penis    rash of the penis    redness, itching, or swelling of the penisRare    Cough    difficulty with swallowing    dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position    dry mouth    faintingThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.The recommended starting dose of FARXIGA is 5 mg once daily, taken in the morning, with or without food. In patients tolerating FARXIGA 5 mg once daily who require additional glycemic control, the dose can be increased to 10 mg once daily.In patients with volume depletion, correcting this condition prior to initiation of FARXIGA is recommended.Patients with Renal ImpairmentAssessment of renal function is recommended prior to initiation of FARXIGA therapy and periodically thereafter.â€‹Initiation of FARXIGA is not recommended in patients with an eGFR less than 60 mL/min/1.73 m2.No dose adjustment is needed in patients with mild renal impairment (eGFR of 60 mL/min/1.73 m2 or greater).â€‹Use of FARXIGA is not recommended in patients with an eGFR persistently between 30 and less than 60 mL/min/1.73 m2Farxiga\00\00\00)\00)\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\97T"\00#\84m\91#\98sFaslodexFulvestrantFulvestrant is used to treat breast cancer that has spread to other areas of the body in women who have gone through "the change of life" (menopause). It is used in patients who have not responded well to other medications (e.g., tamoxifen). Breast cancer cells need the hormone estrogen in order to growCheck with your doctor or nurse immediately if any of the following side effects occur while taking fulvestrant:More common    Bloating or swelling of the face, arms, hands, lower legs, or feet    rapid weight gain    tingling of the hands or feet    unusual weight gain or lossLess common    Difficult or labored breathing    tightness in the chestIncidence not known    Black, tarry stools    chest pain    chills    cough    fever    flushing or redness of the skin    hives or welts, itching, or rash    large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs    pain in the chest, groin, or legs, especially the calves    painful or difficult urination    severe and sudden headache    slurred speech    sore throat    sores, ulcers, or white spots on the lips or in the mouth    sudden and severe weakness or numbness in the arm or leg    sudden loss of coordination    sudden unexplained shortness of breath    swollen glands    unusual bleeding or bruising    unusual tiredness or weakness    vaginal bleedingThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.MonotherapyThe recommended dose is 500 mg to be administered intramuscularly into the buttocks (gluteal area) slowly (1 - 2 minutes per injection) as two 5 mL injections, one in each buttock, on days 1, 15, 29 and once monthly thereafter [see Clinical Studies (14)].Combination Therapy with PalbociclibWhen FASLODEX is used in combination with palbociclib, the recommended dose is 500 mg to be administered intramuscularly into the buttocks (gluteal area) slowly (1 - 2 minutes per injection) as two 5 mL injections, one in each buttock, on days 1, 15, 29 and once monthly thereafter. The recommended dose of palbociclib is a 125 mg capsule taken orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days. Palbociclib should be taken with food. Please refer to the full prescribing information of palbociclib.Pre/perimenopausal women treated with the combination FASLODEX plus palbociclib should be treated with luteinizing hormone-releasing hormone (LHRH) agonists according to current clinical practice standards.Dose ModificationMonotherapyHepatic Impairment:A dose of 250 mg is recommended for patients with moderate hepatic impairment (Child-Pugh class B) to be administered intramuscularly into the buttock (gluteal area) slowly (1 - 2 minutes) as one 5 mL injection on days 1, 15, 29 and once monthly thereafter.FASLODEX has not been evaluated in patients with severe hepatic impairment (Child-Pugh class C)Faslodex\00\00\00\C6\00\C6\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\9A\9A7#\00\84y\8F\A0?FemaraLetrozoleFemara (generic name is letrozole) is an oral drug which can be an effective fertility treatment for women with ovulation problems, or for those with unexplained infertility. This medication is in a class of drug called aromatase inhibitors. Femara has mainly been used to treat certain cases of breast cancer. Check with your doctor immediately if any of the following side effects occur while taking letrozole:Less common    Bone fracture    breast pain    chest pain    chills, fever, or flu-like symptoms    mental depression    shortness of breath    swelling of the feet or lower legsRare    Continuing or severe nervousness    cough    dizziness or lightheadedness    fainting    fast heartbeat    heart attack    increased sweating    nausea    pain in the chest, groin, or legs, especially the calves    severe and sudden, unexplained shortness of breath    severe, sudden headache    slurred speech    sudden loss of coordination    sudden, severe weakness or numbness in the arm or leg    vaginal bleeding    vision changesIncidence not known    Black, tarry stools    blindness    blurred vision    burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings    chest discomfort    decreased visionThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.The recommended dose of Femara is one 2.5 mg tablet administered once a day, without regard to meals.Use in Adjuvant Treatment of Early Breast CancerIn the adjuvant setting, the optimal duration of treatment with letrozole is unknown. In both the adjuvant study and the post approval adjuvant study, median treatment duration was 5 years. Treatment should be discontinued at relapse [see Clinical Studies (14.1)].Use in Extended Adjuvant Treatment of Early Breast CancerIn the extended adjuvant setting, the optimal treatment duration with Femara is not known. The planned duration of treatment in the study was 5 years. In the final updated analysis, conducted at a median follow-up of 62 months, the median treatment duration for Femara was 60 months. Seventy-one (71%) percent of patients were treated for at least 3 years and 58% of patients completed at least 4.5 years of extended adjuvant treatment. The treatment should be discontinued at tumor relapse [see Clinical Studies (14.2)].Use in First and Second-Line Treatment of Advanced Breast CancerIn patients with advanced disease, treatment with Femara should continue until tumor progression is evident [see Clinical Studies (14.4, 14.5)].Use in Hepatic ImpairmentNo dosage adjustment is recommended for patients with mild to moderate hepatic impairment, although Femara blood concentrations were modestly increased in subjects with moderate hepatic impairment due to cirrhosis. The dose of Femara in patients with cirrhosis and severe hepatic dysfunction should be reduced by 50% [see Warnings and Precautions (5.3)]. The recommended dose of Femara for such patients is 2.5 mg administered every other day. The effect of hepatic impairment on Femara exposure in noncirrhotic cancer patients with elevated bilirubin levels has not been determined.Use in Renal ImpairmentNo dosage adjustment is required for patients with renal impairment if creatinine clearance is greater than or equal to 10 mL/minFemara\00\00\00\00in how much urine is passed, blood in the urine, or a big weight gain.    Fever or chills.    Change in color of skin to a bluish color like on the lips, nail beds, fingers, or toes.    Feeling very tired or weak.    Seizures.    Bloating.    Feeling confused.    Swelling.    Very bad dizziness or passing out.    A heartbeat that does not feel normal.    Any unexplained bruising or bleeding.    Mood changes.    Muscle or joint pain.    Change in speech.    Change in eyesight.    Blurred eyesight.    Shakiness.    Sweating a lot.    Very bad belly pain.    Dark urine or yellow skin or eyes.    Very bad irritation where the shot was given.    Lung problems have happened with this drug. Call your doctor right away if you have lung or breathing problems like trouble breathing, shortness of breath, or a cough that is new or worse.This drug may raise the chance of a very bad brain problem called aseptic meningitis. Call your doctor right away if you have a headache, fever, chills, very upset stomach or throwing up, stiff neck, rash, bright lights bother your eyes, feeling sleepy, or feeling confused.The information is not a substitute for medical advice. Always consult your doctor or pharmacist.Usual Adult Dose for Primary Immunodeficiency SyndromeIntravenously:300 to 600 mg/kg, IV, every 3 to 4 weeks-Initial infusion rate: 1 mg/kg/min-Maximum infusion rate (if tolerated): 8 mg/kg/minSubcutaneously:1.37 x current IV dose in grams / number of weeks between IV doses; administer weekly-Infuse subcutaneously at 20 mL/hr/site-Use up to 8 infusion sites simultaneously-Ensure infusion sites are at least 2 inches (5 cm) apartComments:-Begin subcutaneous dosing one week after the patient's last IV infusion.-For subcutaneous administration: convert the previous IV dose (in grams) by multiplying by 1.37, then dividing this dose into weekly doses based on the previous IV interval.Use: Treatment of primary humoral immunodeficiency including, but not limited to, congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.Usual Adult Dose for Idiopathic (Immune) Thrombocytopenic Purpura1 g/kg, IV, on two consecutive days (high dose regimen)or0.4 g/kg, IV, on five consecutive days(total dose 2 g/kg)-Initial infusion rate: 1 mg/kg/min; increase gradually if tolerated-Maximum infusion rate: 8 mg/kg/minComments:-If after administration of the first 1 g/kg (high dose regimen), an adequate increase in platelet count is seen at 24 hours, the second dose may be withheld.-High dose regimen is not recommended if expanded fluid volumes exist or if fluid volume may be a concern.-Do not administer subcutaneously in idiopathic thrombocytopenic purpura (ITP) patients.Use: Treatment of patients with idiopathic thrombocytopenic purpura to raise platelet counts to prevent bleeding or allow surgery to be performed.Usual Pediatric Dose for Primary Immunodeficiency SyndromeIntravenously:300 to 600 mg/kg, IV-Initial infusion rate: 1 mg/kg/min-Maintenance infusion rate (if tolerated): 8 mg/kg/min every 3 to 4 weeksSubcutaneously:1.37 x current IV dose in grams / number of weeks between IV doses; administer weekly-Initial infusion rate: 10 mL/hr/site-Maintenance infusion rate; patients under 25 kg: 10 mL/hr/site-Maintenance infusion rate; patients 25 kg and over: 20 mL/hr/site-Use up to 6 infusion sites simultaneously-Ensure infusion sites are at least 2 inches (5 cm) apartComments:-Begin subcutaneous dosing one week after the patient's last IV infusion.-Convert the previous IV dose (in grams) by multiplying by 1.37, then dividing this dose into weekly doses based on the previous IV interval.Use: Treatment of primary humoral immunodeficiency including, but not limited to, congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.Carimune, Flebogamma, Gammagard, Gammaplex, Octagam, Privigen\00\00\00\FF\00\FF	\A8\B8?\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\A65%\00U\84G\99/\AD/\81GammagardImmune globulin (intravenous) (IGIV)This medication is made from healthy human blood that has a high level of certain defensive substances (antibodies), which help fight infections. It is also used to increase the blood count (platelets) in persons with a certain blood disorder (idiopathic thrombocytopenia purpura-ITP).Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.    Signs of kidney problems like unable to pass urine, change \00\00\00=\A4n(\00\82\94\B3+HalavenEribulinEribulin is used to treat certain types of cancer (breast, liposarcoma). It works by slowing or stopping the growth of cancer cells.Check with your doctor or nurse immediately if any of the following side effects occur while taking eribulin:More common    Black, tarry stools    bladder pain    bloating or swelling of the face, arms, hands, lower legs, or feet    bloody or cloudy urine    body aches or pain    burning, numbness, tingling, or painful sensations    chills    convulsions    cough    decreased urine    decreased weight    difficult or labored breathing    difficult, \00\00\00B\A1l'\00!\84O\8EG\AFcWGlucotrolGlipizide Glipizide is an oral diabetes medicine that helps control blood sugar levels. This medication helps your pancreas produce insulin. Glipizide is used together with diet and exercise to treat type 2 diabetes. Glipizide may also be used for other purposes not listed in this medication guide. Check with your doctor immediately if any of the following side effects occur while taking glipizide:Less common    Anxiety    blurred vision    burning, crawling, \00\00\00A\A4h&\00U\8A\8Ck\B15qGamunex-CImmune globulin (intravenous) (IGIV)This medication is used in people with a certain type of weakened immune system (primary immune deficiency) to strengthen it and to lower the risk of infection. This medication is made from human blood that has a high level of antibodies which help fight infections.This product is also used to increase the number of certain blood cells (platelets) in people with a certain blood disorder (idiopathic thrombocytopenic purpura-ITP). Platelets are needed to stop bleeding and to form normal blood clots.In addition, this medication is used to treat a certain ne\00\00\00@\A7Z$\00!!\84	\8Ds\BCUYGabapentinGabapentinGabapentin is used with other medications to prevent and control seizures. It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection) in adults. Gabapentin is known as an anticonvulsant or antiepileptic drug.Check with your doctor immediately if any of the following side effects occur while taking gabapentin:More common    Clumsiness or unsteadiness    continuous, uncontrolled, back-and-forth, or rolling eye movementsMore common in children    Aggressive behavior or other behavior problems    anxiety    concentration problems and change in school performance    crying    depression    false sense of well-being    hyperactivity or increase in body movements    rapidly changing moods    reacting too quickly, too emotional, or overreacting    restlessness    suspiciousness or distrustLess common    Black, tarry stools    chest pain    chills    cough    depression, irritability\00\00\00M\00\00\00\00not known    Abdominal or stomach pain    back, leg, or stomach pains    black, tarry stools    bleeding gums    blistering, peeling, or loosening of the skin    bloating    blood in the urine or stools    bloody urine    blue lips and fingernails    blurred vision    burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings    chest pain    chills    clay-colored stools    cloudy urine    cold sweats    confusion    constipation    cough or hoarseness    coughing that sometimes produces a pink frothy sputum    coughing up blood    cracks in the skin    darkened urine    decrease in urine output or decrease in urine-concentrating ability    decreased frequency or amount of urine    diarrhea    difficult, fast, or noisy breathing, sometimes with wheezing    difficulty with breathing    difficulty with swallowing    dizziness, faintness, or lightheadedness when getting up from a lying or sitting position    dry mouth    fast or irregular heartbeat    fever    flushed, dry skin    fruit-like breath odor    general body swelling    general feeling of discomfort or illness    general feeling of tiredness or weakness    greatly decreased frequency of urination or amount of urine    headache    hives    increased blood pressureThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.Usual Adult Dose for EdemaUsual dose: 25 mg to 100 mg orally once or twice dailyComments:-Some patients respond to intermittent therapy, (i.e., administration on alternate days or on 3 to 5 days each week). Excessive response and undesirable electrolyte imbalance are less likely to occur with intermittent dosing.Usual Adult Dose for HypertensionInitial dose: 25 mg orally once dailyMaintenance dose: May increase to 50 mg orally daily, as a single or 2 divided dosesComments:-Patients usually do not require doses in excess of 50 mg daily when used concomitantly with other antihypertensive agents.Usual Adult Dose for NephrocalcinosisInitial: 25 mg orally once dailyMaintenance dose: May increase to 50 mg twice dailyUsual Adult Dose for OsteoporosisInitial: 25 mg orally once dailyMaintenance dose: May increase to 50 mg dailyUsual Adult Dose for Diabetes InsipidusInitial: 50 mg orally once dailyMaintenance dose: May increase to 100 mg orally dailyUsual Pediatric Dose for EdemaLess than 6 months: Up to 3 mg/kg/day (up to 1.5 mg/pound) orally in 2 divided dosesLess than 2 years: 1 to 2 mg/kg/day (0.5 to 1 mg/pound) orally daily as a single dose or in 2 divided dosesMaximum dose 37.5 mg per day2 to 12 years: 1 to 2 mg/kg/day (0.5 to 1 mg/pound) orally daily as a single dose or in 2 divided dosesMaximum dose 100 mg per dayUsual Pediatric Dose for HypertensionLess than 6 months: Up to 3 mg/kg/day (up to 1.5 mg/pound) orally in 2 divided dosesLess than 2 years: 1 to 2 mg/kg/day (0.5 to 1 mg/pound) orally daily as a single dose or in 2 divided dosesMaximum dose 37.5 mg per day2 to 12 years: 1 to 2 mg/kg/day (0.5 to 1 mg/pound) orally daily as a single dose or in 2 divided dosesMaximum dose 100 mg per dayRenal Dose AdjustmentsCrCl less than 30 mL/min: Not recommended; thiazide diuretics are considered ineffective below this level.Liver Dose AdjustmentsThiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma.Dose AdjustmentsMany patients with edema respond to intermittent therapy by giving doses on alternate days or 3 to 5 days/week. Patients usually do not require more than 50 mg/day when combined with other antihypertensives.Microzidethe previous IV interval.Use: Treatment of primary humoral immunodeficiency including, but not limited to, congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.Carimune, Flebogamma, Gammagard, Gammaplex, Octagam, Privigen\00\00\00\00rve disorder (chronic inflammatory demyelinating polyneuropathy-CIDP).  Check with your doctor or nurse immediately if any of the following side effects occur while taking immune globulin intravenous:More common    Chills    cough    fast, pounding, or irregular heartbeat or pulse    fever    noisy breathing    tightness in the chest    troubled breathing    unusual tiredness or weaknessLess common    Bluish coloring of the lips or nail beds    burning sensation in the head    faintness or lightheadednessRare    Difficulty with swallowing    hives or welts    itching, especially of the feet or hands    reddening of the skin, especially around the ears    swelling of the eyes, face, or inside of the noseIncidence not known    Back, leg, or stomach pains    blistering, peeling, or loosening of the skin    change in vision    changes in urinationThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.Usual Adult Dose for Chronic Lymphocytic LeukemiaGammagard S/D(R):400 mg/kg, IV, every 3 to 4 weeksUse: Prevention of bacterial infections in hypogammaglobulinemia and/or recurrent bacterial infections associated with B-cell chronic lymphocytic leukemia (CLL).Usual Adult Dose for Idiopathic (Immune) Thrombocytopenic PurpuraCarimune(R): 400 mg/kg, IV, daily for 2 to 5 consecutive days-Initial infusion rate is 0.5 mg/kg/min for 30 minutes.-If initial infusion is tolerated, may increase to 1 mg/kg/min, and gradually increased step-wise as tolerated.-Maximum infusion rate is 3 mg/kg/min.-Chronic ITP maintenance: if, after induction therapy, platelet count falls to less than 30,000/microliter and/or there is clinically significant bleeding, 400 mg/kg may be given as a single infusion. If response is inadequate, dose can be increased to 800 to 1,000 mg/kg given as a single infusion.Gammagard S/D(R): 1 gram/kg, IVMaximum dose: Up to 3 separate doses on alternate daysGammaplex(R): 1 gram/kg, IV, daily for 2 consecutive days-Initial infusion rate is 0.5 mg/kg/min.-May increase rate gradually every 15 minutes.-Maximum infusion rate is 4 mg/kg/min.Octagam(R): 1 gram/kg, IV, daily for 2 consecutive days-Initial infusion rate is 1 mg/kg/min.-Maximum infusion rate is 12 mg/kg/min.Privigen(R): 1 gram/kg, IV, daily for 2 consecutive days (total dose of 2 grams/kg)-Initial infusion rate is 0.5 mg/kg/min.-Maximum infusion rate is 4 mg/kg/min.Comments:-The need for additional doses is determined by clinical response and platelet count.Use: Prevention and/or control of bleeding in adult chronic idiopathic purpura (ITP) patients.Usual Adult Dose for Primary Immunodeficiency SyndromeBivigam(R): 300 to 800 mg/kg, IV, every 3 to 4 weeks-Infuse at 0.5 mg/kg/min for the first 10 minutes of the infusion.-If tolerated, may increase infusion rate by 0.8 mg/kg/min every 20 minutes.-Maximum infusion rate is 6 mg/kg/min.Carimune(R): 400 to 800 mg/kg, IV, every 3 to 4 weeks-Initial infusion rate is 0.5 mg/kg/min for 30 minutes.-If tolerated, may increase to 1 mg/kg/min; gradually increase step-wise as tolerated.-Maximum infusion rate is 3 mg/kg/min.Flebogamma(R): 300 to 600 mg/kg, IV, every 3 to 4 weeks-Initial infusion rate is 0.5 mg/kg/min.-Maximum infusion rate is 5 mg/kg/min.Gammaplex(R): 300 to 800 mg/kg, IV, every 3 to 4 weeks-Initial infusion rate is 0.5 mg/kg/min.-May increase rate gradually every 15 minutes.-Maximum infusion rate is 4 mg/kg/min.Gammagard S/D(R): 300 to 600 mg/kg, IV, every 3 to 4 weeksPrivigen(R): 200 to 800 mg/kg, IV, every 3 to 4 weeks-Initial infusion rate is 0.5 mg/kg/min.-Maximum infusion rate is 8 mg/kg/minComments:-Adjust dose according to clinical response.-Dose and dosing frequency may vary from patient to patient.-No optimum target serum IgG level has been determined.-Target a trough level of 600 mg/dL or higher of IgG; consider dose adjustments if trough IgG levels are less than 500 mg/dL.Use: Treatment of primary immunodeficiencyCarimune, Flebogamma, Gammaplex, Octagam, Privigen\00\00\00\00itching, numbness, prickling, "pins and needles", or tingling feelings    chills    cold sweats    coma    confusion    cool, pale skin    depression    difficulty with moving    dizziness    fainting    fast heartbeat    headache    increased hunger    joint pain    leg cramps    muscle aching or cramping    muscle pain or stiffness    nausea    nervousness    nightmares    pain in the joints    problems in urination or increase in the amount of urine    seizures    shakiness    slurred speech    sweating    swollen joints    unusual tiredness or weaknessRare    Abdominal or stomach pain    bloating    bloody or black, tarry stools    body aches or pain    burning, dry, or itching eyes    clay-colored stoolsThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.Initial DoseThe recommended starting dose is 5 mg, given before breakfast. Geriatric patients or those with liver disease may be started on 2.5 mg.TitrationDosage adjustments should ordinarily be in increments of 2.5â€“5 mg, as determined by blood glucose response. At least several days should elapse between titration steps. If response to a single dose is not satisfactory, dividing that dose may prove effective. The maximum recommended once daily dose is 15 mg. Doses above 15 mg should ordinarily be divided and given before meals of adequate caloric content. The maximum recommended total daily dose is 40 mg.MaintenanceSome patients may be effectively controlled on a once-a-day regimen, while others show better response with divided dosing. Total daily doses above 15 mg should ordinarily be divided. Total daily doses above 30 mg have been safely given on a b.i.d. basis to long-term patients.In elderly patients, debilitated or malnourished patients, and patients with impaired renal or hepatic function, the initial and maintenance dosing should be conservative to avoid hypoglycemic reactions (see PRECAUTIONS section).Patients Receiving InsulinAs with other sulfonylurea-class hypoglycemics, many stable non-insulin-dependent diabetic patients receiving insulin may be safely placed on GLUCOTROL. When transferring patients from insulin to GLUCOTROL, the following general guidelines should be considered:For patients whose daily insulin requirement is 20 units or less, insulin may be discontinued and GLUCOTROL therapy may begin at usual dosages. Several days should elapse between GLUCOTROL titration steps.For patients whose daily insulin requirement is greater than 20 units, the insulin dose should be reduced by 50% and GLUCOTROL therapy may begin at usual dosages. Subsequent reductions in insulin dosage should depend on individual patient response. Several days should elapse between GLUCOTROL titration steps.During the insulin withdrawal period, the patient should test urine samples for sugar and ketone bodies at least three times daily. Patients should be instructed to contact the prescriber immediately if these tests are abnormal. In some cases, especially when patient has been receiving greater than 40 units of insulin daily, it may be advisable to consider hospitalization during the transition period.Patients Receiving Other Oral Hypoglycemic AgentsAs with other sulfonylurea-class hypoglycemics, no transition period is necessary when transferring patients to GLUCOTROL. Patients should be observed carefully (1â€“2 weeks) for hypoglycemia when being transferred from longer half-life sulfonylureas (e.g., chlorpropamide) to GLUCOTROL due to potential overlapping of drug effect.When colesevelam is coadministered with glipizide ER, maximum plasma concentration and total exposure to glipizide is reduced. Therefore, GLUCOTROL should be administered at least 4 hours prior to colesevelam.GlipiZIDE XL, Glucotrol, Glucotrol XL\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00burning, or painful urination    dry mouth    ear congestion    fever    frequent urge to urinate    headache    increased thirst    irregular heartbeat    loss of appetite    loss of voice    lower back or side pain    mood changes    muscle pain or cramps    nasal congestion    nausea or vomiting    numbness or tingling in the hands, feet, or lips    pale skin    rapid weight gain    runny nose    sneezing    sore throat    tightness in the chest    troubled breathing with exertion    ulcers, sores, or white spots in the mouth    unsteadiness or awkwardness    unusual bleeding or bruising    unusual tiredness or weakness    unusual weight gain or loss    weakness in the arms, hands, legs, or feetIncidence not known    Fainting    irregular heartbeat, recurrentThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.Usual Adult Dose for Breast Cancer1.4 mg/m2 IV over 2 to 5 minutes on days 1 and 8 of a 21-day cycleComments:-This drug should be administered under the supervision of a qualified physician experienced in the appropriate use of cytotoxic medicinal products.-Patients may experience nausea or vomiting. Antiemetic prophylaxis including corticosteroids should be considered.-Peripheral neuropathy should be assessed and complete blood cell counts should be obtained prior to each dose.Use: For the treatment of patients with metastatic breast cancer who have previously received at least 2 chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.Renal Dose Adjustments-Mild renal impairment (CrCl 50 to 80 mL/min): No adjustment recommended-Moderate renal impairment (CrCl 30 to 50 mL/min): 1.1 mg/m2 IV over 2 to 5 minutes on days 1 and 8 of a 21-day cycle.-Severe renal impairment (CrCl less than 30 mL/min): Data not availableLiver Dose Adjustments-Mild liver impairment (Child-Pugh A): 1.1 mg/m2 intravenously over 2 to 5 minutes on days 1 and 8 of a 21-day cycle-Moderate liver impairment (Child-Pugh B): 0.7 mg/m2 intravenously over 2 to 5 minutes on days 1 and 8 of a 21-day cycle-Severe liver impairment (Child-Pugh C): Data not availableDose AdjustmentsPLEASE NOTE:-In the EU the recommended dose refers to the base of the active substance (eribulin). Calculation of the individual dose to be administered to a patient should be based on the strength of the ready to use solution that contains 0.44 mg/mL eribulin.-In some other regions (e.g., the US and other countries), the recommended dose is based on the salt form (eribulin mesylate).This drug should not be administered on day 1 or day 8 if:-The patient is experiencing grade 3 or 4 non-hematological toxicities-The absolute neutrophil count (ANC) is less than 1000 cells/mm3-Platelets are less than 75,000/mm3.The day 8 dose may be delayed for a maximum of 1 week if:-Toxicities do not resolve or improve to less than or equal to grade 2 by day 15, the dose should be omitted-Toxicities resolve or improve to less than or equal to grade 2 severity by day 15, this drug should be administered at a reduced dose and the next cycle should be initiated at least 2 weeks laterThe 1.4 mg/m2 dose should be permanently reduced to 1.1 mg/m2 for any of the following:-Absolute neutrophil count (ANC) less than 500 cells/mm3 for more than 7 days-ANC less than 1000 cells/mm3 with fever or infection-Platelets less than 25,000/mm3-Platelets less than 50,000/mm3 requiring transfusion-Non-hematologic grade 3 or 4 toxicities-Omission or delay of day 8 dose in previous cycle for toxicity-The occurrence of any adverse event requiring permanent dose reduction while receiving the 1.1 mg/m2 dose, the dose should be further reduced to 0.7 mg/m2.-The occurrence of any adverse event requiring permanent dose reduction while receiving the 0.7 mg/m2 dose, this drug should be discontinued.The dose of this drug should not be re-escalated after it has been reduced.Halaven\00\00\00\00regular heartbeat    trouble breathing    unusual tirednessSome side effects of ledipasvir / sofosbuvir may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:More common    Cough    diarrhea    headache    irritability    lack or loss of strength    muscle pain    nausea    trouble sleepingLess common    Discouragement    dizziness    feeling sad or empty    lack of appetite    loss of interest or pleasure    trouble concentratingThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.Usual Adult Dose for Chronic Hepatitis C1 tablet orally once a dayRecommended Regimen and Duration of Therapy:GENOTYPE 1:-Therapy-naive patients without cirrhosis or with compensated cirrhosis (Child-Pugh A): Ledipasvir-sofosbuvir for 12 weeks-Therapy-experienced patients without cirrhosis: Ledipasvir-sofosbuvir for 12 weeks-Therapy-experienced patients with compensated cirrhosis (Child-Pugh A): Ledipasvir-sofosbuvir for 24 weeks-Therapy-naive and therapy-experienced patients with decompensated cirrhosis (Child-Pugh B or C): Ledipasvir-sofosbuvir plus ribavirin for 12 weeksGENOTYPE 1 OR 4:-Therapy-naive and therapy-experienced liver transplant recipients without cirrhosis or with compensated cirrhosis (Child-Pugh A): Ledipasvir-sofosbuvir plus ribavirin for 12 weeksGENOTYPE 4, 5, OR 6:-Therapy-naive and therapy-experienced patients without cirrhosis or with compensated cirrhosis (Child-Pugh A): Ledipasvir-sofosbuvir for 12 weeksComments:-Relapse rates are affected by baseline host and viral factors and differ between durations of therapy for some subgroups.-Dose recommendations also apply to HCV/HIV-1-coinfected patients.-Therapy-naive genotype 1 patients without cirrhosis: Ledipasvir-sofosbuvir for 8 weeks can be considered in those who have pretreatment HCV RNA less than 6 million international units/mL.-Therapy-experienced patients have failed a peginterferon alfa/ribavirin-based regimen with or without an HCV protease inhibitor.-Therapy-experienced genotype 1 patients with cirrhosis: Ledipasvir-sofosbuvir plus ribavirin for 12 weeks can be considered in those eligible for ribavirin.-The manufacturer product information for ribavirin should be consulted regarding dosing and dose adjustments (if applicable).Use: For the treatment of chronic HCV-For genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis-In combination with ribavirin: For genotype 1 infection with decompensated cirrhosis-In combination with ribavirin: For genotype 1 or 4 infection in liver transplant recipients without cirrhosis or with compensated cirrhosisUsual Pediatric Dose for Chronic Hepatitis C12 years and older or weighing at least 35 kg: 1 tablet orally once a dayRecommended Regimen and Duration of Therapy:GENOTYPE 1:-Therapy-naive patients without cirrhosis or with compensated cirrhosis (Child-Pugh A): Ledipasvir-sofosbuvir for 12 weeks-Therapy-experienced patients without cirrhosis: Ledipasvir-sofosbuvir for 12 weeks-Therapy-experienced patients with compensated cirrhosis (Child-Pugh A): Ledipasvir-sofosbuvir for 24 weeksGENOTYPE 4, 5, OR 6:-Therapy-naive and therapy-experienced patients without cirrhosis or with compensated cirrhosis (Child-Pugh A): Ledipasvir-sofosbuvir for 12 weeksComments:-Dose recommendations also apply to HCV/HIV-1-coinfected patients.-Therapy-experienced patients have failed an interferon-based regimen with or without ribavirin.Use: For the treatment of HCV genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosisHarvoni\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\F5\00\F5\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\96*\00A\845\88I\9Ei'HavrixHepatitis A adult vaccine HAVRIX is a vaccine used to prevent hepatitis A infection. The vaccine works by causing the body to produce its own protection (antibodies) against this disease. Hepatitis A is an infectious disease, which can affect the liver. This disease is caused by the hepatitis A virus.Check with your doctor or nurse immediately if any of the following side effects occur while taking hepatitis a adult vaccine:More common    Fever more than 99.5 degrees F    general feeling of discomfort or illness    unusual tiredness or weaknessRare    Body aches or pain    chills    congestion    cough    difficulty with breathing or swallowing    dryness or soreness of the throat    ear congestion    headache    hives    hoarseness    itching, especially of the feet or hands    loss of voice    nasal congestionThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.Usual Adult Dose for Hepatitis A ProphylaxisHavrix(R): 1 mL IM followed by a 1 mL booster dose 6 to 12 months following primary immunization.VAQTA(R): 1 mL IM followed by a 1 mL booster dose 6 to 18 months after primary immunization.Primary immunization is recommended at least 2 weeks before expected exposure to hepatitis A virus.Immune globulin may be administered with the vaccine (at a different injection site) to patients requiring immediate prophylaxis or postexposure prophylaxis.Renal Dose AdjustmentsNo adjustment recommended.Liver Dose AdjustmentsNo adjustment recommended.PrecautionsHepatitis A vaccine is contraindicated in patients who have had signs of hypersensitivity after a previous dose of any hepatitis A vaccine, or who are allergic to trace substances (e.g., neomycin) which may be present in certain formulations. The cap and plunger of Havrix(R) prefilled syringes contain latex, which may cause allergic reactions in sensitive patients.Hepatitis A has a long incubation period. This vaccine may not prevent infection in persons with unrecognized infection at time of vaccination.Anaphylaxis may occur, even in patients with no previous hypersensitivity to the vaccine ingredients. Epinephrine and other medications and equipment should be readily available to treat anaphylactic or severe allergic reactions.Delaying vaccination should be considered in patients with febrile illnesses.Caution is recommended in patients with thrombocytopenia or coagulation disorders that would contraindicate intramuscular injection.The expected immune response may not occur in immunosuppressed patients.Hepatitis A vaccine is only intended for intramuscular administration. Injection into a blood vessel should be avoided.Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).Havrix, Vaqta\A2s)\00?\83I\90\B1AHarvoniLedipasvir and sofosbuvirThis medication is a combination of ledipasvir and sofosbuvir and is used to treat chronic (long-lasting) hepatitis C, a viral infection of the liver. It may sometimes be used with another antiviral medication (ribavirin).Check with your doctor immediately if any of the following side effects occur while taking ledipasvir / sofosbuvir:Incidence not known    Chest pain or discomfort    lightheadedness, dizziness, or fainting    slow or ir\00\00\00C\00\00\00Fmended doses are based on a 68 kg patient.-Consult the latest guidelines regarding duration and intensity of anticoagulation for the indicated conditions.-Dosage and administration must be individualized according to the results of suitable laboratory tests.Uses:-Prophylaxis and treatment of venous thrombosis and pulmonary embolism.-Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation.-Treatment of acute and chronic consumption coagulopathies (disseminated intravascular coagulation).-Prophylaxis and treatment of peripheral arterial embolism.5000 units subcutaneously 2 hours before surgery and 5000 units subcutaneously every 8 to 12 hours thereafter for 7 days or until the patient is ambulatory, whichever is longer.Comments:-Administer by deep subcutaneous (intrafat, e.g., above the iliac crest or abdominal fat layer, arm, or thigh) injection with a fine (25 to 26 gauge) needle to minimize tissue trauma.-Consult the latest guidelines regarding duration and intensity of anticoagulation for the indicated conditions.-Dosage and administration must be individualized according to the results of suitable laboratory tests.Use: Low-dose regimen for prevention of postoperative deep venous thrombosis and pulmonary embolism in patients greater than 40 years old undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease.Usual Adult Dose for Deep Vein Thrombosis - ProphylaxisThe manufacturer provides the following dosing guidelines based on clinical experience:Continuous IV infusion:-Initial dose: 5000 units by IV injection-Maintenance dose: 20,000 to 40,000 units per 24 hours by continuous IV infusionIntermittent IV injection:-Initial dose: 10,000 units IV-Maintenance dose: 5000 to 10,000 units IV every 4 to 6 hoursDeep subcutaneous (intrafat) injection:333 units/kg subcutaneously followed by 250 units/kg subcutaneously every 12 hours; the following dosage regimen has also been recommended: 5000 units by IV injection followed by 10,000 to 20,000 units subcutaneously, and then 8000 to 10,000 units subcutaneously every 8 hours or 15,000 to 20,000 units subcutaneously every 12 hours.Comments:-Recommended doses are based on a 68 kg patient.-Consult the latest guidelines regarding duration and intensity of anticoagulation for the indicated conditions.-Dosage and administration must be individualized according to the results of suitable laboratory tests.Uses:-Prophylaxis and treatment of venous thrombosis and pulmonary embolism.-Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation.-Treatment of acute and chronic consumption coagulopathies (disseminated intravascular coagulation).-Prophylaxis and treatment of peripheral arterial embolism.5000 units subcutaneously 2 hours before surgery and 5000 units subcutaneously every 8 to 12 hours thereafter for 7 days or until the patient is ambulatory, whichever is longer.Comments:-Administer by deep subcutaneous (intrafat, e.g., above the iliac crest or abdominal fat layer, arm, or thigh) injection with a fine (25 to 26 gauge) needle to minimize tissue trauma.-Consult the latest guidelines regarding duration and intensity of anticoagulation for the indicated conditions.-Dosage and administration must be individualized according to the results of suitable laboratory tests.Use: Low-dose regimen for prevention of postoperative deep venous thrombosis and pulmonary embolism in patients greater than 40 years old undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease.Usual Adult Dose for Prevention of Thromboembolism in Atrial FibrillationThe manufacturer provides the following dosing guidelines based on clinical experience:Continuous IV infusion:-Initial dose: 5000 units by IV injection-Maintenance dose: 20,000 to 40,000 units per 24 hours by continuous IV infusionIntermittent IV injection:-Initial dose: 10,000 units IV-Maintenance dose: 5\00\00\00G000 to 10,000 units IV every 4 to 6 hoursDeep subcutaneous (intrafat) injection:333 units/kg subcutaneously followed by 250 units/kg subcutaneously every 12 hours; the following dosage regimen has also been recommended: 5000 units by IV injection followed by 10,000 to 20,000 units subcutaneously, and then 8000 to 10,000 units subcutaneously every 8 hours or 15,000 to 20,000 units subcutaneously every 12 hours.Comments:-Recommended doses are based on a 68 kg patient.-Consult the latest guidelines regarding duration and intensity of anticoagulation for the indicated conditions.-Dosage and administration must be individualized according to the results of suitable laboratory tests.Uses:-Prophylaxis and treatment of venous thrombosis and pulmonary embolism.-Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation.-Treatment of acute and chronic consumption coagulopathies (disseminated intravascular coagulation).-Prophylaxis and treatment of peripheral arterial embolism.5000 units subcutaneously 2 hours before surgery and 5000 units subcutaneously every 8 to 12 hours thereafter for 7 days or until the patient is ambulatory, whichever is longer.Comments:-Administer by deep subcutaneous (intrafat, e.g., above the iliac crest or abdominal fat layer, arm, or thigh) injection with a fine (25 to 26 gauge) needle to minimize tissue trauma.-Consult the latest guidelines regarding duration and intensity of anticoagulation for the indicated conditions.-Dosage and administration must be individualized according to the results of suitable laboratory tests.Use: Low-dose regimen for prevention of postoperative deep venous thrombosis and pulmonary embolism in patients greater than 40 years old undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease.Usual Adult Dose for Pulmonary EmbolismThe manufacturer provides the following dosing guidelines based on clinical experience:Continuous IV infusion:-Initial dose: 5000 units by IV injection-Maintenance dose: 20,000 to 40,000 units per 24 hours by continuous IV infusionIntermittent IV injection:-Initial dose: 10,000 units IV-Maintenance dose: 5000 to 10,000 units IV every 4 to 6 hoursDeep subcutaneous (intrafat) injection:333 units/kg subcutaneously followed by 250 units/kg subcutaneously every 12 hours; the following dosage regimen has also been recommended: 5000 units by IV injection followed by 10,000 to 20,000 units subcutaneously, and then 8000 to 10,000 units subcutaneously every 8 hours or 15,000 to 20,000 units subcutaneously every 12 hours.Comments:-Recommended doses are based on a 68 kg patient.-Consult the latest guidelines regarding duration and intensity of anticoagulation for the indicated conditions.-Dosage and administration must be individualized according to the results of suitable laboratory tests.Uses:-Prophylaxis and treatment of venous thrombosis and pulmonary embolism.-Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation.-Treatment of acute and chronic consumption coagulopathies (disseminated intravascular coagulation).-Prophylaxis and treatment of peripheral arterial embolism.5000 units subcutaneously 2 hours before surgery and 5000 units subcutaneously every 8 to 12 hours thereafter for 7 days or until the patient is ambulatory, whichever is longer.Comments:-Administer by deep subcutaneous (intrafat, e.g., above the iliac crest or abdominal fat layer, arm, or thigh) injection with a fine (25 to 26 gauge) needle to minimize tissue trauma.-Consult the latest guidelines regarding duration and intensity of anticoagulation for the indicated conditions.-Dosage and administration must be individualized according to the results of suitable laboratory tests.Use: Low-dose regimen for prevention of postoperative deep venous thrombosis and pulmonary embolism in patients greater than 40 years old undergoing major abdominothoracic surgery or who, for other reasons, are at risk of develop\00\00\00\00ing thromboembolic disease.Usual Adult Dose for Thrombotic/Thromboembolic DisorderThe manufacturer provides the following dosing guidelines based on clinical experience:Continuous IV infusion:-Initial dose: 5000 units by IV injection-Maintenance dose: 20,000 to 40,000 units per 24 hours by continuous IV infusionIntermittent IV injection:-Initial dose: 10,000 units IV-Maintenance dose: 5000 to 10,000 units IV every 4 to 6 hoursDeep subcutaneous (intrafat) injection:333 units/kg subcutaneously followed by 250 units/kg subcutaneously every 12 hours; the following dosage regimen has also been recommended: 5000 units by IV injection followed by 10,000 to 20,000 units subcutaneously, and then 8000 to 10,000 units subcutaneously every 8 hours or 15,000 to 20,000 units subcutaneously every 12 hours.Comments:-Recommended doses are based on a 68 kg patient.-Consult the latest guidelines regarding duration and intensity of anticoagulation for the indicated conditions.-Dosage and administration must be individualized according to the results of suitable laboratory tests.Uses:-Prophylaxis and treatment of venous thrombosis and pulmonary embolism.-Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation.-Treatment of acute and chronic consumption coagulopathies (disseminated intravascular coagulation).-Prophylaxis and treatment of peripheral arterial embolism.5000 units subcutaneously 2 hours before surgery and 5000 units subcutaneously every 8 to 12 hours thereafter for 7 days or until the patient is ambulatory, whichever is longer.Comments:-Administer by deep subcutaneous (intrafat, e.g., above the iliac crest or abdominal fat layer, arm, or thigh) injection with a fine (25 to 26 gauge) needle to minimize tissue trauma.-Consult the latest guidelines regarding duration and intensity of anticoagulation for the indicated conditions.-Dosage and administration must be individualized according to the results of suitable laboratory tests.Use: Low-dose regimen for prevention of postoperative deep venous thrombosis and pulmonary embolism in patients greater than 40 years old undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease.Usual Pediatric Dose for Thrombotic/Thromboembolic DisorderThere are no adequate and well controlled studies in pediatric patients. The manufacturer provides the following dosing guidelines based on clinical experience:-Initial dose: 75 to 100 units/kg IV bolus over 10 minutes-Maintenance dose: Infants: 25 to 30 units/kg/hr; Children greater than 1 year: 18 to 20 units/kg/hrComments:-Use preservative-free formulations of this drug in neonates and infants.-Adjust dose to maintain activated partial thromboplastin time (aPTT) of 60 to 85 seconds, assuming this reflects an anti-Factor Xa level of 0.35 to 0.7.-Infants less than 2 months have the highest requirements (average dose of 28 units/kg/hr).-Older children may require less of this drug, similar to weight-adjusted adult dosage.Renal Dose AdjustmentsMild to moderate renal dysfunction: Data not availableSevere renal dysfunction: Use with cautionLiver Dose AdjustmentsUse with cautionDose AdjustmentsConverting to warfarin: Continue full heparin therapy for several days until INR has reached a stable therapeutic range. Heparin may then be discontinued without tapering.Converting to oral anticoagulants other than warfarin:-Patients receiving heparin continuous IV infusion: Stop heparin immediately after administering the first dose of oral anticoagulant.-Patients receiving heparin intermittent IV injection: Start oral anticoagulant 0 to 2 hours before the time the next dose of heparin was to have been administered.Concomitant use of antithrombin III (human): In patients with antithrombin III deficiency, consider a lower dose of this drug when coadministered with antithrombin III (human).Hep-Pak (obsolete), Heparin Lock Flush (obsolete), Hep-Pak CVC (obsolete), Hep-Lock (obsolete), Heparin Sodium ADD-Vantage\00\00\00\00$\00\BC\CC\00$\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\8B%-\00#\86E\8As\84qIbrancePalbociclibIbrance (palbociclib) is a cancer medicine that interferes with the growth and spread of cancer cells in the body.Ibrance is used in men and women to treat certain types of advanced breast cancer that has spread to other parts of the body.In postmenopausal women, Ibrance is given in combination with a hormonal medicine called letrozole (Femara). In others, it is given together with fulvestrant (Faslodex). Check with your doctor immediately if any of the following side effects occur while taking palbociclib:More common    Black, tarry stools    body aches or pain    chills    cough    ear congestion    fever    headache    loss of voice    lower back or side pain    painful or difficult urination    pale skin    sneezing    sore throat    stuffy or runny nose    swelling or inflammation of the mouth    trouble breathing    ulcers, sores, or white spots in the mouth    unusual bleeding or bruising    unusual tiredness or weaknessLess common    Anxiety    bloody nose    chest pain    dizziness or lightheadedness    fainting    fast heartbeat    hoarsenessThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.The recommended dose of IBRANCE is a 125 mg capsule taken orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days. IBRANCE should be taken with foodIbrance\A1,\0033\85	\96G\A6HydrochlorothiazideHydrochlorothiazideHydrochlorothiazide belongs to a class of drugs known as diuretics/"water pills." It works by causing you to make more urine. This helps your body get rid of extra salt and water. This medication also reduces extra fluid in the body (edema) caused by conditions such as heart failure, liver disease, or kidney disease.Check with your doctor immediately if any of the following side effects occur while taking hydrochlorothiazide:Incidence \00\00\00?\F01+\003\83m\8Ec\81\CBw\82HeparinHeparin (injection)Heparin is an anticoagulant (blood thinner) that prevents the formation of blood clots. Heparin is used to treat and prevent blood clots in the veins, arteries, or lung. Heparin is also used before surgery to reduce the risk of blood clots.Check with your doctor or nurse immediately if any of the following side effects occur while taking heparin:Less common    Abdominal or stomach pain or swelling    back pain or backaches    bleeding from the gums when brushing teeth    blood in the urine    constipation    coughing up blood    dizziness    headaches, severe or continuing    heavy bleeding or oozing from cuts or wounds    joint pain, stiffness, or swelling    menstrual bleeding, unexpected or unusually heavy    unexplained bruising or purplish areas on the skin    unexplained nosebleeds    vomiting of blood or material that looks like coffee groundsRare    Blood under the skin (blood blister) at the place of injection    chest pain    chills or fever    fast or irregular breathing    irritation, pain, redness, or ulcers at the place of injection    itching and burning feeling, especially on the bottom of the feet    nausea or vomitingThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.Usual Adult Dose for Deep Vein ThrombosisThe manufacturer provides the following dosing guidelines based on clinical experience:Continuous IV infusion:-Initial dose: 5000 units by IV injection-Maintenance dose: 20,000 to 40,000 units per 24 hours by continuous IV infusionIntermittent IV injection:-Initial dose: 10,000 units IV-Maintenance dose: 5000 to 10,000 units IV every 4 to 6 hoursDeep subcutaneous (intrafat) injection:333 units/kg subcutaneously followed by 250 units/kg subcutaneously every 12 hours; the following dosage regimen has also been recommended: 5000 units by IV injection followed by 10,000 to 20,000 units subcutaneously, and then 8000 to 10,000 units subcutaneously every 8 hours or 15,000 to 20,000 units subcutaneously every 12 hours.Comments:-Recom\00\00\00E\00\00\00\8D\00\8D\00Lwn    Abdominal or stomach pain    back, leg, or stomach pains    black, tarry stools    bleeding gums    blistering, peeling, or loosening of the skin    bloating    blood in the urine or stools    bloody urine    blue lips and fingernails    blurred vision    burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings    chest pain    chills    clay-colored stools    cloudy urine    cold sweats    confusion    constipation    cough or hoarseness    coughing that sometimes produces a pink frothy sputum    coughing up blood    cracks in the skin    darkened urine    decrease in urine output or decrease in urine-concentrating ability    decreased frequency or amount of urine    diarrhea    difficult, fast, or noisy breathing, sometimes with wheezing    difficulty with breathing    difficulty with swallowing    dizziness, faintness, or lightheadedness when getting up from a lying or sitting position    dry mouth    fast or irregular heartbeat    fever    flushed, dry skin    fruit-like breath odor    general body swelling    general feeling of discomfort or illness    \96\96p0\009\84s\9Ds\8A-5ImdurIsosorbide mononitrateImdur (isosorbide mononitrate) is a nitrate that dilates (widens) blood vessels, making it easier for blood to flow through them and easier for the heart to pump.Imdur is an extended release tablet used to prevent angina attacks (chest pain).Imdur will not treat an angina attack that has already begun.Check with your doctor immediately if any of the following side effects occur while taking isosorbide mononitrate:Less common    Abnormal heart sound    absence of or decrease in body movement    arm, back, or jaw pain    black, tarry stools    bladder pain    bleeding after defecation    bleeding gums    blood in the urine or stools    blurred vision    body aches or pain    burning while urinating    burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings    chest pain or discomfort    chest tightness or heaviness    chills    cold sweats    colds    confusion    convulsions    cough or hoarseness    decreased urine    diarrhea    difficult or labored breathing    difficult, burning, or painful urination    dilated neck veins    dizziness    dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position    dry mouth    ear congestion    extra heartbeats    fainting    fast, slow, irregular, pounding, or racing heartbeat or pulse    fever or chills    flu-like symptoms    frequent urge to urinate    frequent urination    general feeling of discomfort or illness    headache    headache, severe and throbbing    heart murmur    increased need to urinate    increased sweating    increased thirst    increased volume of pale, dilute urine    irregular breathing    itching, pain, redness, or swelling on the leg    joint pain, stiffness, or swelling    lightheadedness    loss of appetite    loss of voice    lower back, side, or stomach pain    muscle aches and pains    muscle cramps    nasal congestion    nausea or vomiting    nervousness    numbness or tingling in the hands, feet, or lips    pain or discomfort in the arms, jaw, back, or neck    pain, tension, and weakness upon walking that subsides during periods of rest    partial or slight paralysisThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.The recommended starting dose of IMDUR Tablets is 30 mg (given as a single 30 mg tablet or as 1/2 of a 60 mg tablet) or 60 mg (given as a single tablet) once daily. After several days, the dosage may be increased to 120 mg (given as a single 120 mg tablet or as two 60 mg tablets) once daily. Rarely, 240 mg may be required. The daily dose of IMDUR Tablets should be taken in the morning on arising. IMDUR Extended Release Tablets should not be chewed or crushed and should be swallowed together with a half-glassful of fluid. Do not break the 30 mg tablet.Imdur, Monoket, ISMO\00\00\00\00ounter)Comment:-Oral doses greater than 400 mg have not been shown to be any more effective than the 400 mg dose.Use: For the relief of mild to moderate painUsual Adult Dose for FeverIV Ibuprofen (Caldolor[R]):-Initial dose: 400 mg IV once-Following initial dose, 100, 200, or 400 mg IV every 4 to 6 hours as needed-Maximum dose: 3200 mg/dayComments:-Patients should be well hydrated prior to infusion to reduce the risk of renal adverse events.-Doses should be infused over at least 30 minutes.Oral:Initial dose: 200 mg orally every 4 to 6 hours-May increase to 400 mg every 4 to 6 hours if additional relief is neededMaximum dose: 1200 mg/dayUse: For the reduction of feverUsual Pediatric Dose for FeverIV Ibuprofen (Caldolor[R]):6 months to less than 12 years: 10 mg/kg IV every 4 to 6 hours as needed-Maximum dose: Single dose: 400 mg; Daily dose: 40 mg/kg or 2400 mg/day, whichever is less12 to 17 years: 400 mg IV every 4 to 6 hours as needed-Maximum dose: 2400 mg/dayComments:-Patients should be well hydrated prior to infusion to reduce the risk of renal adverse events.-Doses should be infused over at least 10 minutes.Oral Suspension (Infant drops: 50 mg/1.25 mL):6 to 11 months; 12 to 17 pounds: 50 mg (1.25 mL) every 6 to 8 hours as needed12 to 23 months; 18 to 23 pounds: 75 mg (1.875 mL) orally every 6 to 8 hours as needed-Maximum dose: 4 doses per dayOral Suspension (100 mg/5 mL):6 months to 2 years:-Baseline temperature less than 102.5F (39.2C): 5 mg/kg orally every 6 to 8 hours-Baseline temperature 102.5F (39.2C) or greater: 10 mg/kg orally every 6 to 8 hours-Maximum dose: 40 mg/kg/day2 to 11 years: 5 to 10 mg/kg orally every 6 to 8 hours as needed-Maximum dose: 40 mg/kg/day or 4 doses per dayOral Chewable Tablets:2 to 11 years: 5 to 10 mg/kg every 6 to 8 hours as needed-Maximum dose: 40 mg/kg/day or 4 doses per dayOral Capsules and Tablets:12 years and older:-Initial dose: 200 mg orally every 4 to 6 hours as needed-May increase to 400 mg every 4 to 6 hours if additional analgesia is neededMaximum dose: 1200 mg/dayComment:-There are multiple over-the-counter formulations with different concentrations of the oral suspension and capsule/tablet strengths; manufacturer labeling may be consulted for weight/age based dosing charts.Use: For the relief of feverUsual Pediatric Dose for PainIV Ibuprofen (Caldolor[R]):6 months to less than 12 years: 10 mg/kg IV every 4 to 6 hours as needed-Maximum dose: Single dose: 400 mg; Daily dose: 40 mg/kg or 2400 mg/day, whichever is less12 to 17 years: 400 mg IV every 4 to 6 hours as needed-Maximum dose: 2400 mg/dayComments:-Patients should be well hydrated prior to infusion to reduce the risk of renal adverse events.-Doses should be infused over at least 10 minutes.Uses: For the management of mild to moderate pain; and the management of moderate to severe pain as an adjunct to opioid analgesicsOral Suspension (Infant drops: 50 mg/1.25 mL):6 to 11 months; 12 to 17 pounds: 50 mg (1.25 mL) every 6 to 8 hours as needed12 to 23 months; 18 to 23 pounds: 75 mg (1.875 mL) orally every 6 to 8 hours as needed-Maximum dose: 4 doses per dayOral Suspension (100 mg/5 mL):6 months to 2 years: 10 mg/kg orally every 6 to 8 hours-Maximum dose: 40 mg/kg/day2 to 11 years: 5 to 10 mg/kg orally every 6 to 8 hours-Maximum dose: 40 mg/kg/day or 4 doses per dayOral Chewable Tablets:2 to 11 years: 5 to 10 mg/kg every 6 to 8 hours as needed-Maximum dose: 40 mg/kg/day or 4 doses per dayOral Capsules and Tablets:12 years or older:Initial dose: 200 mg orally every 4 to 6 hours as needed-May increase to 400 mg every 4 to 6 hours if additional analgesia is neededMaximum dose: 1200 mg/dayComment:-There are multiple over-the-counter formulations with different concentrations of the oral suspension and capsule/tablet strengths; manufacturer labeling may be consulted for weight/age based dosing charts.Use: For the relief of mild to moderate painAdvil, Genpril, Midol IB, Motrin IB, Proprinal, Smart Sense Children's Ibuprofen\00\00\00e\00e\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\BD.\00\83\93)\E1C\81-IbuprofenIbuprofenIbuprofen is used to reduce fever and treat pain or inflammation caused by many conditions such as headache, toothache, back pain, arthritis, menstrual cramps, or minor injury.Ibuprofen is used in adults and children who are at least 6 months old. Check with your doctor immediately if any of the following side effects occur while taking ibuprofen:More common    Abdominal pain    acid or sour stomach    belching    bloating    cloudy urine    decrease in amount of urine    decrease in urine output or decrease in urine-concentrating ability    diarrhea    difficulty having a bowel movement (stool)    excess air or gas in stomach or intestines    full feeling    heartburn    indigestion    itching skin    pain or discomfort in chest, upper stomach, or throat    pale skin    passing gas    nausea    noisy, rattling breathing    rash with flat lesions or small raised lesions on the skin    shortness of breath    swelling of face, fingers, hands, feet, lower legs, or ankles    troubled breathing at rest    troubled breathing with exertion    unusual bleeding or bruising    unusual tiredness or weakness    vomiting    weight gainLess common    Abdominal cramps    stomach soreness or discomfortRare    Agitation    back, leg, or stomach pains    bleeding gums    blistering, peeling, loosening of skin    blood in urine or stools    bloody, black, or tarry stools    blurred vision    burning feeling in chest or stomachThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.Usual Adult Dose for Dysmenorrhea200 to 400 mg orally every 4 to 6 hours as neededMaximum dose: 3200 mg/day (prescription strength); 1200 mg/day (over-the-counter)Comment:-Treatment should begin at the earliest onset of pain.Use: For the relief of signs and symptoms of primary dysmenorrheaUsual Adult Dose for Osteoarthritis1200 to 3200 mg orally per day in divided dosesMaximum dose: 3200 mg/dayComments:-Patients with rheumatoid arthritis may require higher doses than those with osteoarthritis.-Once response to therapy is determined, dose and frequency should be adjusted to the lowest effective dose for the shortest duration possible to suit the individual patient's treatment goals.-Patients treated with 3200 mg orally per day should be observed for sufficient increased clinical benefits to offset potential increased risk.Use: For the relief of signs and symptoms of rheumatoid arthritis and osteoarthritisUsual Adult Dose for Rheumatoid Arthritis1200 to 3200 mg orally per day in divided dosesMaximum dose: 3200 mg/dayComments:-Patients with rheumatoid arthritis may require higher doses than those with osteoarthritis.-Once response to therapy is determined, dose and frequency should be adjusted to the lowest effective dose for the shortest duration possible to suit the individual patient's treatment goals.-Patients treated with 3200 mg orally per day should be observed for sufficient increased clinical benefits to offset potential increased risk.Use: For the relief of signs and symptoms of rheumatoid arthritis and osteoarthritisUsual Adult Dose for PainIV Ibuprofen (Caldolor[R]):400 to 800 mg IV every 6 hours as neededMaximum dose: 3200 mg/dayComments:-Patients should be well hydrated prior to infusion to reduce the risk of renal adverse events.-Doses should be infused over at least 30 minutes.Uses: For the management of mild to moderate pain; and the management of moderate to severe pain as an adjunct to opioid analgesicsOral:200 to 400 mg orally every 4 to 6 hours as neededMaximum dose: 3200 mg/day (prescription strength); 1200 mg/day (over-the-c\00\00\00J\00\00\00\E9\00\E9\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\98/\00!\8BQ\88\9CImbruvica IbrutinibImbruvica is used to treat certain types of non-Hodgkin lymphoma, including mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia, and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in people with or without 17p deletion.Imbruvica is also used to treat marginal cell lymphoma and chronic graft-versus-host disease. It is sometimes given when other medicines have not been effective.Imbruvica was approved to treat mantle cell and marginal lymphomas by the US Food and Drug Administration (FDA) on an "accelerated" basis. In clinical studies, tumors responded to this medicine. However, it has not been shown that ibrutinib can improve symptoms or lengthen survival time in people with this type of lymphoma.Check with your doctor immediately if any of the following side effects occur while taking ibrutinib:More common    Back pain    bladder pain    bloating or swelling of the face, arms, hands, lower legs, or feet    bloody or black, tarry stools    bloody or cloudy urine    blurred vision    body aches or pain    chest pain    chills    confusion    convulsions    cough or hoarseness    decreased frequency or amount of urine    difficult, burning, or painful urination    dizziness or lightheadednessThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.Mantle Cell Lymphoma and Marginal Zone Lymphomaâ€‹The recommended dose of IMBRUVICA for MCL and MZL is 560 mg (four 140 mg capsules) orally once daily until disease progression or unacceptable toxicity.Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and WaldenstrÃ¶m's MacroglobulinemiaThe recommended dose of IMBRUVICA for CLL/SLL and WM is 420 mg (three 140 mg capsules) orally once daily until disease progression or unacceptable toxicity.The recommended dose of IMBRUVICA for CLL/SLL when used in combination with bendamustine and rituximab (administered every 28 days for up to 6 cycles) is 420 mg (three 140 mg capsules) orally once daily until disease progression or unacceptable toxicity.â€‹Chronic Graft versus Host Diseaseâ€‹The recommended dose of IMBRUVICA for cGVHD is 420 mg (three 140 mg capsules) orally once daily until cGVHD progression, recurrence of an underlying malignancy, or unacceptable toxicity. When a patient no longer requires therapy for the treatment of cGVHD, IMBRUVICA should be discontinued considering the medical assessment of the individual patient.Dose Modifications for Adverse ReactionsInterrupt IMBRUVICA therapy for any Grade 3 or greater non-hematological toxicities, Grade 3 or greater neutropenia with infection or fever, or Grade 4 hematological toxicities. Once the symptoms of the toxicity have resolved to Grade 1 or baseline (recovery), IMBRUVICA therapy may be reinitiated at the starting dose. If the toxicity reoccurs, reduce dose by one capsule (140 mg per day). A second reduction of dose by 140 mg may be considered as needed. If these toxicities persist or recur following two dose reductions, discontinue IMBRUVICA.Imbruvica\00\00\00\00, or other mood or mental changes    fever    loss of memory    pain or swelling in the arms or legs    painful or difficult urination    shortness of breath    sore throatThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.Usual Adult Dose for EpilepsyInitial dose: 300 mg orally on day one, 300 mg orally 2 times day on day two, then 300 mg orally 3 times a day on day threeMaintenance dose: 300 to 600 mg orally 3 times a dayMaximum dose: 3600 mg orally daily (in 3 divided doses)-Maximum time between doses in the 3 times a day schedule should not exceed 12 hours-The safety and effectiveness of gabapentin available under the trade name Gralise (R) or Horizant (R) in patients with epilepsy has not been studied.Comment:-May be taken with or without food.-Half-tablets not used within 28 days of breaking the scored tablet should be discarded.Use: Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalizationUsual Adult Dose for Postherpetic Neuralgia-Initial dose: 300 mg orally on day one, 300 mg orally 2 times day on day two, then 300 mg orally 3 times a day on day three-Titrate up as needed for pain relief-Maximum dose: 1800 mg per day (600 mg orally 3 times a day)COMMENT:-May be taken with or without food.-Half-tablets not used within 28 days of breaking the scored tablet should be discarded.Gabapentin available under the trade name GRALISE (R):-Maintenance dose: Gralise (R) should be titrated to 1800 mg orally once daily with the evening meal.-Recommended titration schedule:Day 1: 300 mg orally with the evening mealDay 2: 600 mg orally with the evening mealDays 3 through 6: 900 mg orally with the evening mealDays 7 through 10: 1200 mg orally with the evening mealDays 11 through 14: 1500 mg orally with the evening mealDay 15: 1800 mg orally with the evening mealCOMMENT:-Gralise (R) is not interchangeable with other gabapentin products because of differing pharmacokinetic profiles that affect the frequency of administration.Gabapentin enacarbil extended release tablets are available under the trade name HORIZANT (R):-The recommended dosage is 600 mg orally 2 times a day. Therapy should be initiated at a dose of 600 mg orally in the morning for 3 days of therapy, then increased to 600 mg 2 times a day (1200 mg/day) on day four.COMMENT:Gabapentin enacarbil extended release tablets available under the trade name Horizant (R) and gabapentin are not interchangeable.Use: Postherpetic neuralgiaUsual Pediatric Dose for EpilepsyLess than 3 years: Not recommendedGreater than or equal to 3 and less than 12 years:Starting Dose: Ranges from 10 to 15 mg/kg/day in 3 divided dosesEffective Dose: Reached by upward titration over a period of approximately 3 days; the effective dose in patients 5 years of age and older is 25 to 35 mg/kg/day in divided doses (3 times a day). The effective dose in pediatric patients ages 3 and 4 years is 40 mg/kg/day and given in divided doses (3 times a day). Gabapentin may be administered as the oral solution, capsule, or tablet, or using combinations of these formulations. Dosages up to 50 mg/kg/day have been well tolerated in a long term clinical study. The maximum time interval between doses should not exceed 12 hours.Greater than 12 years:-Initial dose: 300 mg orally on day one, 300 mg orally 2 times a day on day two, then 300 mg orally 3 times a day on day three-Maintenance dose: 900 to 1800 mg orally in 3 divided doses; the dose may be increased up to 1800 mg/day. Dosages up to 2400 mg/day have been well tolerated in long term clinical studies. Doses of 3600 mg/day have also been administered to a small number of patients for a relatively short duration, and have been well tolerated. The maximum time between doses in the three times a day schedule should not exceed 12 hours.Use: Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization in patients 3 years of age and olderGralise, Horizant, Neurontin, Gabarone\00\00\00\00\DA\00;\00\DA\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\8E^2\00A\88e\8D'\86yJalynDutasteride and tamsulosinJalyn contains a combination of dutasteride and tamsulosin. Dutasteride prevents the conversion of testosterone to dihydrotestosterone (DHT) in the body. DHT is involved in the development of benign prostatic hyperplasia (BPH). Tamsulosin is in a group of drugs called alpha-adrenergic blockers. Tamsulosin relaxes the muscles in the prostate and bladder neck, making it easier to urinate.Jalyn is used to treat benign prostatic hyperplasia (BPH) in men with an enlarged prostate.Jalyn may also be used for purposes not listed in this medication guide.Check with your doctor immediately if any of the following side effects occur while taking dutasteride / tamsulosin:More common    Chills    cold sweats    confusion    dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting positionLess common    Chest pain    cough or hoarseness    fever    lower back or side pain    painful or difficult urinationIncidence not known    Blistering, flaking, or peeling of the skin    blurred vision    difficulty with breathing    fast, irregular, pounding, or racing heartbeat or pulse    large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs    pain or swelling of the treated skin    painful or prolonged erection of the penis    shortness of breath    sweating    unusual tiredness or weaknessThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.The recommended dosage of JALYN is 1 capsule (0.5 mg dutasteride and 0.4 mg tamsulosin hydrochloride) taken once daily approximately 30 minutes after the same meal each day.The capsules should be swallowed whole and not chewed or opened. Contact with the contents of the JALYN capsule may result in irritation of the oropharyngeal mucosa.Jalyn\8FB1\00#\85\87\92=JakafiRuxolitinibJakafi (ruxolitinib) works by blocking certain enzymes in the body that affect blood cell production.Jakafi is used to treat myelofibrosis or polycythemia vera, which are bone marrow disorders that affect your body's ability to produce blood cells.Jakafi may also be used for purposes not listed in this medication guide.Check with your doctor immediately if any of the following side effects occur while taking ruxolitinib:More common    Black, tarry stools    bladder pain    bleeding gums    blood in the urine or stools    bruising    chills    cloudy urine    collection of blood under the skin    cough    deep, dark purple bruise    difficult, burning, or painful urination    fever    frequent urge to urinate    itching, pain, redness, or swellingThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.Interrupt treatment for:    Hemoglobin <8 g/dL or    Platelet counts <50 x 109/L or    Absolute neutrophil count (ANC) <1.0 x 109/LAfter recovery of the hematologic parameters(s) to acceptable levels, dosing may be restarted.Use the most severe category of a patientâ€™s hemoglobin, platelet count, or ANC abnormality to determine the corresponding maximum restarting dosePatients who had required dose interruption while receiving a dose of 5 mg twice daily, may restart at a dose of 5 mg twice daily or 5 mg once daily, but not higher, once hemoglobin is greater than or equal to 10 g/dL, platelet count is greater than or equal to 75 X 109/L, and ANC is greater than or equal to 1.5 X 109/LAfter restarting Jakafi following treatment interruption, doses may be titrated, but the maximum total daily dose should not exceed 5 mg less than the dose that resulted in the dose interruption. An exception to this is dose interruption following phlebotomy-associated anemia, in which case the maximal total daily dose allowed after restarting Jakafi would not be limitedJakafi\00\00\00\96\00\96\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\8Ag3\00?\863\87)\875KadcylaAdo-trastuzumab emtansineKadcyla (ado-trastuzumab emtansine) is a cancer medicine that interferes with the growth and spread of cancer cells in the body.Kadcyla is used to treat a certain type of breast cancer that has spread to other parts of the body.Kadcyla is usually given after other cancer medications have been tried without success.Kadcyla (ado-trastuzumab) should not be used in place of Herceptin (trastuzumab).Check with your doctor or nurse immediately if any of the following side effects occur while taking ado-trastuzumab emtansine:More common    Black, tarry stools    bladder pain    bleeding gums    bloating or swelling of the face, arms, hands, lower legs, or feet    bloody or cloudy urine    blurred vision    burning, numbness, tingling, or painful sensations    chills    convulsions    cough    decreased urine    difficult or labored breathingThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.The recommended dose of KADCYLA is 3.6 mg/kg given as an intravenous infusion every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity. Do not administer KADCYLA at doses greater than 3.6 mg/kg. Do not substitute KADCYLA for or with trastuzumab.Closely monitor the infusion site for possible subcutaneous infiltration during drug administrationKadcyla\00\00\00\A5\00\A5\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\98X4\00\86%\94\96aKadianMorphineKadian is strong prescription pain medicine used to manage severe pain that requires daily around-the-clock treatment and is used when other pain treatments, such as non-opioid pain medicines or immediate-release opioid medicines, do not treat the pain well enough.Kadian extended-release capsules are for around-the-clock treatment of pain. They are not for use on an as-needed basis for pain.Check with your doctor immediately if any of the following side effects occur while taking morphine:Less common    Abdominal or stomach pain    blurred vision    bulging soft spot on the head of an infant    burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings    change in the ability to see colors, especially blue or yellow    chest pain or discomfort    confusion    cough    decreased urination    dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position    fainting    fast, pounding, or irregular heartbeat or pulse    headache    hives, itching, or skin rash    increased sweating    loss of appetite    nausea or vomiting    nervousness    pounding in the ears    puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue    severe constipation    severe vomiting    shakiness in the legs, arms, hands, or feet    slow heartbeat    sweating or chillsIncidence not known    Black, tarry stools    cold, clammy skin    feeling of warmth or heat    flushing or redness of the skin, especially on the face and neck    irregular, fast or slow, or shallow breathing    lightheadedness    loss of consciousness    low blood pressure or pulseThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.KADIAN should be prescribed only by healthcare professionals who are knowledgeable in the use of potent opioids for the management of chronic pain.KADIAN 100 mg and 200 mg capsules, a single dose greater than 60 mg, or a total daily dose greater than 120 mg, are only for use in patients in whom tolerance to an opioid of comparable potency has been established. Patients considered opioid-tolerant are those taking, for one week or longer, at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone daily, 25 mg oral oxymorphone per day, 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid.    Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals [see Warnings and Precautions (5)].    Initiate the dosing regimen for each patient individually, taking into account the patient's severity of pain, prior analgesic treatment experience, and risk factors for addiction, abuse, and misuse [see Warnings and Precautions (5.1)].    Monitor patients closely for respiratory depression, especially within the first 24 to 72 hours of initiating therapy and following dosage increases with KADIAN and adjust the dosage accordingly [see Warnings and Precautions (5.2)].Arymo ER, Kadian, MorphaBond ER, MS Contin\00\00\00O\00O\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\97.5\00#\8AI\89%\9ASLamictalLamotrigineLamictal is used either alone or in combination with other medications to treat epileptic seizures in adults and children. Lamotrigine is also used to delay mood episodes in adults with bipolar disorder (manic depression).The immediate-release form of Lamictal (regular tablet and orally disintegrating tablet) can be used in children as young as 2 years old when it is given as part of a combination of seizure medications. However, this form should not be used as a single medication in a child or teenager who is younger than 16 years old.The extended-release form of lamotrigine (Lamictal XR) is for use only in adults and children who are at least 13 years old.Check with your doctor immediately if any of the following side effects occur while taking lamotrigine:More common    Blurred vision    changes in vision    clumsiness or unsteadiness    double vision    poor coordination    skin rashLess common    Anxiety    chest pain    confusion    continuous, uncontrolled back and forth or rolling eye movements    depression    increase in seizures    infection    irritabilityRare    Blistering, peeling, or loosening of the skin    chills    dark-colored urine    fever    flu-like symptoms    itching    memory lossThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.Dosage Forms & Strengthstablet    25mg    100mg    150mg    200mgtablet, chewable    2mg    5mg    25mgtablet, oral-disintegrating    25mg    50mg    100mg    200mgtablet, extended-release    25mg    50mg    100mg    200mg    250mg    300mgSeizure DisorderWith enzyme-inducing AEDs but without valproic acid    Initial: 50 mg PO qDay for 2 weeks, THEN    100 mg/day divided q12hr for 2 weeks    At week 5 and beyond, may increase by 100 mg/day PO q1-2Week to 300-500 mg/day PO divided q12hr    Lamotrigine XR: Start 50 mg PO qDay (weeks 1 and 2), THEN 100 mg qDay (weeks 3 and 4), THEN increase by 100 mg/day PO qWeek through week 7 (400 mg qDay); maintenance dose (week 8+): 400-600 mg PO qDayWith valproic acid    Initial: 25 mg PO qODay for 2 weeks, THEN    25 mg PO qDay for 2 weeks    At 5 weeks may increase by 25-50 mg/day q1-2Week to 100-400 mg/day qDay or divided q12hr    With valproate alone: 100-200 mg/day PO    Lamotrigine XR: Start 25 mg PO qODay for 2 weeks, THEN 25 mg PO qDay for 2 weeks, THEN 50 mg PO qDay (week 5), 100 mg PO qDay (week 6), 150 mg PO qDay (week 7), to maintenance (200-250 mg PO qDay)Without enzyme-inducing AEDs or valproic acid    Initial: 25 mg PO qDay for 2 weeks, THEN    50 mg/day PO for 2 weeks    After 4 weeks may increase by 50 mg/day q1-2Week to 225-375 mg/day divided q12hr    Lamotrigine XR: Start 25 mg PO qDay for 2 weeks, THEN 50 mg PO qDay for 2 weeks, THEN 100 mg qDay (week 5), 150 mg qDay (week 6), 200 mg qDay (week 7), to maintenance (300-400 mg PO qDay)LaMICtal, LaMICtal ODT, LaMICtal XR\00\00\00\00urs, treatment for another 8 weeks may be considered.Uses:-Short-term treatment for healing and symptom relief of all grades of erosive esophagitis-Maintain healing of erosive esophagitisUsual Adult Dose for Duodenal UlcerTreatment: 15 mg orally once a day-Duration of therapy: Up to 4 weeksMaintenance: 15 mg orally once a dayComment: Controlled studies did not extend beyond 12 months.Uses:-Short-term treatment for healing and symptom relief of active duodenal ulcers-Maintain healing of duodenal ulcersUsual Adult Dose for Duodenal Ulcer ProphylaxisTreatment: 15 mg orally once a day-Duration of therapy: Up to 4 weeksMaintenance: 15 mg orally once a dayComment: Controlled studies did not extend beyond 12 months.Uses:-Short-term treatment for healing and symptom relief of active duodenal ulcers-Maintain healing of duodenal ulcersUsual Adult Dose for Duodenal Ulcer MaintenanceTreatment: 15 mg orally once a day-Duration of therapy: Up to 4 weeksMaintenance: 15 mg orally once a dayComment: Controlled studies did not extend beyond 12 months.Uses:-Short-term treatment for healing and symptom relief of active duodenal ulcers-Maintain healing of duodenal ulcersUsual Adult Dose for Gastroesophageal Reflux Disease15 mg orally once a day-Duration of therapy: Up to 8 weeksUse: Short-term treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD)Usual Adult Dose for Gastric Ulcer30 mg orally once a day-Duration of therapy: Up to 8 weeksUse: Short-term treatment for healing and symptom relief of active benign gastric ulcersUsual Adult Dose for Multiple Endocrine AdenomasInitial dose: 60 mg orally once a dayMaintenance dose: 60 to 180 mg/dayComments:-A daily dose higher than 120 mg should be given as divided doses.-Dosage should be patient-specific and should continue as long as clinically necessary. Some patients with Zollinger-Ellison syndrome (ZES) have been on treatment for longer than 4 years.Use: Long-term treatment of pathological hypersecretory conditions, including ZESUsual Adult Dose for Systemic MastocytosisInitial dose: 60 mg orally once a dayMaintenance dose: 60 to 180 mg/dayComments:-A daily dose higher than 120 mg should be given as divided doses.-Dosage should be patient-specific and should continue as long as clinically necessary. Some patients with Zollinger-Ellison syndrome (ZES) have been on treatment for longer than 4 years.Use: Long-term treatment of pathological hypersecretory conditions, including ZESUsual Adult Dose for Zollinger-Ellison SyndromeInitial dose: 60 mg orally once a dayMaintenance dose: 60 to 180 mg/dayComments:-A daily dose higher than 120 mg should be given as divided doses.-Dosage should be patient-specific and should continue as long as clinically necessary. Some patients with Zollinger-Ellison syndrome (ZES) have been on treatment for longer than 4 years.Use: Long-term treatment of pathological hypersecretory conditions, including ZESUsual Adult Dose for Helicobacter pylori InfectionTriple Therapy: 30 mg orally 2 times a day, taken concomitantly with amoxicillin and clarithromycin-Duration of therapy: 10 to 14 daysDual Therapy: 30 mg orally 3 times a day, taken concomitantly with amoxicillin-Duration of therapy: 14 daysComments:-Refer to the manufacturer product information for dosing for amoxicillin and clarithromycin.-Eradication of Helicobacter pylori has been shown to reduce duodenal ulcer recurrence, and may result in duodenal/gastric ulcer healing without the need for continued therapy.Uses:-Triple therapy: Treatment of patients with H pylori infection and duodenal ulcer disease (active/1 year history of a duodenal ulcer) to eradicate H pylori-Dual therapy: Treatment of patients with H pylori infection and duodenal ulcer disease (active/1 year history of a duodenal ulcer) who is either allergic/intolerant to clarithromycin or in whom resistance to clarithromycin is known/suspectedFIRST Lansoprazole, Prevacid, Prevacid OTC, Prevacid SoluTab, Prevacid I.V.\00\00\00\00\00Wg\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\8Cd8\00+\83)\91;\83kiMacrobidNitrofurantoin Macrobid (nitrofurantoin) is an antibiotic that fights bacteria in the body.Macrobid is used to treat urinary tract infections.Macrobid may also be used for purposes not listed in this medication guide.Check with your doctor immediately if any of the following side effects occur while taking nitrofurantoin:More common    Changes in facial skin color    chest pain    chills    cough    fever    general feeling of discomfort or illness    hives    hoarseness    itching    joint or muscle pain    shortness of breath    skin rash    sudden trouble in swallowing or breathing    swelling of the face, mouth, hands, or feet    troubled breathingLess common    Black, tarry stools    blood in the urine or stools    burning, numbness, tingling, or painful sensations    dizziness    drowsiness    headache    pinpoint red spots on the skin    sore throat    unsteadiness or awkwardness    unusual bleeding or bruising    unusual tiredness or weakness    weakness in the arms, hands, legs, or feetRare    Abdominal or stomach pain    blindness    blistering, peeling, or loosening of the skin and mucous membranes    blue-yellow color blindness    bluish color of the fingernails, lips, skin, palms, or nail beds    blurred vision or loss of vision, with or without eye painThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.Macrobid capsules should be taken with food.Adults and Pediatric Patients Over 12 Years: One 100 mg capsule every 12 hours for seven days.Furadantin, Macrobid, Macrodantin, Nitro Macro\A0p7\00!\86\8E\AD=LasixFurosemideLasix (furosemide) is a loop diuretic (water pill) that prevents your body from absorbing too much salt. This allows the salt to instead be passed in your urine.Lasix is used to treat fluid retention (edema) in people with congestive heart failure, liver disease, or a kidney disorder such as nephrotic syndrome.Lasix is also used to treat high blood pressure (hypertension).Check with your doctor immediately if any of the following side effects occur while \00\00\00T\AB6\00%%\86E\89U\C4k\81#LansoprazoleLansoprazoleLansoprazole is used to treat and prevent stomach and intestinal ulcers, erosive esophagitis (damage to the esophagus from stomach acid), and other conditions involving excessive stomach acid such as Zollinger-Ellison syndrome.Over-the-counter lansoprazole (Prevacid OTC) is used to treat frequent heartburn that happens 2 or more days per week.Lansoprazole is not for immediate relief of heartburn symptoms.Check with your doctor immediately if any of the following side effects occur while taking lansoprazole:More common    Diarrhea    skin rash or itchingLess common    Abdominal or stomach pain    increased or decreased appetite    joint pain    nausea    vomitingRare    Anxiety    cold or flu-like symptoms    constipation    increased cough    mental depression    muscle pain    rectal bleeding    unusual bleeding or bruisingIncidence not known    Abdominal or stomach tenderness    back or leg pains    bleeding gums    blistering, peeling, or loosening of the skin    bloatingThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.Usual Adult Dose for Erosive EsophagitisTreatment: 30 mg orally once a day-Duration of therapy: Up to 8 weeksMaintenance: 15 mg orally once a dayComments:-Controlled studies did not extend beyond 12 months.-If patients are not healed after 8 weeks or erosive esophagitis rec\00\00\00R\00\00\00\00taking furosemide:Rare    Chest pain    chills    cough or hoarseness    fever    general feeling of tiredness or weakness    headache    lower back or side pain    painful or difficult urination    shortness of breath    sore throat    sores, ulcers, or white spots on the lips or in the mouth    swollen or painful glands    tightness in the chest    unusual bleeding or bruising    unusual tiredness or weakness    wheezingIncidence not known    Back or leg pains    black, tarry stools    bleeding gums    blistering, peeling, or loosening of the skin    bloating    blood in the urine or stools    blurred vision    burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings    changes in skin color, pain, tenderness, or swelling of the foot or legThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.EdemaTherapy should be individualized according to patient response to gain maximal therapeutic response and to determine the minimal dose needed to maintain that response.Adults -- The usual initial dose of LASIX is 20 to 80 mg given as a single dose. Ordinarily a prompt diuresis ensues. If needed, the same dose can be administered 6 to 8 hours later or the dose may be increased. The dose may be raised by 20 or 40 mg and given not sooner than 6 to 8 hours after the previous dose until the desired diuretic effect has been obtained. The individually determined single dose should then be given once or twice daily (eg, at 8 am and 2 pm). The dose of LASIX may be carefully titrated up to 600 mg/day in patients with clinically severe edematous states.Edema may be most efficiently and safely mobilized by giving LASIX on 2 to 4 consecutive days each week.When doses exceeding 80 mg/day are given for prolonged periods, careful clinical observation and laboratory monitoring are particularly advisable. (See PRECAUTIONS: Laboratory Tests.)Geriatric patients -- In general, dose selection for the elderly patient should be cautious, usually starting at the low end of the dosing range (see PRECAUTIONS: Geriatric Use).Pediatric patients -- The usual initial dose of oral LASIX in pediatric patients is 2 mg/kg body weight, given as a single dose. If the diuretic response is not satisfactory after the initial dose, dosage may be increased by 1 or 2 mg/kg no sooner than 6 to 8 hours after the previous dose. Doses greater than 6 mg/kg body weight are not recommended. For maintenance therapy in pediatric patients, the dose should be adjusted to the minimum effective level.HypertensionTherapy should be individualized according to the patientâ€™s response to gain maximal therapeutic response and to determine the minimal dose needed to maintain the therapeutic response.Adults -- The usual initial dose of LASIX for hypertension is 80 mg, usually divided into 40 mg twice a day. Dosage should then be adjusted according to response. If response is not satisfactory, add other antihypertensive agents.Changes in blood pressure must be carefully monitored when LASIX is used with other antihypertensive drugs, especially during initial therapy. To prevent excessive drop in blood pressure, the dosage of other agents should be reduced by at least 50% when LASIX is added to the regimen. As the blood pressure falls under the potentiating effect of LASIX, a further reduction in dosage or even discontinuation of other antihypertensive drugs may be necessary.Geriatric patients -- In general, dose selection and dose adjustment for the elderly patient should be cautious, usually starting at the low end of the dosing range (see PRECAUTIONS: Geriatric Use).Lasix, Diaqua-2, Lo-Aqua\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00/\00/\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\8FN9\005\85I\87q\90g_MagnesiumMagnesium gluconate Magnesium is a naturally occurring mineral. It is important for many systems in the body, especially the muscles and nerves.Magnesium gluconate is used as a supplement to treat low levels or to maintain adequate levels of this mineral in the body.Magnesium gluconate may also be used for purposes other than those listed in this medication guide.Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:    Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.    Very upset stomach or throwing up.    Very loose stools (diarrhea).The information is not a substitute for medical advice. Always consult your doctor or pharmacist.Usual Adult Dose for Hypomagnesemia500 to 1000 mg magnesium gluconate (27 to 54 mg elemental magnesium) orally 3 times a day.Usual Adult Dose for Dietary Supplement500 to 1000 mg magnesium gluconate (27 to 54 mg elemental magnesium) orally once a day.Usual Pediatric Dose for Hypomagnesemia10 to 20 mg/kg of elemental magnesium per dose orally 4 times a day. Use magnesium gluconate oral liquid preparations for more accurate measurement of dose.Renal Dose AdjustmentsDo not use without physician supervision in patients with renal impairment due to increased risk of hypermagnesemia. The use of magnesium salts are generally contraindicated in patients with severe renal dysfunction.Liver Dose AdjustmentsData not availableDose AdjustmentsMay increase by 500 to 1,000 mg/day (27 to 54 mg elemental magnesium) in order to achieve a normal serum magnesium level. Daily doses > 1,000 mg (54 mg elemental magnesium) should be given in 2 to 3 divided doses.Mag-G, Magonate, Magonate Natal, Magtrate\00\00\00\C8\00\C8\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\905:\00\84e\86C\93e\81UMeclizineMeclizineMeclizine is used to treat or prevent nausea, vomiting, and dizziness caused by motion sickness. It is also used to treat symptoms of vertigo (dizziness or spinning sensation) caused by disease that affects your inner ear.Meclizine may also be used for purposes not listed in this medication guide.Check with your doctor immediately if any of the following side effects occur while taking meclizine:Incidence not known    Cough    difficulty swallowing    dizziness    drowsiness    fast heartbeat    hives    itching    puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue    shortness of breath    skin rash    tightness in the chest    unusual tiredness or weaknessThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.Usual Adult Dose for Vertigo-25 to 100 mg orally per day in divided doses-Dosing dependent upon clinical response.Use: Management of vertigo associated with diseases affecting the vestibular system.Usual Adult Dose for Motion Sickness-Initial Dose: 25 to 50 mg orally 1 hour before travel-Maintenance Dose: Repeat dose every 24 hours if neededUse: Management of nausea, vomiting, and dizziness associated with motion sickness.Usual Pediatric Dose for VertigoAge 12 years and older:-25 to 100 mg orally per day in divided doses-Dosing dependent upon clinical response.Use: Management of vertigo associated with diseases affecting the vestibular system.Usual Pediatric Dose for Motion SicknessAge 12 years and older:-Initial Dose: 25 to 50 mg orally 1 hour before travel-Maintenance Dose: Repeat dose every 24 hours if neededUse: Management of nausea, vomiting, and dizziness associated with motion sickness.Renal Dose AdjustmentsUse with cautionLiver Dose AdjustmentsUse with cautionPrecautionsSafety and efficacy have not been established in patients younger than 12 years.Consult WARNINGS section for additional precautions.Antivert, Bonine, D-Vert, Dramamine Less Drowsy, Driminate II, Meclicot, Medivert, Ru-Vert-M, Meni-D\00\00\00depends upon severity of condition being treated.-Current guidelines should be consulted for additional information.Usual Adult Dose for Lyme Disease - Erythema Chronicum MigransInfectious Diseases Society of America (IDSA) recommendations: 500 mg orally 3 times a day for 14 to 28 daysComments:-Duration of treatment depends upon severity of condition being treated.-Current guidelines should be consulted for additional information.Usual Adult Dose for Lyme DiseaseInfectious Diseases Society of America (IDSA) recommendations: 500 mg orally 3 times a day for 14 to 28 daysComments:-Duration of treatment depends upon severity of condition being treated.-Current guidelines should be consulted for additional information.Usual Adult Dose for PneumoniaImmediate-release:-Mild, moderate, or severe infection: 500 mg orally every 8 hours or 875 mg every 12 hoursUse: For the treatment of infections of the lower respiratory tract due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) S pneumoniae, Staphylococcus species, and H influenzaeIDSA and American Thoracic Society (ATS) recommendations:Pneumonia:-Immediate-release: 1 g orally 3 times a dayComments:-Patients should be treated for a minimum of 5 days, be afebrile for 48 to 72 hours, and have no more than 1 community-acquired pneumonia (CAP)-associated sign of clinical instability before discontinuing therapy.-Used in combination with other medications.-Current guidelines should be consulted for additional information.Use: For outpatient empirical treatment of community-acquired pneumoniaUsual Adult Dose for BronchitisImmediate-release:-Mild, moderate, or severe infection: 500 mg orally every 8 hours or 875 mg every 12 hoursUse: For the treatment of infections of the lower respiratory tract due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) S pneumoniae, Staphylococcus species, and H influenzaeIDSA and American Thoracic Society (ATS) recommendations:Pneumonia:-Immediate-release: 1 g orally 3 times a dayComments:-Patients should be treated for a minimum of 5 days, be afebrile for 48 to 72 hours, and have no more than 1 community-acquired pneumonia (CAP)-associated sign of clinical instability before discontinuing therapy.-Used in combination with other medications.-Current guidelines should be consulted for additional information.Use: For outpatient empirical treatment of community-acquired pneumoniaUsual Adult Dose for SinusitisImmediate-release:-Mild to moderate infection: 250 mg orally every 8 hours or 500 mg every 12 hours-Severe infection: 500 mg orally every 8 hours or 875 mg every 12 hoursComments: Dosing for infections caused by bacteria that are intermediate in their susceptibility should follow recommendations for severe infections.Uses: For the treatment of infections of the ear, nose and throat due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) Streptococcus pneumoniae, Staphylococcus species, or Haemophilus influenzae; for the treatment of infections of the genitourinary tract due to susceptible (only beta lactamase negative) isolates of Escherichia coli, Proteus mirabilis, or Enterococcus faecalis; and for the treatment of infections of the skin and structure due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) S pneumoniae, Staphylococcus species, and H influenzaeUsual Adult Dose for Urinary Tract InfectionImmediate-release:-Mild to moderate infection: 250 mg orally every 8 hours or 500 mg every 12 hours-Severe infection: 500 mg orally every 8 hours or 875 mg every 12 hoursComments: Dosing for infections caused by bacteria that are intermediate in their susceptibility should follow recommendations for severe infections.Uses: For the treatment of infections of the ear, nose and throat due to susceptible (only beta l\00\00\00\DB\00\DB\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\B6;\001\83\89#\DEeNaloxoneNaloxone injectionNaloxone is used to treat a narcotic overdose in an emergency situation. This medicine should not be used in place of emergency medical care for an overdose.Naloxone is also used to help diagnose whether a person has used an overdose of an opioid.Check with your doctor immediately if any of the following side effects occur while taking naloxone:Incidence not known    Abdominal or stomach cramps    body aches    convulsions    diarrhea    difficult or troubled breathing    excessive crying    fast, pounding, or irregular heartbeat or pulse    fever    goosebumps    increased or excessive unconscious or jerking movements    irregular, fast or slow, or shallow breathing    irritability    nausea or vomiting    nervousness    pale or blue lips, fingernails, or skin    restlessness    runny nose    shiveringThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.Usual Adult Dose for Opioid OverdoseInitial dose: 0.4 mg to 2 mg IV; alternatively, may give IM or subcutaneously-If desired response is not obtained, doses should be repeated at 2 to 3 minute intervals-If no response is observed with a total dose of 10 mg, the diagnosis of opioid-induced or partial opioid-induced toxicity should be questionedAuto-injector: For emergency use in the home or other non-medical setting-Administer 0.4 mg (1 actuation) IM or subcutaneously into the anterolateral aspect of the thigh (through clothing if necessary)-If desired response is not achieved, a second dose may be administered after 2 or 3 minutes; additional doses may be administered every 2 to 3 minutes until emergency medical assistance arrivesNasal Spray:-Administer 1 spray intranasally into 1 nostril-If desired response is not achieved after 2 or 3 minutes, give a second dose intranasally into alternate nostril; additional doses may be administered every 2 to 3 minutes in alternating nostrils until emergency medical assistance arrivesComments:-IV route is recommended in emergency situations since it has the most rapid onset of action.-The duration of action of some opioids exceed that of this drug, therefore, repeat doses may be needed; the need for repeat doses will depend on the amount, type, and route of administration of the opioid being antagonized.-Patients should remain under continued surveillance; if a patients responds and relapses back into respiratory depression, additional doses should be given.-Additional supportive and/or resuscitative measures may be helpful while awaiting emergency medical assistance.Use: For the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression.Usual Adult Dose for Reversal of Opioid SedationInitial dose: 0.1 to 0.2 mg I\00\00\00c\00\00\00)\00)\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\97T<\00\84=\92;\97{3NamendaMemantineNamenda (memantine) reduces the actions of chemicals in the brain that may contribute to the symptoms of Alzheimer's disease.Namenda is used to treat moderate to severe dementia of the Alzheimer's type.Namenda may also be used for purposes not listed in this medication guide.Check with your doctor immediately if any of the following side effects occur while taking memantine:Less common    Bloating or swelling of the face, arms, hands, lower legs, or feet    blurred vision    dizziness    headache    nervousness    pounding in the ears    rapid weight gain    slow or fast heartbeat    tingling of the hands or feet    unusual weight gain or lossIncidence not known    Abdominal or stomach pain    agitation    black, tarry stools    bleeding gums    blistering, peeling, or loosening of the skin    blood in the urine or stools    chest pain    coma    constipation    continuing vomiting    convulsions    dark-colored urine    decreased urine output    depression    fainting    fast, pounding, or irregular heartbeat or pulse    general feeling of tiredness or weakness    high fever    high or low blood pressure    hostility    increased sweating    indigestion    infection from breathing foreign substances into the lungs    itching    lethargy    light-colored stools    lip smacking or puckering    loss of consciousness    muscle twitching    no blood pressure    no breathing    no pulseThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.The recommended starting dose of NAMENDA is 5 mg once daily. The dose should be increased in 5 mg increments to 10 mg/day (5 mg twice daily), 15 mg/day (5 mg and 10 mg as separate doses), and 20 mg/day (10 mg twice daily). The minimum recommended interval between dose increases is one week. The dosage shown to be effective in controlled clinical trials is 20 mg/day.NAMENDA can be taken with or without food. If a patient misses a single dose of NAMENDA, that patient should not double up on the next dose. The next dose should be taken as scheduled.If a patient fails to take NAMENDA for several days, dosing may need to be resumed at lower doses and retitrated as described above.Do not mix NAMENDA oral solution with any other liquid. The oral solution is administered with a dosing device that comes with the drug and consists of a syringe, syringe adaptor cap, tubing and other supplies a patient needs to administer the drug. The supplied syringe should be used to withdraw the correct volume of oral solution and the oral solution should be slowly squirted into the corner of the patient's mouth.Special PopulationsRenal ImpairmentA target dose of 5 mg twice daily is recommended in patients with severe renal impairment (creatinine clearance of 5 â€“ 29 mL/min based on the Cockroft-Gault equation).Hepatic ImpairmentNAMENDA should be administered with caution to patients with severe hepatic impairment Namenda, Namenda XR\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\91|=\003\87\8Ec\8C9INexiumEsomeprazole (oral)Nexium is used to treat symptoms of gastroesophageal reflux disease (GERD) and other conditions involving excessive stomach acid such as Zollinger-Ellison syndrome. It is also used to promote healing of erosive esophagitis (damage to your esophagus caused by stomach acid).Nexium may also be given to prevent gastric ulcer caused by infection with helicobacter pylori (H. pylori), or by the use of nonsteroidal anti-inflammatory drugs (NSAIDs).Nexium is not for immediate relief of heartburn symptoms.Check with your doctor immediately if any of the following side effects occur while taking esomeprazole:Incidence not known    Blistering, peeling, or loosening of the skin    bloating    chills    constipation    cough    darkened urine    difficulty with swallowing    dizziness    drowsiness    fast heartbeat    fever    indigestion    joint or muscle pain    loss of appetite    mood or mental changes    muscle spasms (tetany) or twitching    nausea    pains in the stomach, side, or abdomen, possibly radiating to the back    puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue    red skin lesions, often with a purple center    red, irritated eyes    seizures    skin rash, hives, itching    sore throat    sores, ulcers, or white spots in the mouth or on the lips    tightness in the chest    trembling    unusual tiredness or weakness    vomiting    yellow eyes or skinThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.Gastroesophageal Reflux Disease (GERD)Healing of erosive esophagitis (EE)Maintenance of healing of EESymptomatic GERD 	20 mg or 40 mg20 mg20 mg 	Once daily for 4 to 8 weeks*Once dailyâ€ Once daily for 4 weeksâ€¡Pediatric GERD12 to 17 year oldsHealing of EESymptomatic GERD 	20 mg or 40 mg20 mg	Once daily for 4 to 8 weeksOnce daily for 4 weeksRisk reduction of NSAID-associated gastric ulcer 	20 mg or 40 mg 	Once daily for up to 6 monthsâ€ Helicobacter pylori eradication to reduce the riskof duodenal ulcer recurrenceTriple Therapy:NEXIUMAmoxicillinClarithromycin 	40 mg1000 mg500 mg 	Once daily for 10 daysTwice daily for 10 daysTwice daily for 10 daysEsomeprazole Strontium, Nexium\00\00\00\D1\00\D1\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\9C,>\00#\86\90\A2OcrevusOcrelizumabOcrevus (ocrelizumab) is a monoclonal antibody that affects the actions of the body's immune system. Monoclonal antibodies are made to target and destroy only certain cells in the body. This may help to protect healthy cells from damage.Ocrevus is used to treat multiple sclerosis (relapsing or progressive forms).Ocrevus may also be used for purposes not listed in this medication guide.Check with your doctor or nurse immediately if any of the following side effects occur while taking ocrelizumab:More common    Back pain    blurred vision    body aches or pain    chest tightness    chills    confusion    cough    difficulty with breathing    dizziness    dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position    ear congestion    fast, pounding, or irregular heartbeat or pulse    feeling of warmth    fever    headache    hives, itching, or skin rash    itching, pain, redness, swelling, tenderness, or warmth on the skin    loss of voice    nasal congestion    nausea and vomiting    redness of the face, neck, arms, and occasionally, upper chest    runny nose    sneezing    sore throat    sweating    trouble breathing    unusual tiredness or weaknessLess common    Burning or stinging of the skin    painful cold sores or blisters on the lips, nose, eyes, or genitalsIncidence not known    Convulsions    drowsinessAssessments Prior to First Dose of OCREVUSHepatitis B Virus ScreeningPrior to initiating OCREVUS, perform Hepatitis B virus (HBV) screening. OCREVUS is contraindicated in patients with active HBV confirmed by positive results for HBsAg and anti-HBV tests. For patients who are negative for surface antigen [HBsAg] and positive for HB core antibody [HBcAb+] or are carriers of HBV [HBsAg+], consult liver disease experts before starting and during treatment [see Warnings and Precautions (5.2)].VaccinationsBecause vaccination with live-attenuated or live vaccines is not recommended during treatment and after discontinuation until B-cell repletion, administer all necessary immunizations according to immunization guidelines at least 6 weeks prior to initiation of OCREVUS [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.2)].Preparation Before Every InfusionInfection AssessmentPrior to every infusion of OCREVUS, determine whether there is an active infection. In case of active infection, delay infusion of OCREVUS until the infection resolves [see Warnings and Precautions (5.2)].Recommended PremedicationPre-medicate with 100 mg of methylprednisolone (or an equivalent corticosteroid) administered intravenously approximately 30 minutes prior to each OCREVUS infusion to reduce the frequency and severity of infusion reactions [see Warnings and Precautions (5.1)]. Pre-medicate with an antihistamine (e.g., diphenhydramine) approximately 30-60 minutes prior to each OCREVUS infusion to further reduce the frequency and severity of infusion reactions.The addition of an antipyretic (e.g., acetaminophen) may also be considered.Recommended Dosage and Dose AdministrationAdminister OCREVUS under the close supervision of an experienced healthcare professional with access to appropriate medical support to manage severe reactions such as serious infusion reactions.    Initial dose: 300 mg intravenous infusion, followed two weeks later by a second 300 mg intravenous infusion.    Subsequent doses: single 600 mg intravenous infusion every 6 months.    Observe the patient for at least one hour after the completion of the infusionOcrevus\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\91r?\00_\8A1\89U\8Em/OdefseyEmtricitabine, rilpivirine, and tenofovirOdefsey contains a combination of emtricitabine, rilpivirine, and tenofovir. Emtricitabine, rilpivirine, and tenofovir are antiviral medicines that prevent human immunodeficiency virus (HIV) from multiplying in your body. HIV-1 is the virus that causes AIDS (Acquired Immune Deficiency Syndrome).Odefsey is a prescription medicine that is used to treat Human Immunodeficiency Virus-1 (HIV-1) in people who have never taken HIV medicines before. This medicine is not a cure for HIV or AIDS.Odefsey is for use in adults and children who are at least 12 years old.Odefsey should not be taken together with other antiviral medications to treat HIV or AIDS. Check with your doctor immediately if any of the following side effects occur while taking emtricitabine / rilpivirine / tenofovir alafenamide:More common    Discouragement    feeling sad or empty    irritability    lack of appetite    loss of interest or pleasure    mental depression    thoughts of killing oneself    tiredness    trouble concentrating    trouble sleepingLess common    Body aches or pain    burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings    chest pain    cough    difficulty with breathing    ear congestion    fever or chillsThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.ODEFSEY is a 3-drug fixed dose combination product containing 200 mg of emtricitabine (FTC), 25 mg of rilpivirine (RPV), and 25 mg of tenofovir alafenamide (TAF). The recommended dosage of ODEFSEY is one tablet taken orally once daily with a meal in the following patient population: adults and in pediatric patients 12 years of age and older with body weight greater than or equal to 35 kg and a creatinine clearance greater than or equal to 30 mL per minute.Testing After Initiation of ODEFSEYIn virologically-suppressed patients, additional monitoring of HIV-1 RNA and regimen tolerability is recommended after replacing therapy to assess for potential virologic failure or rebound.Not Recommended in Patients with Severe Renal ImpairmentODEFSEY is not recommended in patients with estimated creatinine clearance below 30 mL per minute Complera, Odefsey\00\00\00\00\F4\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\A0!A\00!!\86{\8Es\A9+\81OmeprazoleOmeprazoleOmeprazole is used to treat symptoms of gastroesophageal reflux disease (GERD) and other conditions caused by excess stomach acid. It is also used to promote healing of erosive esophagitis (damage to your esophagus caused by stomach acid).Omeprazole may also be given together with antibiotics to treat gastric ulcer caused by infection with helicobacter pylori (H. pylori).Omeprazole is not for immediate relief of heartburn symptoms.Check with your do\00\00\00^\9A	@\00!\8AG\88\A13OfevNintedanibOfev (nintedanib) is used to treat a lung disease called idiopathic pulmonary fibrosis (IPF). IPF causes scar tissue to form deep within your lungs. The scar tissue thickens and becomes stiff over time, which can make it harder for your lungs to work. Decreased lung function can make it hard for you to breathe. Other medical problems can occur when your brain, heart, and other organs do not get enough oxygen.The cause of IPF is often unknown, but this condition is a progressive disease that can be fatal. Ofev is not a cure for IPF, but this medicine may slow the progress of this disease.Ofev may also be used for purposes not listed in this medication guide.Check with your doctor immediately if any of the following side effects occur while taking nintedanib:More common    Diarrhea    nausea    severe stomach pain    vomitingLess common    Abdominal or stomach pain or swelling    black, tarry stools    blood in the urine    blurred vision    bruising or purple areas on the skin    chest pain or discomfort    coughing up blood    decreased alertness    dizziness    headache    irregular heartbeat    joint pain or swelling    nervousnessThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.The recommended dosage of OFEV is 150 mg twice daily administered approximately 12 hours apart.OFEV capsules should be taken with food and swallowed whole with liquid. OFEV capsules should not be chewed or crushed because of a bitter taste. The effect of chewing or crushing of the capsule on the pharmacokinetics of nintedanib is not known.If a dose of OFEV is missed, the next dose should be taken at the next scheduled time. Advise the patient to not make up for a missed dose. Do not exceed the recommended maximum daily dosage of 300 mg.In patients with mild hepatic impairment (Child Pugh A), the recommended dosage of OFEV is 100 mg twice daily approximately 12 hours apart taken with food.Dosage Modification due to Adverse ReactionsIn addition to symptomatic treatment, if applicable, the management of adverse reactions of OFEV may require dose reduction or temporary interruption until the specific adverse reaction resolves to levels that allow continuation of therapy. OFEV treatment may be resumed at the full dosage (150 mg twice daily), or at the reduced dosage (100 mg twice daily), which subsequently may be increased to the full dosage. If a patient does not tolerate 100 mg twice daily, discontinue treatment with OFEV .Dose modifications or interruptions may be necessary for liver enzyme elevations. For aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3 times to <5 times the upper limit of normal (ULN) without signs of severe liver damage, interrupt treatment or reduce OFEV to 100 mg twice daily. Once liver enzymes have returned to baseline values, treatment with OFEV may be reintroduced at a reduced dosage (100 mg twice daily), which subsequently may be increased to the full dosage (150 mg twice daily) . Discontinue OFEV for AST or ALT elevations >5 times ULN or >3 times ULN with signs or symptoms of severe liver damage.In patients with mild hepatic impairment (Child Pugh A), consider treatment interruption, or discontinuation for management of adverse reactions.Ofev\00\00\00\00ctor immediately if any of the following side effects occur while taking omeprazole:Rare    Back, leg, or stomach pain    bleeding or crusting sores on the lips    blisters    bloody or cloudy urine    chills    continuing ulcers or sores in the mouth    difficult, burning, or painful urination    fever    frequent urge to urinate    general feeling of discomfort or illness    joint pain    loss of appetite    muscle aches or cramps    pain    red or irritated eyes    redness, tenderness, itching, burning, or peeling of the skin    skin rash or itching    sore throat    sores, ulcers, or white spots on the lips, in the mouth, or on the genitals    unusual bleeding or bruising    unusual tiredness or weaknessIncidence not known    Drowsiness    fast, racing, or uneven heartbeat    mood or mental changes    muscle spasms (tetany) or twitching seizures    nausea or vomiting    tremblingThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.Usual Adult Dose for Duodenal Ulcer20 mg orally once a day-Duration of therapy: 4 weeksComment: If patients are not fully healed after 4 weeks, treatment may continue for another 4 weeks.Use: Short-term treatment of active duodenal ulcerUsual Adult Dose for Helicobacter pylori InfectionDual therapy: 40 mg orally once a day, taken concomitantly with clarithromycin-Duration of therapy: 14 daysTriple therapy: 20 mg orally 2 times a day, taken concomitantly with amoxicillin and clarithromycin-Duration of therapy: 10 daysComments:-Patients presenting with an ulcer at the time of treatment should continue treatment with a 20 mg dose orally once a day for 14 days (dual therapy) or 18 days (triple therapy).-Antibiotic selection should be determined by local bacterial resistance, duration of treatment, and appropriate use.-Refer to the manufacturer product information for dosing for amoxicillin and/or clarithromycin.Uses: Helicobacter pylori eradication to reduce the risk of duodenal ulcer recurrence-TRIPLE THERAPY: Treatment of patients with H pylori infection and active or a history of duodenal ulcer disease (within 1 year)-DUAL THERAPY: Treatment of patients with H pylori infection and duodenal ulcer diseaseUsual Adult Dose for Gastric Ulcer40 mg orally once a day-Duration of therapy: 4 to 8 weeksUse: Short-term treatment of active benign gastric ulcerUsual Adult Dose for Erosive EsophagitisTreatment: 20 mg orally once a day-Duration of therapy: 4 to 8 weeksMaintenance: 20 mg orally once a dayComments:-Controlled studies for maintenance therapy did not extend past 12 months.-Patients who do not respond after 8 weeks of treatment may continue for an additional 4 weeks.-If there is a recurrence of erosive esophagitis (EE) or gastroesophageal reflux disease (GERD) symptoms, an additional 4 to 8 week course of treatment should be considered.Uses:-Treatment of EE due to acid-mediated GERD-Maintenance of healing of EE due to acid-mediated GERDUsual Adult Dose for Multiple Endocrine AdenomasInitial dose: 60 mg orally once a dayMaximum dose: 360 mg/day (as 120 mg orally 3 times a day)Comments:-Doses higher than 80 mg should be given in divided doses.-The treatment duration should be for as long as clinically necessary. Some patients with Zollinger-Ellison Syndrome have been treated for longer than 5 years.Use: Long-term treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine adenomas, systemic mastocytosis)FIRST Omeprazole, PriLOSEC, PriLOSEC OTC, Zegerid (Original Formulation)\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00the eyes    incomplete, sudden, or unusual body or facial movements    increased sensitivity of the eyes to light    poor coordination    red or purple patches on the skin    restlessness    shivering    sweating    talking, feeling, and acting with excitement and activity you cannot control    trembling or shaking, or twitchingThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.Usual Adult Dose for DepressionImmediate-release tablets and suspension:Initial dose: 20 mg orally once a dayMaintenance dose: 20 to 50 mg orally once a dayMaximum dose: 50 mg orally once a dayControlled-release tablets:Initial dose: 25 mg orally once a dayMaintenance dose: 25 to 62.5 mg orally once a dayMaximum dose: 62.5 mg orally once a dayDuration: Acute episodes of major depressive disorder require several months or longer of sustained pharmacologic therapy; systemic evaluation has shown that efficacy was maintained for up to one year.Comments:-Immediate-release oral formulations: The daily dose may be increased in 10 mg increments at weekly intervals, according to clinical response and tolerability-Extended-release oral formulations: The daily dose may be increased in 12.5 mg increments at weekly intervals, according to clinical response and tolerability-Efficacy of up to one year was demonstrated with a daily dose averaging 30 mg for the immediate-release formulations and 37.5 mg for the controlled-release formulationUse: Treatment of Major Depressive DisorderUsual Adult Dose for Social Anxiety DisorderImmediate-release tablets and suspension:Initial dose: 20 mg orally once a dayMaintenance dose: 20 to 60 mg orally once a dayMaximum dose: 60 mg orally once a dayControlled-release tablets:Initial dose: 12.5 mg orally once a dayMaintenance dose: 12.5 to 37.5 mg orally once a dayDuration: Efficacy has been demonstrated for up to 12 weeks; being a chronic condition, continuation of treatment beyond this time may be considered in responding patientsComments:-Immediate-release oral formulations: The daily dose may be increased in 10 mg increments at weekly intervals, according to clinical response and tolerability-Extended-release oral formulations: The daily dose may be increased in 12.5 mg increments at weekly intervals, according to clinical response and tolerabilityUsual Adult Dose for Panic DisorderImmediate-release tablets and suspension:Initial dose: 10 mg orally once a dayMaintenance dose: 10 to 40 mg orally once a dayMaximum dose: 60 mg orally once a dayControlled-release oral tablets:Initial dose: 12.5 mg orally once a dayMaintenance dose: 12.5 to 75 mg orally once a dayMaximum dose: 75 mg orally once a dayDuration: Efficacy has been demonstrated for up to 12 weeks; being a chronic condition, continuation of treatment beyond this time may be considered in responding patientsComments:-Immediate-release oral formulations: The daily dose may be increased in 10 mg increments at weekly intervals, according to clinical response and tolerability-Extended-release oral formulations: The daily dose may be increased in 12.5 mg increments at weekly intervals, according to clinical response and tolerability-The target dose is 40 mg once a dayUsual Adult Dose for Premenstrual Dysphoric DisorderControlled-release tablets:Continuous regimen:Initial dose: 12.5 mg orally once a day during the menstrual cycleMaintenance dose: 25 mg orally once a day during the menstrual cycleCyclic regimen:Initial dose: 12.5 mg orally once a day, starting 14 days prior to the anticipated start of menstruation through to the first full day of menses, and repeated with each new cycleMaintenance dose: 12.5 to 25 mg orally once a dayDuration: Efficacy has been demonstrated for up to 3 menstrual cycles; continuation of treatment beyond this time may be considered in responding patientsComments:-The daily dose may be increased in 12.5 mg increments at weekly intervals, according to clinical response and tolerabilityBrisdelle, Paxil, Paxil CR, Pexeva\00\00\00\E7\00\EB\E7\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\ADyC\00#\86G\8F\C3A\81ePepcid FamotidinePepcid is used to treat and prevent ulcers in the stomach and intestines. It also treats conditions in which the stomach produces too much acid, such as Zollinger-Ellison syndrome. Pepcid also treats gastroesophageal reflux disease (GERD) and other conditions in which acid backs up from the stomach into the esophagus, causing heartburn.Pepcid may also be used for purposes not listed in this medication guide.Check with your doctor immediately if any of the following side effects occur while taking famotidine:Rare    Bleeding gums    blistering, peeling, or loosening of the skin    blood in the urine or stools    bloody, black, or tarry stools    chest pain    chills    cough or hoarseness    diarrhea    fever    fever with or without chills    general feeling of tiredness or weakness    high fever    itching    joint or muscle pain    lower back or side pain    painful or difficult urination    pale skin    pinpoint red spots on the skin    red, irritated eyes    red skin lesions, often with a purple center    shortness of breath    sore throat    sores, ulcers, or white spots on the lips or in the mouth    swollen glands    unusual bleeding or bruising    unusual tiredness or weaknessIncidence not known    Abdominal or stomach pain    anxiety    burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings    clay-colored stools    dark urineThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.Duodenal UlcerAcute Therapy: The recommended adult oral dosage for active duodenal ulcer is 40 mg once a day at bedtime. Most patients heal within 4 weeks; there is rarely reason to use PEPCID at full dosage for longer than 6 to \00\00\00a\AAB\00!!\89c\8F=\BAQParoxetineParoxetineParoxetine is an antidepressant in a group of drugs called selective serotonin reuptake inhibitors (SSRIs). Paroxetine affects chemicals in the brain that may be unbalanced in people with depression, anxiety, or other disorders.Paroxetine is used to treat depression, obsessive-compulsive disorder, anxiety disorders, post-traumatic stress disorder (PTSD), and premenstrual dysphoric disorder (PMDD).The Brisdelle brand of paroxetine is used to treat hot flashes related to menopause. Brisdelle is not for treating any other conditions.Paroxetine may also be used for purposes not listed in this medication guide. Check with your doctor immediately if any of the following side effects occur while taking paroxetine:Less common    Agitation    chest congestion    chest pain    chills    cold sweats    confusion    difficulty with breathing    dizziness, faintness, or lightheadedness when getting up from a lying or sitting position    fast, pounding, or irregular heartbeat or pulse    muscle pain or weakness    skin rashRare    Absence of or decrease in body movements    bigger, dilated, or enlarged pupils (black part of the eye)    convulsions (seizures)    difficulty with speaking    dry mouth    fever    inability to move \00\00\00_\00\00\00\008 weeks. A regimen of 20 mg b.i.d. is also effective.Maintenance Therapy: The recommended adult oral dose is 20 mg once a day at bedtime.Benign Gastric UlcerAcute Therapy: The recommended adult oral dosage for active benign gastric ulcer is 40 mg once a day at bedtime.Gastroesophageal Reflux Disease (GERD)The recommended oral dosage for treatment of adult patients with symptoms of GERD is 20 mg b.i.d. for up to 6 weeks. The recommended oral dosage for the treatment of adult patients with esophagitis including erosions and ulcerations and accompanying symptoms due to GERD is 20 or 40 mg b.i.d. for up to 12 weeks (see CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies).Dosage for Pediatric Patients <1 year of age Gastroesophageal Reflux Disease (GERD)See PRECAUTIONS, Pediatric Patients <1 year of age.The studies described in PRECAUTIONS, Pediatric Patients <1 year of age suggest the following starting doses in pediatric patients <1 year of age: Gastroesophageal Reflux Disease (GERD) - 0.5 mg/kg/dose of famotidine oral suspension for the treatment of GERD for up to 8 weeks once daily in patients <3 months of age and 0.5 mg/kg/dose twice daily in patients 3 months to <1 year of age. Patients should also be receiving conservative measures (e.g., thickened feedings). The use of intravenous famotidine in pediatric patients <1 year of age with GERD has not been adequately studied.Dosage for Pediatric Patients 1-16 years of ageSee PRECAUTIONS, Pediatric Patients 1-16 years of age.The studies described in PRECAUTIONS, Pediatric Patients 1-16 years of age suggest the following starting doses in pediatric patients 1-16 years of age:Peptic ulcer - 0.5 mg/kg/day p.o. at bedtime or divided b.i.d. up to 40 mg/day.Gastroesophageal Reflux Disease with or without esophagitis including erosions and ulcerations - 1.0 mg/kg/day p.o. divided b.i.d. up to 40 mg b.i.d.While published uncontrolled studies suggest effectiveness of famotidine in the treatment of gastroesophageal reflux disease and peptic ulcer, data in pediatric patients are insufficient to establish percent response with dose and duration of therapy. Therefore, treatment duration (initially based on adult duration recommendations) and dose should be individualized based on clinical response and/or pH determination (gastric or esophageal) and endoscopy. Published uncontrolled clinical studies in pediatric patients 1-16 years of age have employed doses up to 1 mg/kg/day for peptic ulcer and 2 mg/kg/day for GERD with or without esophagitis including erosions and ulcerations.Pathological Hypersecretory Conditions (e.g., Zollinger-Ellison Syndrome, Multiple Endocrine Adenomas)The dosage of PEPCID in patients with pathological hypersecretory conditions varies with the individual patient. The recommended adult oral starting dose for pathological hypersecretory conditions is 20 mg q 6 h. In some patients, a higher starting dose may be required. Doses should be adjusted to individual patient needs and should continue as long as clinically indicated. Doses up to 160 mg q 6 h have been administered to some adult patients with severe Zollinger-Ellison Syndrome.Concomitant Use of AntacidsAntacids may be given concomitantly if needed.Dosage Adjustment for Patients with Moderate or Severe Renal InsufficiencyIn adult patients with moderate (creatinine clearance <50 mL/min) or severe (creatinine clearance <10 mL/min) renal insufficiency, the elimination half-life of PEPCID is increased. For patients with severe renal insufficiency, it may exceed 20 hours, reaching approximately 24 hours in anuric patients. Since CNS adverse effects have been reported in patients with moderate and severe renal insufficiency, to avoid excess accumulation of the drug in patients with moderate or severe renal insufficiency, the dose of PEPCID may be reduced to half the dose or the dosing interval may be prolonged to 36-48 hours as indicated by the patient's clinical response.Heartburn Relief, Pepcid, Pepcid AC, Pepcid AC Maximum Strength, Pepcid RPD, Mylanta AR, Leader Acid Reducer\00\00\00	\FA\00	\FA\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\00\8CD\00G\85c\89c\87%oPercocet Acetaminophen and oxycodone Percocet contains a combination of acetaminophen and oxycodone. Oxycodone is an opioid pain medication. An opioid is sometimes called a narcotic. Acetaminophen is a less potent pain reliever that increases the effects of oxycodone.Percocet is used to relieve moderate to severe pain.Percocet may also be used for purposes not listed in this medication guide.Check with your doctor immediately if any of the following side effects occur while taking acetaminophen / oxycodone:More common    Abdominal or stomach pain    black, tarry stools    chills    dark urine    dizziness    fever    headache    itching    light-colored stools    loss of appetite    nausea    rash    unpleasant breath odor    unusual tiredness or weakness    vomiting of blood    yellow eyes or skinRare    Cough or hoarseness    fever with or without chills    general feeling of tiredness or weakness    lower back or side pain    painful or difficult urination    sore throaThe information is not a substitute for medical advice. Always consult your doctor or pharmacist.Initiating Treatment with PERCOCETInitiate treatment with PERCOCET tablets 2.5 mg/325 mg adult dosage, with one or 2 tablets every 6 hours as needed for pain. The total daily dose of acetaminophen should not exceed 4 grams.The usual adult dosage is one tablet every 6 hours as needed for pain. The total daily dose of acetaminophen should not exceed 4 grams.Endocet, Percocet, Primlev, Roxicet, Xartemis XR\00\00\00\00V at 2 to 3 minute intervals to the desired degree of reversal-Supplemental doses administered IM have been shown to produce a longer lasting effectIntravenous Infusion:-A concentration of 0.004 mg/mL may be administered by IV infusion; titrate in accordance with patient's responseComments:-For the partial reversal of opioid depression following the use of opioids during surgery, smaller doses of naloxone are usually sufficient; larger than necessary doses may result in significant reversal of analgesia and increases in blood pressure.Use: For the complete or partial reversal of opioid depression including respiratory depression, induced by natural and synthetic opioids and certain mixed agonist-antagonist analgesics.Usual Pediatric Dose for Opioid OverdoseNeonates:Initial dose: 0.01 mg/kg IV, IM, or subcutaneously; repeat dose every 2 to 3 minutes as neededChildren:Initial dose: 0.01 mg/kg IV; if desired response is not obtained, may give 0.1 mg/kg IV-If IV route is not available may give IM or subcutaneously in divided dosesAuto-injector: For emergency use in the home or other non-medical setting-Administer 0.4 mg (1 actuation) IM or subcutaneously into the anterolateral aspect of the thigh (through clothing if necessary); if desired response is not achieved, a second dose may be administered after 2 or 3 minutes; additional doses may be administered every 2 to 3 minutes until emergency medical assistance arrives-Under 1 year of age: Thigh muscle should be pinched while administering injectionNasal Spray:-Administer 1 spray intranasally into 1 nostril-If desired response is not achieved after 2 or 3 minutes, give a second dose intranasally into alternate nostril; additional doses may be administered every 2 to 3 minutes in alternating nostrils until emergency medical assistance arrivesComments:-Neonatal opioid withdrawal syndrome may be life-threatening and should be treated according to protocols developed by neonatology experts.- To avoid precipitating opioid withdrawal symptoms, consider use of a naloxone product that can be dosed according to weight and titrated to effect.-The duration of action of some opioids will exceed that of this drug, therefore, repeat doses may be needed; the need for repeat doses will depend on the amount, type, and route of administration of the opioid being antagonized.-Patients should remain under continued surveillance; if a patients responds and relapses back into respiratory depression, additional doses should be given.-Additional supportive and/or resuscitative measures may be helpful while awaiting emergency medical assistance.Use: For the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression.Usual Pediatric Dose for Reversal of Opioid SedationNeonates:Initial dose: 0.01 mg/kg IV, IM or subcutaneously at 2 to 3 minute intervals to the desired degree of reversalChildren: 0.005 mg to 0.01 mg IV at 2 to 3 minute intervals to the desired degree of reversalIntravenous Infusion:-A concentration of 0.004 mg/mL may be administered by IV infusion; titrate in accordance with patient's responseComments:-For the partial reversal of opioid depression following the use of opioids during surgery, smaller doses of naloxone are usually sufficient; larger than necessary doses may result in significant reversal of analgesia and increases in blood pressure.Use: For the complete or partial reversal of opioid depression including respiratory depression, induced by natural and synthetic opioids and certain mixed agonist-antagonist analgesics.Renal Dose AdjustmentsUse with cautionLiver Dose AdjustmentsUse with cautionDose AdjustmentsReversal of respiratory depression by partial agonists or mixed agonist/antagonists, such as buprenorphine and pentazocine, may be incomplete or require higher doses; if an incomplete response is observed, respirations should be mechanically assisted as clinically indicated.PrecautionsConsult WARNINGS section for additional precautions.Evzio\00\00\00eactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) Streptococcus pneumoniae, Staphylococcus species, or Haemophilus influenzae; for the treatment of infections of the genitourinary tract due to susceptible (only beta lactamase negative) isolates of Escherichia coli, Proteus mirabilis, or Enterococcus faecalis; and for the treatment of infections of the skin and structure due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) S pneumoniae, Staphylococcus species, and H influenzaeUsual Adult Dose for Tonsillitis/PharyngitisExtended-release: 775 mg orally once a day within 1 hour after a meal for 10 daysComments: The full 10-day course of treatment should be completed in order to be effective.Uses: For the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenesIDSA recommendations:Immediate-release: 1000 mg orally once a day or 500 mg orally twice a dayUse: For the treatment of Group A Streptococcal pharyngitisUsual Adult Dose for Skin and Structure InfectionImmediate-release:-Mild to moderate infection: 250 mg orally every 8 hours or 500 mg every 12 hours-Severe infection: 500 mg orally every 8 hours or 875 mg every 12 hoursComments: Dosing for infections caused by bacteria that are intermediate in their susceptibility should follow recommendations for severe infections.Use: For the treatment of infections of the skin and structure due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) S pneumoniae, Staphylococcus species, and H influenzaeIDSA recommendations:-Immediate-release: 500 mg orally 3 times a day for 7 to 10 daysUse: For the treatment of erysipeloidUsual Adult Dose for Cutaneous Bacillus anthracisUS CDC Recommendations: 1 g orally every 8 hoursDuration of prophylaxis: 60 daysComments:-Recommended as an alternative oral regimen for postexposure prophylaxis and cutaneous anthrax without systemic involvement; recommended for penicillin-susceptible strains-Current guidelines should be consulted for additional information.Usual Adult Dose for Anthrax ProphylaxisUS CDC Recommendations: 1 g orally every 8 hoursDuration of prophylaxis: 60 daysComments:-Recommended as an alternative oral regimen for postexposure prophylaxis and cutaneous anthrax without systemic involvement; recommended for penicillin-susceptible strains-Current guidelines should be consulted for additional information.Usual Pediatric Dose for Bacterial Endocarditis ProphylaxisAHA recommendations:Children:-Immediate-release: 50 mg/kg orally as a single dose 30 to 60 minutes prior to procedure; maximum of 2 g/doseComments:-Prophylaxis should be used for patients at high risk of adverse outcomes from endocarditis with underlying cardiac conditions who undergo any dental procedure that involves manipulation of gingival tissue or periapical region of a tooth and for those procedures that perforate oral mucosa.-Prophylaxis should also be used for patients at high risk of adverse outcomes from endocarditis who undergo invasive respiratory tract procedures.-Current guidelines should be consulted for additional information.Usual Pediatric Dose for SinusitisImmediate-Release Formulations:Mild, Moderate, or Severe Infection:3 months or younger: Up to 30 mg/kg/day orally in divided doses every 12 hoursComments:-Treatment should be continued for a minimum of 48 to 72 hours beyond the time the patient becomes asymptomatic or evidence of bacterial eradication occurs.-At least 10 days of treatment for any infection caused by Streptococcus pyogenes is recommended to prevent the occurrence of acute rheumatic fever.Immediate-Release Formulations:Mild to Moderate Infection:4 months or older:-Less than 40 kg: 20 mg/kg/day orally in divided doses every 8 hours or 25 mg/kg/day in divided doses every 12 hours-At least 40 kg: 250 mg orally every 8 hours or 500 mg every 12 hoursSevere Infection:4 months \00\00\00for older:-Less than 40 kg: 40 mg/kg/day orally in divided doses every 8 hours or 45 mg/kg/day in divided doses every 12 hours-At least 40 kg: 500 mg orally every 8 hours or 875 mg every 12 hoursComments: Dosing for infections caused by bacteria that are intermediate in their susceptibility should follow recommendations for severe infections.Uses: For the treatment of infections of the ear, nose and throat due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) Streptococcus pneumoniae, Staphylococcus species, or Haemophilus influenzae; for the treatment of infections of the genitourinary tract due to susceptible (only beta lactamase negative) isolates of Escherichia coli, Proteus mirabilis, or Enterococcus faecalis; and for the treatment of infections of the skin and structure due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) S pneumoniae, Staphylococcus species, and H influenzaeUsual Pediatric Dose for Skin or Soft Tissue InfectionImmediate-Release Formulations:Mild, Moderate, or Severe Infection:3 months or younger: Up to 30 mg/kg/day orally in divided doses every 12 hoursComments:-Treatment should be continued for a minimum of 48 to 72 hours beyond the time the patient becomes asymptomatic or evidence of bacterial eradication occurs.-At least 10 days of treatment for any infection caused by Streptococcus pyogenes is recommended to prevent the occurrence of acute rheumatic fever.Immediate-Release Formulations:Mild to Moderate Infection:4 months or older:-Less than 40 kg: 20 mg/kg/day orally in divided doses every 8 hours or 25 mg/kg/day in divided doses every 12 hours-At least 40 kg: 250 mg orally every 8 hours or 500 mg every 12 hoursSevere Infection:4 months or older:-Less than 40 kg: 40 mg/kg/day orally in divided doses every 8 hours or 45 mg/kg/day in divided doses every 12 hours-At least 40 kg: 500 mg orally every 8 hours or 875 mg every 12 hoursComments: Dosing for infections caused by bacteria that are intermediate in their susceptibility should follow recommendations for severe infections.Uses: For the treatment of infections of the ear, nose and throat due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) Streptococcus pneumoniae, Staphylococcus species, or Haemophilus influenzae; for the treatment of infections of the genitourinary tract due to susceptible (only beta lactamase negative) isolates of Escherichia coli, Proteus mirabilis, or Enterococcus faecalis; and for the treatment of infections of the skin and structure due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) S pneumoniae, Staphylococcus species, and H influenzaeUsual Pediatric Dose for Urinary Tract InfectionImmediate-Release Formulations:Mild, Moderate, or Severe Infection:3 months or younger: Up to 30 mg/kg/day orally in divided doses every 12 hoursComments:-Treatment should be continued for a minimum of 48 to 72 hours beyond the time the patient becomes asymptomatic or evidence of bacterial eradication occurs.-At least 10 days of treatment for any infection caused by Streptococcus pyogenes is recommended to prevent the occurrence of acute rheumatic fever.Immediate-Release Formulations:Mild to Moderate Infection:4 months or older:-Less than 40 kg: 20 mg/kg/day orally in divided doses every 8 hours or 25 mg/kg/day in divided doses every 12 hours-At least 40 kg: 250 mg orally every 8 hours or 500 mg every 12 hoursSevere Infection:4 months or older:-Less than 40 kg: 40 mg/kg/day orally in divided doses every 8 hours or 45 mg/kg/day in divided doses every 12 hours-At least 40 kg: 500 mg orally every 8 hours or 875 mg every 12 hoursComments: Dosing for infections caused by bacteria that are intermediate in their susceptibility should follow recommendations for severe infections.Uses: For the treatment of infe\00\00\00gctions of the ear, nose and throat due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) Streptococcus pneumoniae, Staphylococcus species, or Haemophilus influenzae; for the treatment of infections of the genitourinary tract due to susceptible (only beta lactamase negative) isolates of Escherichia coli, Proteus mirabilis, or Enterococcus faecalis; and for the treatment of infections of the skin and structure due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) S pneumoniae, Staphylococcus species, and H influenzaeUsual Pediatric Dose for PneumoniaImmediate-Release Formulations:Mild, Moderate, or Severe infection:3 months or younger: Up to 30 mg/kg/day orally in divided doses every 12 hours4 months or older:-Less than 40 kg: 40 mg/kg/day orally in divided doses every 8 hours or 45 mg/kg/day in divided doses every 12 hours-At least 40 kg: 500 mg orally every 8 hours or 875 mg every 12 hoursUse: For the treatment of infections of the lower respiratory tract due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) S pneumoniae, Staphylococcus species, and H influenzaeIDSA and the Pediatric Infectious Diseases Society recommendations:Immediate-release formulations:4 months or older:-Empiric therapy for presumed bacterial pneumonia: 90 mg/kg/day orally in 2 divided doses; maximum 4 g/day-Streptococcus pneumoniae (penicillin minimum inhibitory concentration of 2 mcg/mL or less): 90 mg/kg/day orally in 2 divided doses or 45 mg/kg/day in 3 divided doses-Group A Streptococcus: 50 to 75 mg/kg/day orally in 2 divided doses-Haemophilus influenza typeable (A to F) or nontypeable: 75 to 100 mg/kg/day orally in 3 divided dosesComments: Current guidelines should be consulted for additional information.Use: For the management of community-acquired pneumoniaUsual Pediatric Dose for BronchitisImmediate-Release Formulations:Mild, Moderate, or Severe infection:3 months or younger: Up to 30 mg/kg/day orally in divided doses every 12 hours4 months or older:-Less than 40 kg: 40 mg/kg/day orally in divided doses every 8 hours or 45 mg/kg/day in divided doses every 12 hours-At least 40 kg: 500 mg orally every 8 hours or 875 mg every 12 hoursUse: For the treatment of infections of the lower respiratory tract due to susceptible (only beta lactamase negative) isolates of Streptococcus species (alpha and beta-hemolytic isolates only) S pneumoniae, Staphylococcus species, and H influenzaeIDSA and the Pediatric Infectious Diseases Society recommendations:Immediate-release formulations:4 months or older:-Empiric therapy for presumed bacterial pneumonia: 90 mg/kg/day orally in 2 divided doses; maximum 4 g/day-Streptococcus pneumoniae (penicillin minimum inhibitory concentration of 2 mcg/mL or less): 90 mg/kg/day orally in 2 divided doses or 45 mg/kg/day in 3 divided doses-Group A Streptococcus: 50 to 75 mg/kg/day orally in 2 divided doses-Haemophilus influenza typeable (A to F) or nontypeable: 75 to 100 mg/kg/day orally in 3 divided dosesComments: Current guidelines should be consulted for additional information.Use: For the management of community-acquired pneumoniaUsual Pediatric Dose for Tonsillitis/Pharyngitis12 years or older:-Extended-release: 775 mg orally once a day within 1 hour after a meal for 10 daysComments: The full 10-day course of treatment should be completed in order to be effective.Uses: For the treatment of tonsillitis and/or pharyngitis secondary to S pyogenesIDSA recommendations:Immediate-release: 50 mg/kg (maximum 1000 mg) orally once a day or 25 mg/kg (maximum 500 mg) twice a dayUse: For the treatment of Group A Streptococcal pharyngitisUsual Pediatric Dose for Lyme DiseaseIDSA recommendations:Children:-Immediate-release: 50 mg/kg/day orally in 3 divides doses for 14 to 28 days; maximum single dose of 500 mgComments:-Duration of treatment depends upon sever\00\00\00hity of condition being treated.-Current guidelines should be consulted for additional information.Usual Pediatric Dose for Otitis MediaAmerican Academy of Pediatrics (AAP) and American Academy of Family Physicians (AAFP) recommendations:-Immediate-release: 80 to 90 mg/kg/day orally in 2 divided doses; some experts recommend 90 mg/kg orally in 2 divided doses as initial therapyComments:-Optimal duration of treatment uncertain; however, for young children and children with severe disease at any age, a 10 day course is recommended; children 6 years or older with mild or moderate disease should find a duration of 5 to 7 days appropriate.-Current guidelines should be consulted for additional information.Use: For the treatment of acute otitis mediaUsual Pediatric Dose for Inhalation Bacillus anthracisAAP Recommendations:Up to 1 week of age:-Gestational age 32 to 37 weeks: 50 mg/kg orally in divided doses every 12 hours-Term neonate: 75 mg/kg orally in divided doses every 8 hours1 to 4 weeks:-Gestational age 32 to 37 weeks: 75 mg/kg orally in divided doses every 8 hours-Term neonate: 75 mg/kg/day orally in divided doses every 8 hours1 month or older: 75 mg/kg/day orally in divided doses every 8 hours; not to exceed 1 g/doseDuration of Therapy:Postexposure prophylaxis for B anthracis infection: 60 days after exposureCutaneous anthrax without systemic involvement:-Bioterrorism-related cases: To complete an antimicrobial regimen of up to 60 days from onset of illness-Naturally-acquired cases: 7 to 10 daysFollow-up for severe anthrax:-To complete a regimen of 10 to 14 days or longer (up to 4 weeks of age) or to complete a regimen of 14 days or longer (1 month or older)-Patients may require prophylaxis to complete an antimicrobial regimen of up to 60 days from onset of illness.Comments:-Recommended as an alternative regimen for postexposure prophylaxis, the treatment of cutaneous anthrax without systemic involvement, and oral follow-up therapy for severe anthrax-Recommended as an alternative for penicillin-susceptible strains-Recommended for use with a protein synthesis inhibitor when used for follow-up therapy for severe anthrax (includes anthrax meningitis, inhalation anthrax, injection anthrax, gastrointestinal anthrax, and cutaneous anthrax with systemic involvement, extensive edema, or lesions of the head or neck).-Current guidelines should be consulted for additional information.Usual Pediatric Dose for Cutaneous Bacillus anthracisAAP Recommendations:Up to 1 week of age:-Gestational age 32 to 37 weeks: 50 mg/kg orally in divided doses every 12 hours-Term neonate: 75 mg/kg orally in divided doses every 8 hours1 to 4 weeks:-Gestational age 32 to 37 weeks: 75 mg/kg orally in divided doses every 8 hours-Term neonate: 75 mg/kg/day orally in divided doses every 8 hours1 month or older: 75 mg/kg/day orally in divided doses every 8 hours; not to exceed 1 g/doseDuration of Therapy:Postexposure prophylaxis for B anthracis infection: 60 days after exposureCutaneous anthrax without systemic involvement:-Bioterrorism-related cases: To complete an antimicrobial regimen of up to 60 days from onset of illness-Naturally-acquired cases: 7 to 10 daysFollow-up for severe anthrax:-To complete a regimen of 10 to 14 days or longer (up to 4 weeks of age) or to complete a regimen of 14 days or longer (1 month or older)-Patients may require prophylaxis to complete an antimicrobial regimen of up to 60 days from onset of illness.Comments:-Recommended as an alternative regimen for postexposure prophylaxis, the treatment of cutaneous anthrax without systemic involvement, and oral follow-up therapy for severe anthrax-Recommended as an alternative for penicillin-susceptible strains-Recommended for use with a protein synthesis inhibitor when used for follow-up therapy for severe anthrax (includes anthrax meningitis, inhalation anthrax, injection anthrax, gastrointestinal anthrax, and cutaneous anthrax with systemic involvement, extensive edema, or lesions of the head or neck).-Current gu\00\00\00\00idelines should be consulted for additional information.Usual Pediatric Dose for Anthrax ProphylaxisAAP Recommendations:Up to 1 week of age:-Gestational age 32 to 37 weeks: 50 mg/kg orally in divided doses every 12 hours-Term neonate: 75 mg/kg orally in divided doses every 8 hours1 to 4 weeks:-Gestational age 32 to 37 weeks: 75 mg/kg orally in divided doses every 8 hours-Term neonate: 75 mg/kg/day orally in divided doses every 8 hours1 month or older: 75 mg/kg/day orally in divided doses every 8 hours; not to exceed 1 g/doseDuration of Therapy:Postexposure prophylaxis for B anthracis infection: 60 days after exposureCutaneous anthrax without systemic involvement:-Bioterrorism-related cases: To complete an antimicrobial regimen of up to 60 days from onset of illness-Naturally-acquired cases: 7 to 10 daysFollow-up for severe anthrax:-To complete a regimen of 10 to 14 days or longer (up to 4 weeks of age) or to complete a regimen of 14 days or longer (1 month or older)-Patients may require prophylaxis to complete an antimicrobial regimen of up to 60 days from onset of illness.Comments:-Recommended as an alternative regimen for postexposure prophylaxis, the treatment of cutaneous anthrax without systemic involvement, and oral follow-up therapy for severe anthrax-Recommended as an alternative for penicillin-susceptible strains-Recommended for use with a protein synthesis inhibitor when used for follow-up therapy for severe anthrax (includes anthrax meningitis, inhalation anthrax, injection anthrax, gastrointestinal anthrax, and cutaneous anthrax with systemic involvement, extensive edema, or lesions of the head or neck).-Current guidelines should be consulted for additional information.Renal Dose AdjustmentsExtended-release Tablets:-Severe renal dysfunction (CrCl less than 30 mL/min): Not recommended.Immediate-release formulations:Mild to moderate renal dysfunction: No adjustment recommended.Severe renal dysfunction:-GFR 10 to 30 mL/min: 250 or 500 mg orally every 12 hours, depending on severity of infection-GFR less than 10 mL/min: 250 or 500 mg orally every 24 hours, depending on severity of infectionComments: Patients with severe renal dysfunction (CrCl less than 30 mL/min) should not receive the 875 mg tablets.Liver Dose AdjustmentsData not availablePrecautionsExtended-release tablets: Safety and efficacy have not been established in patients younger than 12 years.Consult WARNINGS section for additional precautions.DialysisHemodialysis:-Extended-release Tablets: Not recommended.-Immediate-release: 250 or 500 mg orally every 24 hours, depending on severity of infection; patients should receive an additional dose both during and at the end of dialysisOther CommentsAdministration advice:-Extended-release tablets: Do not crush or chew; take with food.-Oral suspension: Shake well before use; after reconstitution, the required amount of suspension should be placed directly on patient's tongue and swallowed; alternatively, may add to milk, fruit juice, water, ginger ale, or cold drinks and taken immediately.Storage requirements:-Dispense in a tight container.-Oral suspension: Keep bottle tightly closed; refrigeration preferable but not required; discard after 14 days.Reconstitution/preparation techniques:-Oral suspension: The manufacturer product information should be consulted.General:-To reduce the development of drug-resistant bacteria and maintain efficacy, this drug should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.-When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy; in absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.Patient advice:-Seek medical attention immediately if an allergic reaction occurs.-Contact your healthcare provider if watery and bloody stools develop.-The full course of therapy should be completed.Moxatag